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Patients with schizophrenia, as a group, have several abnormalities of brain structure and
function as compared with normal controls. In particular, they have enlarged ventricles and a loss
of brain substance ("atrophy") on Computerised Tomography; and a reduction in the volumes of
the whole brain and mesial temporal lobe structures on Magnetic Resonance Imaging (MRI).
Functional brain scanning studies, such as Single Photon Emission Tomography (SPET) and
Positron Emission Tomography, have generally revealed reduced regional cerebral blood flow
(rCBF) or neuronal metabolism in the frontal lobes ("hypofrontality"). Chapter 1 reviews this
literature, including a systematic and quantitative review of the volumetric MRI studies to date,
and examines the links between such biological findings and the clinical features of the illness.
Chapter 2 describes an original piece of research designed to examine the biological
associations of treatment response in schizophrenia with MRI, SPET and detailed
neuropsychological testing. Forty patients were selected as treatment responsive or resistant
using standardised criteria. A quantitative analysis of particular regional volumes on MRI revealed
that the treatment resistant group had a consistent, but not statistically significant, tendency to
smaller cerebral structures. Qualitative ratings showed a tendency to greater atrophy in the
treatment resistant patients. The SPET scans did not detect any significant between group
differences. Treatment resistant cases demonstrated significantly worse performance on several
cognitive measures, and the difference on a test of episodic memory remained after controlling for
global intellectual deficits, years of education or current medication levels.
The forty SPET scans were subsequently used in a comparison of rCBF in medicated and
unmedicated schizophrenia, other psychotic patients and normal controls. The schizophrenic
patients showed the predicted hypofrontality, but this was limited to the anterior cingulate and
medial pre-frontal cortex (Ebmeier et a/., 1995). Given some evidence, from post-mortem studies,
of a preferential loss of gaba-ergic neurones in the anterior cingulate in schizophrenia, with a
compensatory upregulation of non-specific GABA-A receptor binding, a study ofGABA receptor
binding on SPET was conducted using the benzodiazepine ligand Iomazenil. As described in
Chapter 3, the expectation was that Iomazenil binding would be increased in frontal regions, but
this was not confirmed in a comparison of ten schizophrenics and ten normal controls; and an
apparent reduction of subcortical receptor binding was attributed to methodological problems.
Finally, Chapter 4 describes the likely technical and experimental developments in brain
imaging studies of schizophrenia in the foreseeable future. Some recommendations are made,
based on these advances and the studies described in the thesis, that would help to exploit the full
potential of neuroimaging to improve understanding of the pathophysiology of schizophrenia.
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Chapter 1: Literature review
1. INTRODUCTION
There is a consensus nowadays that the syndrome of schizophrenia is largely a
manifestation of one or more disturbances in brain structure and function. This idea has
received most support over the past twenty years, mainly from a variety of techniques
used to image the brain, but was proposed a century ago. Emil Kraepelin was not only the
first to suggest a distinction between the two main types of 'functional' psychosis, but also
among the first to suggest that 'dementia praecox' was associated with some
neuropathological disturbance (Kraepelin, 1919). Shortly afterwards, his subjective and
qualitative observations were supported by investigations with pneumoencephalography,
which was the first attempt to image the brain in vivo. After lumbar puncture, cerebro¬
spinal fluid (CSF) was withdrawn and replaced with air to outline the cerebral ventricles
and cortical surface on x-ray reoentography (Dandy, 1918). The technique was first
applied to psychiatric patients by Jacobi & Winkler (1927), who described an apparent
loss of brain tissue in patients with schizophrenia. As a result of the risks and discomfort
involved, pneumoencephalography was not extensively used to study clinical populations,
but patients with schizophrenia appeared to exhibit enlarged lateral and third ventricles, as
well as widened cortical sulci (Haug, 1982; Weinberger & Wyatt, 1982).
These findings were largely ignored, probably because of a psychoanalytical
hegemony within the psychiatric profession, but it has not been possible to disregard
subsequent findings with an increasing array of sophisticated and complimentary neuro-
imaging methods. This introductory chapter will briefly describe these methods and their
limitations, summarise the main findings obtained with them, and identify some important
questions for future study. Structural techniques - computerised tomography and, in
particular, magnetic resonance imaging - will be reviewed first; followed by an account of
the main functional imaging methods of single photon emission (computed) tomography
and positron emission tomography. Relevant results from post-mortem studies will be
mentioned where pertinent to this and subsequent chapters.
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1.1 COMPUTERISED TOMOGRAPHY tCTl
The last study to use pneumoencephalography (Haug, 1982) was actually
published several years after the first account ofCT in schizophrenia, which, as a relatively
safe and non-invasive method of imaging the brain, presented researchers with many new
experimental opportunities. CT images are obtained from the reconstruction of X-ray
radiation transmission from multiple projections around the object of interest; the accurate
measurement of the X-ray attenuation depending on the sensitivity of photomultiplier
tubes and a sodium iodide detector. The independent realisation of this possibility earned
Cormack and Hounsfield a joint award of the 1979 Nobel prize for medicine/physiology.
The clinical use of CT began in 1971 and findings were first published in 1973
(Hounsfield, 1973). The first use of the technique in patients with schizophrenia quickly
followed, in which the outline of the ventricles and the brain were traced by planimetry
and the Ventricle:Brain Ratio (VBR) was calculated (Johnstone et al, 1976). The finding
of relatively enlarged ventricles in chronic schizophrenics as opposed to controls of similar
age was soon replicated (Weinberger et al., 1979), and has now been so in over 100
controlled CT studies (Lewis, 1990). Despite the inevitable scanning artefacts (especially
"beam hardening" and partial volume effects), limitations of the technique (to area
measures in one plane) and variations in study methodology (particularly in ascertaining
measurements and the composition of patient and control groups) a remarkable degree of
consensus has emerged - that patients with schizophrenia have, as a group, enlarged lateral
and third ventricles and increased cerebral 'atrophy' (Lewis, 1990). Thus, early
suggestions from pneumoencephalography have been confirmed and certain other
differences between schizophrenic and control populations were also suggested. These
findings and their clinical associations will be briefly reviewed, after a consideration of
some of the more pertinent artefacts that can be troublesome in the interpretation of CT
scan images.
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1.1.2 POTENTIAL ARTEFACTS ON CT
The main artefacts of CT scanning, given that the x-ray source and detection is
correctly aligned and calibrated, arise from the absorption of lower energy x-ray photons
as they pass through tissue so that the beam becomes composed of higher energy rays and
attenuation values are generally lowered - particularly around bony structures - so that
peripheral structures are assigned relatively less dense CT values ("beam hardening").
Scattering ofx-rays around dense objects such as bone can produce streak effects, as does
patient motion. Partial volume effects are common to all imaging techniques, arising from
the fitting of linear geometry onto non-linear anatomical structures, and leading to a loss
of spatial and tissue resolution (of at least 1-2 mm), although the exact cause and nature of
the effect differs between different imaging methods. In CT scanning, boundary tissue will
be assigned the CT number of the average of the adjacent tissues, which may be invalid
and is particularly problematic if comparatively thick slices are used. For all the above
reasons comparing absolute CT numbers, as measures of "cerebral density", can be highly
misleading (Jacobson et al., 1985; Coffman, 1989). Researchers have nonetheless tried to
do this as a way of localising the neuroanatomical deficit(s) in schizophrenia, and many
have reported variable abnormalities of 'hypodensity' or in left-right asymmetry. Perhaps
the most interesting finding in this area is from the study ofmonozygotic discordant twins
(Reveley et al., 1987), where the schizophrenic co-twins were found to have consistently
less dense left cerebral hemispheres. However, such results have not been consistently
replicated - probably because of the inherent unreliability of these measures, the fact that
they could simply reflect a generalised loss of cerebral substance, and because of the
limited spatial resolution with CT. For these reasons, most researchers have concluded
that CT cannot provide sufficiently detailed information on regional abnormalities in
schizophrenia (e.g. Pearlson et al., 1989; Daniel et al., 1991a). Attention has been more
usefully devoted towards identifying the clinical associations and course of consistently
reported CT abnormalities, such as ventriculomegaly and cerebral atrophy.
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1.1.3 CT FINDINGS IN SCHIZOPHRENIA
1.1.3.1 Lateral Ventricle Enlargement
Although the vast majority of studies have demonstrated relative ventriculomegaly
in groups of schizophrenics (Coffinan, 1989; Lewis, 1990), only about a third of individual
patients exhibit this to a degree well above (i.e. two standard deviations) a control mean.
Moreover, such case-control differences are more marked when medical controls, with
proven normal scans, are used (Smith & Iacono, 1986; Smith et al., 1988); suggesting the
possibility of Type I error. The findings that malnutrition (Heinz et al., 1977; Handler et
al., 1981), hypercortisolaemia (Heinz et al., 1977; Bentson et al., 1978) and alcoholism
(Carlen et al., 1978) can cause (reversible) ventriculomegaly suggest that psychiatric
treatment, institutionalisation or superimposed medical illness could play a part in the
process(es) determining ventricular enlargement. However, repeated findings that
treatment exposure and length of hospitalisation do not correlate strongly with the VBR
supports the validity of venticulomegaly in schizophrenia as compared the comparisons
with normal controls (e.g. Johnstone et al., 1976; Weinberger et al., 1979; Golden et al.,
1980; Nasrallah et al., 1983a; Luchins et al., 1984; Williams et al., 1985; Owens et al.,
1985; Pfefferbaum et al., 1988; Johnstone et al., 1989a; Coffman, 1989; Lewis, 1990).
Illness duration, however, has been associated with ventricular enlargement in quantitative
reviews of the literature (Raz & Raz, 1990; van Horn & McManus, 1992), suggesting that
there may be a progressive component or that ventriculomegaly may be a marker for poor
prognosis.
Stronger evidence that ventriculomegaly is not simply explained by clinical
confounders comes from repeated findings that ventricular enlargement is present at onset
in first episode cases (Weinberger et al., 1982; Schulz et al., 1983a; Turner et al., 1986).
Furthermore, most studies suggest that it does not appear to progress with time beyond
what would be expected with age (Nasrallah et al., 1986a; Illowsky et al., 1988; Vita et
al., 1988; Jaskiw et al., 1994), but some do suggest some progression (Woods et al.,
5
Chapter 1: Literature review
1990) and methodological considerations are important here. Woods et al. (1991) have
shown that a 1mm variation in slice positioning for estimation of the VBR can alter the
value by as much as 10%, making it particularly difficult to reliably measure changes over
time. Regression to the mean is another consideration, as illustrated by two studies where
patients with the smallest VBR show the greatest apparent progression, while those with
the largest ventricles actually show a reduction in size over time (Nasrallah et al., 1986a;
Kemali etal, 1989).
The lack of relationship to clinical measures, however, raises the possibility that an
increased VBR may only be an epiphenomenon of the pathophysiological process leading
to schizophrenia. It is therefore reassuring to note that some consistent associations have
been found with performance on cognitive testing and to a lesser extent with outcome or
treatment response. Indeed, cognitive impairment was significantly associated with
ventriculomegaly in the very first CT study in schizophrenia (Johnstone et al., 1976),
which was subsequently confirmed by the same authors in a further study (Johnstone et
al., 1978), and has been by almost all the other research groups that have examined the
relationship (Donnelly et al., 1980; Golden et al., 1980 & 1982, Kemali et al., 1985;
Owens et al., 1985; Johnstone et al., 1989). Some have reported that a certain level of
cognitive impairment can predict those schizophrenics with and without enlarged
ventricles (Donnelly et al., 1980; Golden et al., 1982), although Owens et al. (1985)
described a curvilinear (inverted-U) relationship.
Less consistently, clinical associations have also been reported between ventricular
enlargement and poor premorbid adjustment (Weinberger et al., 1980; Williams et al.,
1985; Pearlson et al., 1985); poor treatment response and/or global outcome (Delisi et al.,
1983; Smith et al., 1983 & 1985; Schulz et al., 1983b; Luchins et al., 1984; Williams et
al., 1985); and extrapyramidal side effects with neuroleptic treatment (Luchins et al.,
1983; Owens et al., 1985; Johnstone et al., 1989). However, it is noticeable that most
studies have failed to find significant associations between the VBR and (after Crow,
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1980) either more negative or less positive symptomatology (Nasrallah et al., 1983a;
Pearlson et al, 1984; Williams et al., 1985; Owens et al., 1985; Pfefferbaum et al., 1988;
Johnstone etal., 1989a; Kaiya etal, 1989; McCreadie et al., 1989; Pearlson et al., 1989).
Neat clinical associations, into sub-types of schizophrenia, are extremely unlikely given the
lack of a bimodal distribution of the VBR (Daniel et al., 1991b).
Following a suggested aetiological distinction between two syndromes in
schizophrenia (Crow, 1980), many workers tried to establish that patients with greater
ventriculomegaly would be those with a more environmental, and less genetic, type of
disorder. However, very few studies have reported a positive correlation between
obstetric complications and ventricular size (e.g. Turner et al., 1986; Pearlson et al.,
1989), and more have not (Pearlson et al., 1985; Nimgaonkar et al., 1988; Johnstone et
al., 1989a; Kaiya et al., 1989). Similarly, very few papers have described a significant
inverse correlation between family history and ventricular size (e.g. Turner et al., 1986),
most have reported no association (Kemali et al., 1985; Pearlson et al., 1985; Nimgaonkar
et al., 1988; Johnstone et al., 1989a; Pearlson et al., 1989; Kaiya et al., 1989), while
some even suggest a positive correlation (Nasrallah et al., 1983a; Owens et al., 1985;
Cannon et al., 1989). CT studies have therefore not elucidated the reasons for
ventriculomegaly in schizophrenia.
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1.1.3.2 Third Ventricle Enlargement
Although fewer studies have addressed the size of the third ventricle in
schizophrenics subjects and controls, the results are much as those described for the lateral
ventricles (Coffinan, 1989; Lewis, 1990). Indeed, the relationship may be stronger, as
schizophrenics more consistently show relative enlargement of this structure when
compared to medical controls (Boronow et al., 1985; Smith et al., 1988). In their meta¬
analysis, Raz & Raz (1990) concluded that the third ventricle was affected to a greater
extent than the lateral ventricle once the differences in measurement method (linear and
planimetric respectively) were taken into account. Interestingly, therefore, the duration of
illness has more often shown a relationship with third ventricle size than lateral ventricular
size (e.g. Rieder et al., 1983; Coffman, 1989) and shows a stronger overall association
(Raz & Raz, 1990).
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1.1.3.3 Widening of Cortical Sulci
Widened sulci are another manifestation of a lack of brain tissue ('atrophy').
Methodological issues are an even greater consideration here than in research on the
ventricular system as beam hardening is more pronounced and reliable measurement is
more difficult. Despite the many different techniques used to estimate sulcal width, the
majority of case-control studies report enlarged sulci in schizophrenic patients (Coffman,
1989; Lewis, 1990). Such 'atrophy' is noticeable in anything up to 40% of patient,
depending on definition (Lewis, 1990), although the overall effect size appears to be
smaller than for the ventriculomegaly (Raz & Raz, 1990). Clinical correlations are
generally weak or non-existent, but have often been found with indices of cognitive
dysfunction (Johnstone et ah, 1978; Weinberger et al., 1979; Nasrallah et al., 1983b;
Pfefferbaum et al., 1988; McCreadie et al., 1989; Raz & Raz, 1990). There are
suggestions that sulcal widening is most apparent in the frontal and temporal cortex, and
the Sylvian fissure in particular, but regional differences did not reach significance on
meta-analysis (Raz & Raz, 1990). Intriguingly, from an aetiological perspective, VBR and
atrophy ratings do not usually show a significant correlation (Weinberger et al., 1979;
Boronow et ah, 1985; McCreadie et al., 1989), and any relationship is at most weak
(Nasrallah et ah, 1983b; Vita et ah, 1988), suggesting that two or more distinct disease
processes may be operating in schizophrenia (Cannon et ah, 1989).
This highlights a potential problem in most CT studies of the clinical associations
of the VBR in schizophrenia. In using a ratio measure of ventriculomegaly corrected for
variations in brain size, researchers missed the possibility that ventricular enlargement and
atrophy could have differing associations. Unfortunately, the importance of this issue was
not recognised until late in the research effort (Pearlson et ah, 1989), since when some
workers have advocated that the effect of brain size on ventricular area should be
controlled for with multivariate statistical techniques (Harvey et ah, 1990a&b).
9
Chapter 1: Literature review
1.1.3.4 Other findings
Several CT studies have suggested that cerebellar atrophy may also be found in
groups of schizophrenic patients, with a median estimate of 10% as compared to 1% in
controls (Coffman, 1989), but posterior fossa structures are particularly prone to artefact
on CT. A number of macroscopic abnormalities (e.g. tumours, cysts, vascular
malformations) are also occasionally found in patients with schizophrenia - with a
prevalence of approximately 6-9% - but these are generally over-represented among
psychiatric populations, appear mainly developmental and rarely change medical
management (Owens et al., 1980; Lewis, 1990). Another possible abnormality of interest
is an apparent reversal of the normal brain asymmetry, where schizophrenics do not show
the usual picture of relatively larger right frontal and left occipital lobes ("brain torque") or
a longer length of the right hemisphere; but less than half the studies examining this issue
have reported it, and uncorrected tilting of the head in the scanning machine could account
for the apparent deficit (Coffman, 1989; Zipursky et al., 1990).
One of the key tests of the significance of such CT abnormalities is whether or not
they are found in other psychiatric patients. It is sobering to note that all of the above CT
findings reported in schizophrenic populations have also been reported in patients with
affective disorders (e.g. Rieder et al., 1983; Pearlson et al., 1984), albeit to a lesser extent
(e.g. Pearlson et al., 1989), and that the pattern of their clinical associations is very
similar, though less well established due to the smaller number of studies (Coffman, 1989).
Of interest, however, is the repeated finding that the VBR in affective disorders is
generally larger in those with positive psychotic symptoms (and hypercortisolism) as
opposed to the putative association with negative symptoms in schizophrenia (Coffman,
1989; Lewis, 1990). However, this could simply be a marker of severity, where a
neurodevelopmental model is pertinent to the affective disorders and schizophrenia;
although it should be borne in mind that patients with affective disorders who are scanned
are likely to be inpatients and may be less typical than scanned schizophrenic subjects.
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1.1.4 CONCLUSIONS FROM CT STUDIES IN SCHIZOPHRENIA
The best available evidence supports the view that patients with schizophrenia
have enlarged ventricular structures, perhaps particularly the third ventricle, and to a lesser
extent enlarged cortical sulci, in comparison with groups of normal controls. These
abnormalities are undoubtedly present at the onset of the illness, the possibility remains of
a greater progression than that associated with age alone. This supports the view that
brain abnormalities are found in schizophrenia and that they primarily reflect a
neurodevelopmental aberration, but a neurodegenerative component cannot be excluded.
The lack of consistent clinical associations - other than with cognitive impairment - is
disappointing, but this can be partly explained by the relatively small sample size in many
of these studies. More importantly, such longstanding abnormalities are likely to be trait
rather than state markers, although the failure to find consistent clinical associations of
ventriculomegaly could also be attributable to confounding comparisons between
ventricular and brain areas. However, the lack of a bimodal distribution of ventricular size
argues against any distinctive sub-group of schizophrenic patients with brain
abnormalities; rather, they should be seen as risk factors for the development of
schizophrenia (and possibly all psychosis) that are neither necessary nor sufficient.
The considerable methodological problems associated with CT - being restricted to
the axial plane and linear or area measures rather than volumes, exposing patients to x-
rays, and difficulties viewing the posterior fossa or peripheral structures with any reliability
- all suggest that this technique is now of little research value in comparison with
structural magnetic resonance imaging. MRI not only has technical advantages over CT -
of improved resolution, multiplanar three dimensional image acquisition (for volume
estimation), enhanced soft tissue contrast, and visualisation of temporal or posterior
structures without bone artefact - but it also does not expose patients to the potentially
harmful effects of radiation.
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1.2 MAGNETIC RESONANCE IMAGING CMHI)
The observation that the structure of a tissue could be inferred from studying the
changes when a magnetic field was applied to atomic nuclei was made by both Bloch and
Purcell in 1946, for which they shared the Nobel prize for physics in 1952 (Andreasen,
1989). This principle was later developed so that visual images could be developed from
the properties of small units of a tissue (Lauterbur, 1973). With technological advances,
leading to the availability of the requisite hardware - of both static and gradient magnets, a
radio frequency transmitter and receiver, and a computer for data analysis - clinical
applications were soon realised (Budinger & Lauterbur, 1984).
The physical basis of the MRI signal is complex and still incompletely understood
(Schild, 1990). When a head is placed in the scanner, the protons ofwater molecules align
themselves in the longitudinal orientation of the external magnetic field, either parallel
(low energy protons) or anti-parallel (high energy protons), and precess with a rate
proportional to the strength of the field. (According to the Larmor equation, the
precession frequency is the product of the gyro-magnetic ratio, which is a constant of 42.5
MHz/Tesla for protons, and the field strength in Tesla). The magnetic vectors of proton
precession cancel, but there remains some longitudinal magnetisation (LM) of the patients'
own magnetic field.
To measure the patients' magnetic field, some transverse magnetisation (TM) is
induced by emitting a radio frequency (RF) pulse to synchronise proton precession. The
RF pulse must be of the same frequency as the protons so that energy can be exchanged -
a phenomenon called resonance. Some protons are lifted to higher energy levels, aligning
themselves anti-parallel longitudinally and so reducing LM. The TM changes with the
precession frequency of the protons, inducing an electrical current that can be traced
anatomically as it is most strong where the magnetic field is strongest and is altered by the
proton composition of neighbouring tissues. When the RF pulse is switched off the LM
increases and the protons' energy is returned to the surrounding structural lattice (spin-
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lattice-relaxation) over time (Tl). Simultaneously, the TM is reduced as protons lose their
coherence (spin-spin-relaxation) over time (T2). The Tl time constant (300-2000ms) is
about lOx longer than the T2 time constant (30-150ms) - in practice, Tl is defined as the
time until about 63% of the original LM signal intensity is attained, and T2 as the time
until about 37% of the original TM value is returned.
Different tissues have varying relaxation values as they contain differing amounts
of hydrogen protons. Tissues with a high water content have both a long Tl and T2 as
the transfer of proton energy is difficult at the high frequency precession of water
molecules. Fatty tissues have short Tl and T2 values as carbon bonds have frequencies
near the Larmor frequency allowing effective energy transfer. The white matter of the
brain therefore has a shorter T2 than grey matter. Thus, tissue characteristics and the
frequency and timing of RF pulses (in different 'pulse sequences') determine the image
derived. Differing pulse sequences have been developed for particular imaging tasks, but
the most pertinent to psychiatry are spin-echo and fast imaging sequences.
In a spin echo (SE) sequence, a 180° RF pulse is emitted a certain length of time
(tau) after the initial 90° RF pulse (which cancels LM and induces TM), so that protons
begin to precess in the opposite direction and faster protons catch up with (previously
'behind') slower protons until they return to phase. A stronger signal will then be
generated at the measurement time (2.tau) or time to echo (TE). Further 180° pulses can
be repeated after time for complete relaxation (TR). The TE must be long enough to
allow tissue contrast, but not so long as to result in low signal to noise - in practice, TE is
short if less than 30ms, and long if greater than 80ms. With a SE sequence of long TR
and short TE the resultant image is largely free of Tl and T2 effects and determined by
proton or spin density (CSF is seen as black, grey matter as white due to higher proton
density, and white matter as grey). With a long TE (and long TR) the image is T2
weighted (CSF white, brain as black), while with a short TR (and short TE) the image will
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be T1 weighted (CSF black, grey matter grey and white matter white). These sequences
generate distinctive images that are useful for identifying brain lesions.
Fast imaging sequences, such Fast Low Angle Shot (FLASH) or Gradient Recalled
Acquisition at Steady State (GRASS), shorten the TR and therefore the total imaging time
by inducing an additional magnetic field gradient to produce greater field inhomogeneities
so that protons dephase faster (according to the T2* curve). Low flip angles, of less than
90° (usually 10°-35°), prevent LM being abolished. If the gradient is switched off and
then on again in the opposite direction, a rephasing "gradient echo" is produced. The
main problem with fast sequences is that intense flow signals are observed.
The acquisition time is the product of the TR, the number of excitations, and the
number of rows in the image matrix (usually 256 rows of 256 picture elements or pixels)
and can be shortened by imaging multiple slices simultaneously. Particular orientations are
examined by varying the gradient field strength (and therefore precession frequency)
produced by the gradient coils; while slice thickness is determined by the slope of the
gradient field so that the RF pulse excites only those protons in a location with a particular
precession frequency. The anatomical position of the signals emitted is determined by
applying gradient fields along the y-axis rows (during RF) and y-axis columns (switched
on and off after the RF), so that frequency and phase of particular protons differs slightly
according to their location. By Fourier (fast) transformation, the computer assigns
location, amplitude, frequency and time to the signals and reconstructs the image. The
visual images are produced by automatically assigning shades of white/grey/black to the
strength of the signal from relaxing protons detected by the radiofrequency receiver.
These signals are subdivided as cubes or voxels (volume elements) of signal corresponding
to tissue types, and therefore as shades of grey for integration into picture elements.
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1.2.2 METHODOLOGICAL PROBLEMS AND ARTEFACTS IN MRI STUDIES
MRI image acquisition is complex and the final result is dependent on many
variables. Small differences in hardware, such as varying field strength, and scanning
sequence parameters can have substantial effects on the data collected, making it difficult
to reliably conduct multi-centre studies. Visual inspection can identify any lack of
standardisation in scan quality, and detect lesions or motion artefact, but the necessary
quantitative image analysis is sensitive to a number of potential biases.
Scanner reproducibility should ideally be ensured by establishing the test-retest
reliability in the same subjects across time, which has only very recently been reported for
the first time (Giedd et al., 1995), but sufficient reliability is likely if scans of a phantom
test object are repeated over the duration of a study to allow correction for any signal
drift. A standardised head position in the magnetic coil is important to ensure similar
signal intensities from the same brain regions in different subjects. Inevitable coil
inhomogeneities, which can themselves selectively affect particular regions unless
corrected for with a phantom, will otherwise be exaggerated. Head tilt can also cause
substantial problems in comparing volumes between cerebral hemispheres either within or
between subjects. Tracing regions according to internal anatomical landmarks, if reliable,
reduces this problem - as long as all of a structure is examined. If only a set number of
slices containing a region are examined, however, tilt correction is essential to avoid
omitting the anterior or posterior parts of a structure on one or other side. Partial volume
effects are lesser with MRI than CT due to enhanced resolution, but remain a problem
where slice thickness exceeds that of the anatomical structure of interest and can also be
more pronounced in particular regions if viewed in certain orientations e.g. the ventricular
system in transverse rather than coronal section. All of these effects can exceed the
inevitable measurement error, particularly in smaller regions (Plante & Turkstra, 1991).
Owing to the time consuming nature of MRI area or volume estimations, even
with semi-automated techniques, more than one rater is usually required (and desirable if
15
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reliable volume measurements are to be established) necessitating the calculation of inter-
rater reliabilities or mean differences between raters (Bland & Altman, 1986) for the
regions examined. Volumetric analyses of anatomical regions are more reliable than linear
or area methods, which are inherently unsatisfactory as one or two dimensional measures
of complex structures but are also prone to difficulties in ensuring that exactly the same
part of the brain is examined in different subjects. Contiguous slices are also preferable to
non-contiguous slices for the same reasons. However, even with automatic edge
detection programmes and three dimensional images, structure boundaries can be difficult
to identify, particularly in complicated structures such as the ventricles.
Inevitably, the earliest MRI studies in schizophrenia reported areas rather than
volumes. Moreover, researchers seem to have developed a preoccupation with the size of
corpus callosum, perhaps partly because it was so prominent and easily measured on mid-
sagital MRI localisers. This early MRI literature will therefore be quickly reviewed, after
a brief discussion of studies examining the qualitative appearance of the brain and signal
intensity values, before a systematic and detailed consideration of all the published
volumetric MRI reports in schizophrenia up to and including June 1996.
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1.2.3 MRI STUDIES IN PATIENTSWITH SCHIZOPHRENIA
1,2.3.1 Qualitative MR1 appearances
The most obvious advantage ofMRJ over CT is that of enhanced resolution and
greater anatomical detail. As well as improving gross lesion detection, this allows
assessment of certain 'qualitative' abnormalities that cannot be easily quantified - such as
the degree of cortical atrophy or numbers and types of high intensity signal (HIS) lesions.
Indeed, it has been suggested that "visual inspection is as good a measure of cortical
atrophy as any, if objectivity is increased by using atrophy rating scales, as no quantitative
measure of this is currently in routine use" (Andreasen, 1989). There are, however, few
qualitative MRI studies available and they give cortical atrophy rates that vary between 4-
40% depending on definition, although these are substantially higher than control rates of
4-7% (Waddington et al., 1990; Harvey et al., 1993; Lewine et al., 1995). The rates of
HIS lesions have been reported as 5-22% in patients and 3-19% in controls (Waddington
et al., 1990; Harvey et al., 1993; Lewine et al., 1995), with no significant increase in
schizophrenia (Johnstone et al., 1986; Harvey et al., 1993) and similar numbers in other
psychiatric populations (Lewine et al., 1995), although they may be of a greater extent or
volume in patients with schizophrenia than in normal controls (Jernigan et al., 1991).
The most valuable information gained from qualitative MRI scan analysis in
schizophrenia research thus far is from studies of the amount and types of gross lesions.
Although findings of cerebellar hypoplasia and agenesis of the corpus callosum are rare,
with a frequency of only 0-4% (Waddington et al., 1990; Lewine et al., 1995), there have
been a number of reports of cavum septum pellucidum in schizophrenia being more
common than in psychiatric or normal control subjects (e.g. 25% compared to 10%, Juijus
et al., 1993). Such reports indicate that abnormal midline structures, including the
cerebellum (Martin & Albers, 1995), are disturbed as part of the putative
neurodevelopmental aberration in schizophrenia, although their precise aetiological
significance is uncertain.
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1.2.3.2 QuantitativeMRI signal parameters
Some early research reported signal intensity values and relaxation times in
patients with schizophrenia and controls. Smith et al. (1987b) reported increased signal
intensities for grey and white matter, especially in left anterior regions, but these results
have not been replicated (Johnstone et al., 1986; Kelsoe et al., 1988). Besson et al.,
(1987) examined spin-lattice (Tl) relaxation times in 23 patients and found no differences
with controls but did find that increased Tl in frontal, temporal and basal ganglia regions
was associated with negative, positive and dyskinetic symptoms respectively. However,
these results have also not been directly replicated (Andreasen et al., 1991; Harvey et al.,
1991; Buckley et al., 1995), although associations have been reported between prolonged
T2 in frontal regions and negative symptoms (Williamson et al., 1991). Quite apart from
these inconsistencies, which could be attributed to technical problems such as radio-
frequency pulse imperfections, magnetic field inhomogeneities and the need for multiple
collections, there is no clear understanding of what changes in Tl or T2 represent
pathologically. Relaxation values reflect the concentrations of all the substances in a
region of interest and may therefore be affected by a variety ofmedications (Karlik, 1986).
Although specific evidence for similar drug effects are still awaited for psychotropics in
the human brain, lithium has been shown to reduce Tl values in bipolar patients (Rangel-
Guerra et al., 1982; Rosenthal et al., 1986). Much more information, and a clearer idea
of its' meaning, is available from studies of changes in the area or volume of specific brain
regions in schizophrenia.
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1.2.3.3 Area studies
The first MRI studies in schizophrenia were conducted on small samples and
examined areas in machines with very low field strength (0.15-0.5T). Given the
unreliability of slice positioning, it is not surprising that the results were inconsistent.
Smith et ah. (1987b) failed to find significant differences between patients and controls in
the VBR, third ventricle and sulcal width, or the corpus callosum to brain ratio. Matthew
and colleagues did not identify abnormalities in posterior fossa structures (cerebellar
vermis and fourth ventricle), nor cerebral or corpus callosum areas, but did report
increased rates of septum pellucidum and corpus callosal lengths (Matthew et al., 1985).
Although workers in Iowa (Nasrallah et al., 1986b) found increased callosal area, but not
length, their relatively large sample made this an influential paper. Subsequent studies
have occasionally reported increased (Uematsu & Kaiya, 1988a) or decreased (Rossi et
ah, 1989; Woodruff et al, 1993) indices of the corpus callosum, but the most consistent
findings have been of no significant case-control differences (e.g. Kelsoe et al., 1988;
Raine et al., 1990) and a recent meta-analysis found no significant reduction in callosal
area or length relative to brain area (Woodruff et al., 1995). Moreover, methodological
problems plague such comparisons (Coppola et al., 1995).
Another report in 1986 from the Iowa group (Andreason et ah, 1986) also had a
great impact, but mainly because findings of reduced frontal, cerebral and cranial areas in
schizophrenia were later attributed to educational and economic advantages in the original
hospital staff controls and thereby demonstrated the importance of matching for such
variables (Andreasen et ah, 1990). This reinforced the findings ofDeMyer et ah (1988),
who reported reductions in the areas of the right hemisphere as well as left and right
frontal cortex, of which only the left frontal area remained significant after controlling for
educational level. These studies, together with post-mortem findings (e.g. Bogerts et ah,
1985; Brown et ah, 1986), also established a greater interest in those parts of the brain
that could be considered likely to be involved in schizophrenia, such as frontal and
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temporo-limbic structures. Subsequent studies examining such areas of a priori interest
have reported statistically significant smaller temporal lobes (DeLisi et al., 1988),
particularly on the left (Rossi et ciL, 1991), or with an abnormal pattern of left-right
asymmetries (Johnstone et al., 1989b; Young et al., 1991); an increased VBR (Andreasen
et al., 1990) or third ventricle area (Kelsoe et al., 1988); reductions in bilateral (Raine et
al., 1992) or left frontal area (DeMyer et al., 1988); as well as reports of smaller thalamic
nuclei (Buchsbaum et al., 1996). Some studies have found such abnormalities, of the
thalamus (Andreasen et al., 1990) or temporal horns (Johnstone et al.., 1989), to be
limited to male patients with schizophrenia.
It should be noted however that almost an equally large number of individual
reports have not found significant differences in the areas of the temporal lobes (Johnstone
etal., 1989; Young et al., 1991; Colombo et al., 1993); the lateral ventricles (Johnstone et
al., 1989; Colombo et al., 1993); the frontal lobes (Andreasen et al.., 1990; Schwarzkopf
et al., 1991; Young et al., 1991); the parietal and occipital lobes (Andreasen et al., 1990),
cingulate gyrus (Andreasen et al., 1990; Young et al., 1991); total cerebral or cranial area
(Uematsu & Kaiya, 1988b; Andreasen et al., 1990; Schwarzkopf et al., 1991; Aylward et
al., 1994); and measures of posterior fossa structures such as the cerebellum and fourth
ventricle (Mathew et al., 1985; Nasrallah et al., 1986; Uematsu & Kaiya, 1988b;
Andreasen et al., 1990; Aylward et al., 1994). Although these studies do usually find that
the structures of interest are smaller in patients with schizophrenia than controls, a reliable
quantitative review of these studies - to allow for any Type II error - is not feasible given
the varying methods used to identify the areas examined. As already discussed, volumetric
studies are more methodologically reliable and comparable, permitting a more reliable
quantitative comparison.
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1.2.3.4 Volumetric studies
The first MRI study in schizophrenia to include information on structure volumes
was published as recently as 1988 by Kelsoe and colleagues at the National Institute for
Mental Health in Washington DC (NIMH). They reported a bilateral increase in lateral
ventricular volumes of approximately 10ml (62%) that was most marked on the left and
posteriorly - at the level of the anterior thalamus; but no significant reductions in the
volumes of pre-callosal frontal lobes, temporal lobes, the amygdala-hippocampal complex
or cerebral hemispheres. The NIMH group followed this study with a comparison
between age and sex matched patients and controls. Temporal lobe volumes were
reduced in the schizophrenics by about 15%, with the differences being most apparent in
left (21%) and right (18%) grey matter, and particularly the central region containing the
amygdala and hippocampus (23%, 20%), while the lateral ventricular volume was
substantially (67%) larger (Suddath et al., 1989). In another careful study, these workers
provided more evidence for some regional specificity and causes of the brain disturbances
in schizophrenia with a comparison between discordant monozygotic twins (Suddath et
al, 1990). The affected twins had significantly larger lateral and third ventricles, as well
as left and right hippocampi (but not the anterior temporal lobes), such that they could be
identified in almost all cases with the naked eye. This result reveals the extent to which
many genetic and environmental effects and their interactions determine neural
development, and may confound simple case-control comparisons unless some attempt is
made to control for them.
Table 1.1 (pp. 23-24) describes these and subsequent MRI case-control studies
which have measured the entire volume of at least one of the regions they have examined,
although many have included some area measurements and/or inadequate coverage of
structures of interest (see below). Table 1.1 also includes the matched case-control
characteristics in each study for reference to the other tables. Table 1.2 (p.25) lists those
studies that have distinguished grey from white matter in the whole brain, pre-ffontal and
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temporal lobes. Table 1.3 (p.31) details reports giving results for the volume of the pre¬
frontal and/or temporal lobes and/or smaller components of the mesial temporal lobe;
while Table 1.4 (p.38) describes studies of the superior temporal gyrus. In each case, the
tables list the numbers of subjects and the percentage differences (rounded to the nearest
0.5% if less than 10% and to the nearest 1% thereafter) between patients and controls in
each region for which raw uncorrected volumes are given in the original paper, together
with whether these were reported as statistically significant or not. All the figures given
refer to patients diagnosed with schizophrenia according to DSM-III or DSM-IIIR
criteria.
In addition to considering the varying methods and results of these studies with a
traditional 'narrative' review, a quantitative comparison has been made by deriving the
median of the percentage differences for each region of interest across methodologically
comparable studies (where at least two employed similar methods). Table 1.5 (p.44)
shows these median differences across all relevant volumetric studies for each region of
interest, according to side and sex where available. In many cases, the largest number of
results are given for male patients versus controls, as many studies have only examined
such patients as a means of controlling for sex. Studies are included in these median
calculations if they measured the entire volume of the structure with the conventional
method of isolating the region on single slices - adding these 'areas' together to generate
volumes ('serial slice counting'). The reasons for excluding particular studies are given in
the text.
For ease of comprehension, this literature review will now discuss all the MRJ
studies examining particular regions, starting with the cranium and whole brain, followed
by the cerebro-spinal fluid (CSF) and ventricular system, and then specific lobar
structures.
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Table 1.1 - Percenta£e differences in cranial, cerebral, CSF and ventricular volumes
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a (T -2) - - (T +34*) (T +55*)
Key: N number of, m/fmale/female, Pts patients and Cls controls; match(ed) for: a - age, s
- sex, h - handedness, e - educational level, r - race, p - paternal occupation or social class;
T total, L left, R right; * reported as statistically significant difference in original paper
('x') figures in brackets not included in median calculations due to methodological
differences (see text for further details).
Note: A further 9 volumetric MR! studies (to the 29 in Table 1.1) are in the literature.
However, these are excluded due to: incomplete temporal 'volumes' (Rossi, 1991);
different scan sequences in cases/controls (Shenton, 1991); same cerebral volume data
(Noga, 1994; Menon, 1995) as a previous study (Barta, 1990); or are described in Tables
1.2 (Wible, 1995), or 1.3 (Becker, 1990; Swayze, 1992; Bogerts, 1993; Turetsky, 1995),
or 1.4 (Menon, 1995) - see text for further details. Figures quoted for DeLisi, 1991 refer
only to chronic cases as several first onset were later described as schizo-affective.
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Table 1.2 - Segmentation studies of percentage differences in regional grey and



































































































Key: N number of, m/fmale/female, Pts patients and Cls controls; match(ed) for: a - age, s
- sex, h - handedness, e - educational level, r - race, p - paternal occupation or social class;
T total, L left, R right; * reported as statistically significant difference in original paper
('x') figures in brackets do not include the whole volume of the structure (see text for
further details).
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(i> The intracranial and whole brain volumes
Most of the eight studies examining the volume of the cranial vault in
schizophrenics and controls have reported non-significant differences, and three studies
have actually identified a small increase in the size of the cranium in males (Shenton et al.,
1991 & 1992; Zipursky et al., 1994). Nonetheless, the single largest sample (Flaum et al.,
1995), the two studies that report statistically significant differences (Jernigan et al., 1991;
Gur et al., 1994), and the two that have given values for men and women individually
(Harvey et al., 1993; Flaum et al., 1995) all suggest the cranium is smaller in patients with
schizophrenia, at least in women. This possible sex difference is shown in the median
values from the two studies of the entire cranial vault in both sexes, as shown in Table 1.5
(p.44), where (excluding the Harvey, Zipursky, Flaum and Lim studies which did not
cover the whole structure, as well as the 1991 Shenton study which used different scan
sequence in cases and controls) the median difference is -2.5% for schizophrenics overall,
but +4% for men in the single comparable study (Shenton et al., 1992).
The figures for the volume of the whole brain and the cerebral hemispheres are
more consistent. Seventeen independent studies report volume reductions, including first
episode cases (DeLisi et al., 1991; Nopoulos et al., 1995), with only one exception
(Shenton et al., 1991), although these were only significant in three relatively large series
(Zipursky et al., 1992; Andreasen et al., 1994; Gur et al., 1994) and one further study
which only included the anterior portion of the brain (Dauphinais et al., 1990). Small
reductions have also been found with segmentation (Gur et al., 1991), or automated
methods (Andreasen et al., 1994a; Nopoulos et al., 1995). The median figures from slice
counting studies show a reduction of 3.25% in the whole brain volume in both sexes (six
studies), and of 4% in men and 3.25% in women individually, with similar reductions in
the left and right hemispheres in men (see Table 1.5) - with similar results in studies which
excluded inferior (Flaum) or posterior (Harvey) portions. This deficit appears to be
largely a loss ofgrey matter (median 4.5%), as white matter may be increased (Table 1.2).
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(ii) Cerebro-Spinal Fluid (CSF)
Such a loss of whole brain volume, with a lesser reduction or even an increase in
the cranial volume, suggests that the amount of CSF will be increased in schizophrenia
although relatively few (eight) studies have examined this issue. Four studies have
reported significant increases in men (Jernigan el al., 1991; Harvey et cil., 1993), both men
and women (Andreasen et al., 1994a) and in first episode cases (Nopoulos et al., 1995).
Gur et al. (1991) reported small reductions in CSF in women, with 16-17% increases in
men and a significant increase in sulcal CSF: brain ratio in men. However, they found that
the whole brain reduction equalled that of the cranium in a later study (Gur et al., 1994);
while the small studies of men from Harvard have reported an atypical picture of larger
craniums and smaller amounts of subarachnoidal CSF (Shenton et al., 1991 & 1992).
Taken together, the median value for total CSF is of a 10% increase overall (two studies),
with only one slice counting study giving results for men (Shenton et al., 1992) and none
for women. The automated studies, however, report larger increases and particularly in
men (Gur et al., 1991; Andreasen et al., 1994a; Nopoulos et al., 1995), as do Harvey et
al. (1993).
There is very limited information available about any regional variation in the
putative increase in CSF volumes, but Harvey and co-workers (1993) also examined the
Sylvian fissures and did find significant differences in both sexes and on both sides - with
particular increases on the left in men (48%/37%) and on the right in women (34%/45%).
Andreason et al. (1994a) used an automated method to establish regional CSF volumes
and found that the increase was most marked in ffonto-temporal regions, as did Lim et al.
(1996), while another study found significantly increased temporal but not frontal CSF
(Turetsky et al., 1995). One qualitative MRI study used the protocol established by the
Consortium for Alzheimer's Disease and found that general atrophy ratings for both the
Sylvian fissures were significantly increased in schizophrenia, with non-significantly
increased atrophy in temporal lobe and superficial cerebral sulci (Schwartz et al., 1992).
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(iii) The ventricular system
Following on from the CT findings, the ventricular system has been examined in
more MRI studies than any other region and there can be little doubt that there is a
dramatic increase in the volume of the ventricles in schizophrenia. Four groups have
reported increased volumes of the entire ventricular system with various methods
(Jernigan et al., 1991; Andreasen et al., 1994a; Gur et al., 1994; Nopoulos et al., 1995).
Taking the lateral ventricles alone, all thirteen studies to date has found significant volume
increases - with only one exception (Shenton et al., 1991). The pattern of these
differences varies amongst studies, with some reporting significance on only the left side
(Kelsoe et al., 1988; Shenton et al., 1992), or in women (Flaum et al.., 1995), but most
studies reporting no significant sex or laterality differences (e.g. O'Callaghan et al., 1992).
Excluding those that did not cover all the ventricles posteriorly (Andreasen et al., 1990;
Dauphinais et al., 1990; Harvey et al., 1993; Lim et al., 1996), the overall median
ventricular volume increase is by 64% in total, and by 44% on the left and 36% on the
right (see Table 1.5 on p.44). The only study to examine sex differences in the entire
structure has found that the changes are minimal in men and much greater in women
(Flaum et al., 1995). This result, from the largest MJRI study in schizophrenia to date,
challenges earlier results suggesting greater changes in men (Andreasen et al., 1990;
Harvey et al., 1993). However, in the three studies giving figures for men alone, the
median total increase is of 31% (Shenton et al., 1992; Zipursky et al., 1992; Flaum et al.,
1995), as compared to 24% in a single study ofwomen (Flaum et al., 1995).
Several groups have also reported data on sub-divisions of the lateral ventricles.
Some have found the frontal horns to be most enlarged (Andreasen et al., 1990), others
the temporal horns (Kawasaki etal., 1993), or even the occipital horns (Vita et al., 1995).
However, the largest differences are for the body of the lateral ventricles where every
results has been statistically significant (40% on the left, and 33% on the right, Degreef et
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al., 1992; 50/75%, Kawasaki et al., 1993; 58/68%, Zipursky et al., 1994; 59/61% Vita et
al., 1995 - medians, from two studies each, of 50/47% overall and 54/72% in men).
Seven studies have reported measures of the temporal horn volume, with four
reporting statistically significant increases of as much as 200% on the left and 74% on the
right in men alone (12/11%, Becker et al., 1990; 180/74%, Shenton et al., 1992;
200/50%, Kawasaki et al., 1993) or in both sexes (21/13%, Degreef et al., 1992), with
three studies finding non-significant differences (18/14%, DeLisi et al., 1991; 55/65%,
Zipursky et al., 1994; 2/-l%, Vita et al., 1995). Thus, the median increase is of 18% on
the left and 13% on the right side in the three studies to examine both sexes together
(Degreef, DeLisi, Vita). In the four studies examining the sexes individually, Bogerts et
al.. (1990) found general increases, but these were only significant for the left side in
women (15/10% male, 32/9% female); Dauphinais et al. (1990) reported small increases
that were most marked on the left in women and the right in men (-7.5/10% men, 10/5%
women); while Flaum et al. (1995) found smaller increases in men on both sides (3/2.5%
and 17/11% respectively). Only one study has reported increases that were greatest in
men, but there was no diagnosis-side interaction and no specific figures for the sexes were
given (Degreef et al., 1992). Thus, the evidence (medians of 15/11% increases in men and
17/11% in women) does not strongly support the often reported impression of greater
abnormalities in men although the increases do appear larger on the left side in both cases.
Four studies give figures for the frontal horns of the lateral ventricle (+15% left,
+2.5% right, Delisi et al., 1991; 35/24%, Degreef et al., 1992; 22/23% in men, Kawasaki
et al., 1993; -8.5/+2%, Vita et al., 1995). Again, overall enlargement is evident (median
left 15%, right 2.5%), with some suggestion of leftward laterality (see Table 1.5). Similar
conclusions can be drawn from the three studies reporting on the volume of the occipital
horns (30/14%, Degreefetal., 1992; 24/35%, Kawasaki et al., 1993; 32/41%, Vita et al.,
1995).
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The final component of the ventricular system to receive concentrated attention
has been the third ventricle (see Table 1.1). Eleven volumetric studies have been
conducted, five ofwhich reported significant increases (Degreef et al., 1992; Marsh et al.,
1994; Flaum et al., 1995) although two of these did not cover the full length (Rossi et al.,
1994) or depth of the structure (Lim et al., 1996). The median increases are of 19%
overall, and more so in men (21%) than women (5%). One study reported a small
reduction in the volume of third and fourth ventricles combined (Shenton et al., 1991),
while two studies have found a small increase (8%, Degreef et al., 1992) or decrease
(12%, Shenton et al, 1992) of the fourth ventricle itself.
In summary, there is convincing evidence that the volume of the lateral ventricle,
and to a lesser extent the third ventricle, is substantially increased in schizophrenia, with
the body of the lateral ventricle enlarged by about 50%. The temporal, frontal and
occipital horns are also increased, by about 15%, 15% and 30% respectively, with a
possible leftward laterality. However, there is less certainty that these figures can be
reliably compared as few reports explicitly reported that they examined the whole volume
of these sub-divisions or gave their anatomical boundaries as the ventricles have
"naturalistic boundaries'. Finally, there is some evidence for the presence of greater
abnormalities in male patients, but as with much of the brain imaging literature in
schizophrenia relatively few female patients have been scanned. This review will now turn
to putative abnormalities in particular brain regions, starting with the frontal lobes.
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(iv) Frontal lobes
The increased resolution of MRI has allowed researchers to examine the
suggestions from CT studies that the frontal lobes are reduced in size. Most of the ten
MRI studies have employed a serial slice counting technique from the frontal pole to the
genu of the corpus callosum, although others have used the optic chiasm as the posterior
boundary (DeLisi et ah, 1991) and some have used alternative methods. The Iowa group
have allocated pixels to lobes and automatically derived volumes thereafter (Andreasen et
al., 1994a; Nopoulos et al., 1995), while workers in Philadelphia first isolate the frontal
(and temporal) lobes on axial slices (Turetsky et ah, 1995). Although only three studies
have described significant reductions of the whole pre-frontal lobe volume (Breier et ah,
1992; Andreasen et ah, 1994a; Nopoulos et ah, 1995), the median reductions over five
comparable studies in both sexes are of 3.5% and 1.5% in the left and right hemispheres
respectively. Although the differences may be of about 8% in males (Kawasaki et ah,
1993; Bilder et ah, 1994), the overall figures are no greater than those for the whole brain
- contrary to the early findings of the Iowa group (Andreasen et ah, 1994a; Nopoulos et
ah, 1995). Three studies in total have segmented the pre-frontal lobe into grey and white
matter and suggest that the volume deficit is largely attributable to the former (see Table
1.2). Wible et ah (1995) examined only male subjects and found reductions of about 3% in
grey matter, with smaller increases in white matter, that were greater (up to 7%) after
correcting for intracranial volume.
Thus, although some researchers have found that volume deficits in the pre¬
frontal lobes are greater than those in the whole brain, the balance of the evidence does
not support this view - except, possibly, in men. Similarly, some authors have reported
that the frontal lobe deficit is greater than or equal to temporal lobe reductions (Kawasaki
et ah, 1993; Andreasen et ah, 1994a; Flaum et ah, 1995; Nopoulos et ah, 1995; Turetsky
et ah, 1995; Vita et ah, 1995), but the MRI studies of the temporal lobes and constituent
parts provide the strongest evidence for abnormalities of brain structure in schizophrenia.
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(v) Temporal Lobes
A total of sixteen studies have examined the volume of temporal lobe itself and
the vast majority have matched for at least age and sex. The structure has been taken as
stretching from the temporal pole back approximately 60mm to the colliculi (Kelsoe et al.,
1988; Vita et al., 1995) or the auditory canal (DeLisi et al., 1991); 70mm to the last slice
containing the Sylvian fissure (Suddath et al., 1989; Harvey et al., 1993; Flaum et al.,
1995) or to where the fornix forms the medial wall of the lateral ventricle (Bogerts et al.,
1990) or to the splenium (Bilder et al., 1994); and even 80mm until the appearance of the
posterior horn of the lateral ventricle (Kawasaki et al., 1993) - measurements taken from
Duvernoy (1991). Although Zipursky et al. (1994) used the latter posterior definition,
neither they nor Becker et al. (1990) included the poles. Other methods have been used
as described for the frontal lobes (Andreasen et al., 1994a; Nopoulos et al., 1995,
Turetsky et al., 1995). Some researchers have simply allocated a certain number of slices
to be measured, but only one has included sufficient slices to cover a comparable amount
of the structure (50-60mm, Swayze et al.., 1992). Not included in Table 1.3, or the
median calculations, are two studies which used an insufficient number of slices to cover
the structure - both of which found significant differences, of 7-11%, in nine 3mm thick
slices (Barta et al., 1990), or three 10mm slices (Dauphinais et al., 1990).
Despite these varying methods some consensus has been achieved, although only a
minority of studies have shown statistically significant differences (Bogerts et al., 1990;
Andreasen et al., 1994a; Nopoulos et al., 1995). Early studies reported non-significant
reductions of 10-15% (Kelsoe et al., 1988; Suddath et al., 1989; DeLisi et al., 1991),
which have been confirmed in first episode cases (Bogerts et al., 1990) and do not appear
to progress (DeLisi et al., 1992). The median reduction across the five slice counting
studies reporting in both sexes is of 6% on the left and 9.5% on the right, without any
apparent difference according to posterior boundary (see Tables 1.3 and 1.5). For the
sexes individually, however, the median reductions are in the order of 2-3% which is
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similar to the figures from automated methods and no greater than that for the whole
brain; although fewer studies are included in this estimate and it is therefore less reliable.
There are again suggestions from segmentation studies that these volume
reductions are attributable to grey matter loss (Suddath et al., 1989; Zipursky et al.,
1994). Jernigan et al. (1991) reported a reduced 'inferior-anterior' cortical volume, which
included mesial temporal and orbitofrontal regions, that was most apparent in men, while
Lim et al. (1996) found grey matter deficits in frontal, temporal and parietal regions that
were most marked fronto-temporally. However, one study reported reductions in both
grey and white matter (Harvey et al., 1993), and Schlaepfer et al. (1994) examined
heteromodal association cortex and found significant reductions that were no greater than
generalised grey matter deficits (of 4.5%).
Taken together, there is some evidence that the temporal lobes are preferentially
affected in schizophrenia, but this is not as convincing as the results from studies that have
examined individual anatomical components of the temporal lobe.
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(vi) Amygdala-Hippocampal Complex
These structures have been of particular interest to schizophrenia researchers since
a number of post-inortem studies suggested that they may be preferentially affected (e.g.
Bogerts et al., 1985; Brown el al., 1986). The NIMH workers were the first to report
reductions in such mesial structures on MRI (Kelsoe et al., 1988), and they have now
been examined in a total of 17 MRI studies, which have taken a number ofmethodological
approaches.
Ten published papers have examined the entire amygdala-hippocampal complex
(see Table 1.3), seven of which reported statistically significant reductions that have
usually been evident bilaterally. Again, some have attempted to do so without sufficient
coverage of a structure that is at least 50mm long in the coronal plane (Duvernoy, 1990).
Suddath et al. (1989) described substantial reductions, but in only one of three single
10mm slices; Dauphinais et al. (1990, analysis#2) found differences of 7-14% that were
significant on the right side in male subjects but only used two 10mm slices; and Marsh et
al. (1994) again examined two 10mm sections and reported significant reductions of 12-
14%. However, four of the seven studies which did include all the complex, with the same
anatomical definitions as for the temporal lobe, have also found statistically significant
reductions (the figures for the study of Shenton et al. 1992, being given in McCarley et
al., 1993). The median reductions are of about 6% overall, with the possibility that the
differences are largely attributable to men (about 7%) rather than women who show small
increases (see Table 1.5). Additional information has been given by some research groups
on the volumes of amygdala and/or hippocampus and/or parahippocampal gyrus
individually.
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(vii) Amygdala
Six studies have examined comparable volumes of the amygdala in isolation,
although this has been measured in both sexes together (Breier et al., 1992) or individually
(Bogerts et al., 1990) in only one study each. Again, a variety of ways of delineating the
structure have been employed. Some workers have simply measured the structure on a set
number of slices, which have given sufficient (2x10mm, Kawasaki et al., 1993; 2x5mm,
Rossi et al., 1994) or insufficient coverage (2x3mm, Barta et al., 1990), or only an area
rather than a volume (IxlOmm, Suddath et al., 1989; Swayze et al., 1992; Marsh et al.,
1994). Others have arbitrarily separated amygdala from hippocampus as anterior and
posterior, respectively, to the mammillary bodies (Bogerts et al.., 1990 & 1993; Shenton
et al., 1992) or excluded this transition area from the measures (Breier et al., 1992). Four
of the six comparable studies only examined male subjects, with two of them and one of
the other reports finding significant reductions on only the left side (Barta et al., 1990;
Shenton et al., 1992; Rossi et al., 1994). However, two of the studies using internal
landmark boundaries actually found increases on the left side in men (Bogerts et al.., 1990
& 1993), suggesting that the results are dependent on methodological or population
differences. Furthermore, the fact that Shenton et al. (1992) do not give a figure for the
non-significant difference on the right side suggests that publication bias may be operating
in these figures. The median calculation can only be made for men but suggests a large
and bilateral reduction in the volume of the region of about 10%.
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(viii) Hippocampus
Seven comparable studies have examined the entire hippocampus (see Tables 1.3
and 1.5). Most have only examined male subjects, but one gave figures for both sexes
together (Breier et al., 1992) and two studies give results for either sex - with conflicting
results as to whether men or women show the greatest reductions (Bogerts et al., 1990;
Flaum et al., 1995). The hippocampus has been distinguished from the amygdala
arbitrarily (Bogerts et al., 1990 & 1993; Breier et al., 1992), by a set number of slices
(7x4mm, Becker et al., 1990), or by visual tracing (Zipursky et al., 1994; Flaum et al.,
1995; Fukuzako et al., 1996). Five of these studies have reported significant volume
reductions, most commonly on the left side in men. Excluding studies which did not
include anything approaching the whole volume (2x10mm, Swayze et al., 1992; 2x10mm,
Kawasaki et al., 1993; 2x5mm, Rossi et al., 1994; lxlOmm, Marsh et al., 1994), the
median reductions are 7-8% in men (six studies) and 2-3% in women (two studies). These
findings are complemented by a report that visual inspection of the pes hippocampus could
distinguish cases from non-cases in most monozygotic twin pairs (Suddath et al., 1990).
fix) Parahippocampal Gyrus
A small number of studies have examined the volume of the parahippocampal
gyrus. In each case, the structure has been visually isolated in slices covering the entire
temporal lobe. Reductions on the left side have been equal to or greater than those on the
right (-4.5/-l%, Becker et al., 1990; -10/-10%, DeLisi et al., 1991; -14/-9%, Shenton et
al., 1992; -15/-10% Kawasaki et al., 1993), with five of these eight differences being
statistically significant. The median reductions in men (three studies) are therefore -14%
on the left and -9% on the right, which are the greatest cortical reductions in the literature
(see Table 1.5). It is however conceivable that these results are skewed by selective
reporting of significant results. The final component of the temporal lobe of interest to
schizophrenia researchers is the superior temporal gyrus (STG, see Table 1.4 overleaf).
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Table 1.4 - Volumetric MRI studies of the STG in DSM-Ill-(R) schizophrenia, with
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Key: Number of male/female (m/f) patients (Pts) and controls (Cls); match - matched or
(almost identical) for a-age, s-sex, h-handedness, r-race, e-education, p-paternal social
class, sc-social class; ant-anterior, mid-middle, post-posterior, tot-total, mam.-mammillary
body, temp.- temporal.; * significant in original paper. Note: Approximate volumes are
given in brackets for comparison; the Shenton (1992) study was of grey matter only.
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(x) Superior Temporal Gyrus (STG)
Barta et al. (1990) were the first to examine this component of the temporal lobes
and reported significant reductions in the (anterior) volume of the structure. Subsequent
studies (see Table 1.4) have provided a confusing array of results, due to varying methods,
as demonstrated by the substantially different volumes derived. Shenton et al. (1992)
reported significant reductions in the amount ofgrey matter in all three components they
measured, without giving figures for the non-significant differences on the right side
although one of these can be found in McCarley et al. (1993). DeLisi et al. (1994) found
reductions in first episode cases, that were significant for women, but included an
unspecified schizoaffective patients in their sample. Other workers have reported non¬
significant differences in parts of or the whole gyrus (see Table 1.4). Although differing
boundary definitions limit the comparability of these studies, it can be seen from the Table
that median differences for the anterior STG would be small and, if anything, greater on
the right side and in women (see DeLisi et al., 1994b). Values for the middle and
posterior portions are too few and varied to allow a reliable comparison. The differences
for the whole STG are perhaps in the region of -2% in men and -6% in women, with no
substantial laterality. Kulynych et al. (1996) also compared results from the standard
serial slice measurements with surface rendering techniques. They found small reductions
(of about -2%) using the standard approach, which were only evident posteriorly, but
much greater differences with the newer technique (-12%) that were limited to the left
side. The NIMH group have also reported non-significant surface area reductions of the
planum temporale (PT, -1.5/-7.5%) and increases in Heschl's gyrus (HG, +7.5/8%), in the
middle and posterior portions of the STG respectively, with surface rendering (Kulynych
et al., 1995).
However, the segmentation studies that have discriminated grey from white matter
in the STG have delivered a much more consistent pattern of results. Grey matter
reductions, at least in male patients, are apparent in the anterior (-33%, Shenton et al.,
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1992), middle (-20 left/-26% right, Menon et al., 1995), and posterior (-14%, Shenton et
al., 1992; -24/-11%, Menon et al., 1995) portions, as well as in the whole STG (-15%,
Shenton et al., 1992; -5/+l%, Zipursky et al., 1994), with only the latter study failing to
find statistically significant differences. These differences are also most pronounced on the
left side in most regions. The only report to include an examination ofwhite matter in the
STG has found it to be non-significantly increased by 9-10% (Zipursky et al., 1994).
The STG, PT and HG are highly functionally specialised and lateralised, and have
therefore been most closely examined for the putative abnormality in cerebral asymmetry
in schizophrenia.
Cxi) Cerebral Asymmetry
Although many research groups have not found any evidence of cerebral
asymmetry, in terms of diagnosis by side interactions, in a variety of brain structures in
patients with schizophrenia (Suddath et al., 1989; Dauphinais et al., 1990; DeLisi et al.,
1991 & 1992; Zipursky et al., 1994; Flaum et al., 1995), it is noticeable that many of the
regional volumetric reductions are most pronounced on the left side (see Table 1.1). For
example, the Harvard group have reported more marked reductions in the left lateral
ventricle (Shenton et al., 1991) and mesial temporal lobe structures (Shenton et al., 1992),
and workers in Philadelphia have found greater deficits in the left rather than the right
temporal lobes in patients as compared to controls (Turetsky et al., 1995). These
impressions are strengthened by many of the median figures (see Table 1.5), particularly
for ventricular structures. It should be noted, however, that the left lateral ventricle and
the right temporal lobe are larger than their contralateral partners in normal controls (Jack
et al., 1988) and these results may therefore reflect an excess of asymmetry rather than
any reduction or reversal. Nonetheless, the fact that many of the median reductions are
more marked in temporal structures on the right does support the asymmetry hypothesis
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The most systematic attention to this issue has been through studies of cerebral
'torque'. In normal subjects, the right frontal and left occipital lobes are relatively larger
than their left and right sided equivalents whereas some CT studies suggested that this
difference was reduced or even reversed in patients with schizophrenia. Thus far, three
MRI studies have addressed this phenomenon with the necessary explicit correction for
any tilt or rotation of the cranium in the scanner. Bilder and colleagues (1994) found
reduced asymmetries in frontal and occipital regions in first episode patients, which was
associated in post hoc tests with paranoid sub-type and negative symptoms in men.
Zipursky et al. (1994) however, found no evidence for this loss of torque, whereas
Turetsky et al. (1995) did find reduced torque in the frontal and temporal lobes.
More studies have examined the smaller components of the temporal lobe - the
planum temporale (PT), Heschl's gyrus (HG) and the superior temporal gyrus (STG) - in
the search for abnormalities of asymmetry. These structures are intimately associated with
language functions and are normally larger on the left side. The planum temporale has
been reported as showing less asymmetry in schizophrenics (Rossi et al., 1992 & 1994;
DeLisi et al., 1994), or only in females with schizophreniform psychosis (Hoff et al.,
1992), or no significant difference (Bartley et al., 1993; Kleinschmidt et al., 1994). One
group has also reported reversed asymmetry (right larger than left) of the PT but not of
the HG (Petty et al., 1995). DeLisi et al. (1994) and Menon et al. (1995) have found no
diagnosis by side interaction in STG volumes. These discrepancies clearly indicate
methodological problems. Laterality is influenced by handedness and gender, which are
not always adequately controlled; raters are generally not blind to the side of the brain they
are examining; and 'asymmetry quotients' may not control for overall brain size differences
(Bullmore et al., 1995), particularly if any head tilt is uncorrected (Zipursky et al., 1991).
NIMH workers have been the first to deal with these issues and found no evidence for
reversed asymmetry of the PT or HG (Kulynych et al., 1995), and only found some in the
STG on measurement with the more reliable surface rendering (Kulynych et al., 1996).
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(xii) Other cortical structures
Morphometric studies have concentrated on the frontal and temporal lobes, but
several researchers have also examined other regions although they generally report less
substantial or significant differences. In Iowa, Andreasen et al. (1994a) found brain tissue
deficits were generalised to all lobes in males (albeit by only about 3%) but only to frontal
lobes in females, and volume reductions were not found in parietal and occipital lobes in
first episode patients (Nopoulos et al, 1995). Bilder et al. (1994) did find significant
reductions in the occipito-parietal lobes, particularly on the left side in women (-11%), and
of the premotor cortex but not the sensorimotor areas. The cerebellum has also been
shown to be smaller in patients than in controls, again particularly in females, in two
studies (Andreasen et al., 1994a; Flaum et al., 1995), as have the cingulate gyrus (Noga et
al., 1995) and pineal gland (Rajarethinum et al., 1995) in one study each, but the
reductions have been small and apparently no greater than that of the brain in general (3-
5%).
(xiii) Thalamus and Basal Ganglia
In 1994, the Iowa group published the results of the innovative analysis technique
of brain averaging, which identified smaller volumes of the thalamus and adjacent white
matter (Andreasen et ah, 1994b). However, such putative abnormalities may be no
greater than those expected due to a general reduction in brain volumes as found in the
only other pertinent study (-2.5%, Jernigan et al., 1991). Such mesial effects could also
be attributable to compressing the image of smaller schizophrenic brains 'on average' and
awaits independent replication, although the Iowa workers have internally replicated their
result with a standard serial slice analysis (6-7% smaller bilaterally, Flaum et al., 1995).
In contrast to the volumetric reductions in cortical regions, the most persuasive
evidence of abnormalities in subcortical nuclei is for volume increases with time and
exposure to antipsychotic medication. Kelsoe et al. (1988) found increased areas of the
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pallidus and putamen, but the first volumetric study of the basal ganglia (DeLisi et al.,
1991) reported 2.5-4% increases in caudate and lenticular nuclei volumes in chronic
hospitalised patients as compared to controls. These results have been supported by
subsequent findings of increased lenticular nuclei volumes, more so on left and in early
onset subjects (Jernigan et ciL, 1991), putamen (and lesser caudate) enlargement in young
chronic male patients (Swayze et al., 1992), larger caudate volumes in both deficit and
non-deficit patients (Buchanan et al., 1993), bilateral pallidal and right putamen increases
in chronic cases (Elkashef et al., 1994), and an increase in all components of the basal
ganglia in schizophrenia (Hokama et al., 1995) - although some studies have reported
small reductions in caudate volume (Jernigan et al., 1991; Flaum et al., 1995). Most
persuasively, volume increments of 6% (Chakos et al., 1994) and 15% (Keshavan et al.,
1994) have been observed in first episode and neuroleptic naive patients respectively over
one year to eighteen months of treatment. These increases showed a dose response
relationship with typical antipsychotics (Chakos et al., 1994), but reversed on treatment
with clozapine (Chakos et al., 1995), suggesting that D2 receptor blockade is responsible.
Such normalisation with clozapine treatment has also been described in childhood onset
cases of schizophrenia (Frazier et al., 1996), although a relationship has not been found
with tardive dyskinesia in adults (Elkashef et al., 1994). This sensitivity to medication
effects over a relatively short period of time suggests that prospective cohort studies could
determine whether the regional brain volume abnormalities in patients with schizophrenia
summarised in Table 1.5 (overleaf) are static and therefore neurodevelopmental or
progressive and probably neurodegenerative.
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Table 1.5 - Median percentage differences in MRI volumes from studies using
comparable methods (N, range of results) in patients with schizophrenia.
REGION BOTH SEXES MEN WOMEN




-3.25 (6, -9.5 to -0.5) -4 (5, -7 to-1.5)
-4 (3,-4.5 to-1.5)
-4.5 (3, -4.5 to -3)
-3.25 (2, -4 to -2.5)




+64 (2, +62 to +67)
+44 (5, +31 to +66)
+36(5, +21 to +67)
+31 (3,0 to+34)
-
LV body - Left side
LV body - Right side
+50 (2, +40 to +49)
+47 (2, +33 to +61)
+54 (2, +50 to +58)
+72 (2, +68 to +75)
Frontal horn - Left
Frontal horn - Right
+15(3,-8.5 to +35)
+2.5 (3, +2 to +24)
Temporal horn - Left
Temporal horn - Right
+18 (3,+2 to +21)
+13 (3, -1 to+14)
+15(7,-7.5 to+200)
+11 (7,+2.5 to +74)
+17 (3,+10 to+32)
+9 (3,+5 to+11)
Occipital horn - Left
Occipital horn - Right
+31 (2, +30 to +32)
+28 (2,+14 to +41)
Third Ventricle +19(5, +6 to+44) +21 (7, -5 to +52) +5 (3,0 to+12)
Pre-frontal lobe - Left




-7.5 (2, -9.5 to -5.5)
-
Temporal lobe - Left
Temporal lobe - Right
-6 (5,-13 to +2.5)
-9.5(5,-15 to +3.5)
-2.25 (4, -5 to +3.5)
-3.75 (4, -9 to +0.5)
+2 (3, -4.5 to +5)
-2 (3,-3.5 to +5)
Amyg. & Hipp. - Left
Amyg. & Hipp. - Right
-6.75 (4,-12 to+2.5)
-5.5(4,-15 to +2.5)
-6.75 (4,-11 to +0.5)
-7.75 (4,-12 to+1.5)









- -7 (6,-20 to +1)
-8.5(6,-15 to-1.5)
-3.25 (2, -7.5 to +1)
-2.5 (2,-12 to +7)
Parahippocampus - Left
Parahippocampus - Right
- -14(3,-15 to -4.5)




- -1.25 (4, -7.5 to+1.5)
-2.25 (4, -5 to +2.5)
-7.25 (2, -9 to -5.5)
-5.75 (2,-6 to -5.5)
Note: Figures are only given where at least two comparable studies in a su )ject group are
available.
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(xiv) Static or progressive ?
A small number of studies have examined first episode patients and suggest that
most of the brain changes described in the literature are found at illness onset. Bogerts et
al. (1990) reported substantial reductions in the temporal lobes and its' component parts,
as did Bilder et al. (1994). Nopoulos et al. (1995) found that the reductions were most
marked in the frontal lobes but that these were overshadowed by large increases in total
(26%), sulcal (26%) and ventricular (22%) CSF volumes. Without greater certainty about
the degree of abnormality found in chronic patients, it is not possible to state whether
these changes are entirely developmental, but is safe to say that at least a large part of the
structural differences between groups of patients with schizophrenia and normal controls
predate the development of florid psychotic symptoms. A more definitive answer could be
expected from prospective follow-up studies of patients cohorts.
This issue has been most systematically addressed DeLisi and colleagues at Stony
Brook in New York. They first examined a group of 30 first episode 'schizophrenia-like'
patients and 15 chronic schizophrenics, and reported significantly larger lateral ventricles
(20-44%) in both groups (DeLisi et al., 1991). These differences were generally greater
in the chronic patients, and the temporal lobe volumes correlated with duration but not
age at onset - suggesting some progression - although ventricular and temporal horn
volumes were correlated with age at onset and outcome, but not duration. However,
selection of particularly bad outcome patients and a relationship with pre-morbid
functioning are alternative explanations (DeLisi et al., 1991). In 24 of these patients who
were followed up after two years, non-significant decreases in male and increases in
female ventricular volumes were reported and these inversely correlated with symptoms
and hospitalisation time - with a greater variance in the volumes in patients (DeLisi et al..,
1992). At four years, 20 (15 male) of the original sample were shown to have significantly
reduced volumes of both cerebral hemispheres (of about 7cc/year), with a lesser but
significant increase of about lcc per year in the lateral ventricles (left>right). Although
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suggestive of true cortical atrophy, interpretation is hindered by the decreasing group sizes
(only 5 controls), frequent substance abuse in (at least) 6 patients, and diagnostic changes
to schizoaffective disorder in eight cases. No significant deterioration in cognitive
functioning was found, but 'left hemisphere function' improvement was strongly and
negatively correlated with the reduction in hemisphere volumes (DeLisi et al., 1994)
Although such methodological limitations prevent a definite conclusion, these
results do suggest that there is a neurodegenerative component to schizophrenia. The
main problem is whether current methods are sufficiently sensitive to detect what is at
most a very small difference over and above the inaccuracy of the volumetric technique.
For example, Chakos et al. (1994) found that cortical volume actually increased, although
the ventricular volume decreased, over eighteen months in first episode patients. Clearly,
any further cohort studies will need to be conducted on large patient populations. In the
meantime, however, some insights into the pathophysiology of schizophrenia can be
gleaned from the pattern of correlations between clinical features and MR! regional
volumes (and areas).
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1.2.3.5 - Correlations of MR1 regional areas and volumes
It should be stated at the outset of attempting to review the literature on the
associations of brain indices in schizophrenia that it is fraught with dangers of
misinterpretation. In particular, the generally small sample sizes ofmost studies increases
the likelihood of Type II errors, while selectivity in reporting of significant correlations
(publication bias) is a distinct possibility. Moreover, patients who can consent to and co¬
operate with scanning procedures may not reflect the generality of all sufferers.
Nevertheless, some useful information is available, particularly about the associations with
age at onset, outcome, duration and symptom profiles.
(i> Clinical correlations
Area studies have provided conflicting results, with significant correlations
reported between brain and cranium areas and negative symptoms (Andreasen et al.,
1986); the cerebellar vermis and drug response, and ffontakbrain area ratio and negative
symptoms (Uematsu & Kaiya, 1988b); the lateral ventricles and poor social outcome
(Johnstone et al., 1989b); and between the VBR and positive symptoms, or a small
caudate nucleus (and right hippocampus) and more symptoms in general (Young et al.,
1991). Andreasen et al. (1990) reported that both the VBR and (partial) ventricular
volume were related to negative symptoms (and ECT treatment).
Subsequent volumetric studies have failed to find evidence for relationships
between brain measures and treatment with either ECT or duration of neuroleptic
treatment (Harvey et al., 1993). Indeed, no study has reported a significant correlation
between cortical reductions or ventricular increases and antipsychotic medication
exposure, and only one has found an association between poor pre-morbid adjustment and
any regional volume - the (anterior) cerebral volume, although this was not related to
outcome (Harvey et al., 1993). Age at onset has been linked to sulcakCSF ratio (Mozley
et al., 1994), but not to any regional volumes (Zipursky et al., 1994) in individual studies.
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Arguably the most consistent correlational finding is the lack of an association
between brain parameters and the duration of illness (Kelsoe el al., 1988; Young el al.,
1991; Kawasaki et al., 1993; Gur et al., 1994; Zipursky et al., 1994), especially if
controlling for age related changes (O'Callaghan et al., 1992; Marsh et al., 1994),
although one study did find that duration and total CSF volume were related with or
without controlling for age (Gur et al., 1991). There has also been a failure to find
regional volume associations with duration in first episode patients (Bilder et al., 1994).
The severity of negative symptoms has been significantly correlated with the
volume of the temporal horns of the lateral ventricle (Degreef et al., 1992; Kawaski et al.,
1993); the left temporal lobe parenchymal and CSF volumes (Turetsky et al., 1995);
cortical grey matter deficits, particularly in frontal regions (Zipursky et al., 1992); and
frontal lobe white matter on the left side (Wible et al., 1995). The severity of positive
symptoms has been related to the volumes of mesiotemporal structures (Bogerts et al.,
1993) and the temporal horns (Degreef et al., 1992), although more studies have not
found significant correlations with the volumes of the temporal lobes (Zipursky et al.,
1994; Turetsky et al., 1995), the temporal horns (Kawasaki et al., 1993) or the frontal
lobes (Wible et al., 1995). Two studies have reported an association between global
symptom severity and the volume of the third ventricle (Degreef et al., 1992; Zipursky et
al., 1994).
Studies of the links between STG volume and psychopathology have probably
provided the best evidence of structural-clinical associations. The first report described a
strong correlation (r=+0.7) between left anterior STG deficits and the severity of auditory
hallucinations (Barta et al., 1990). However, this result has only been replicated once -
for total left STG volume (Flaum et al., 1995), two reports specifically mention finding no
association (DeLisi et al., 1994b; Zipursky et al., 1994), and another study found a
correlation with the volume of the left anterior cingulate gyrus (Noga et al., 1995). The
(left posterior grey) STG has also been linked with thought disorder (r=-0.8, Shenton et
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ah, 1992), although the Harvard group had previously described an association with
asymmetrical lateral ventricle volume (Shenton et at., 1991). Zipursky et at. (1994) failed
to replicate this result, but further studies have reported an intriguing pattern of
volumetric-clinical associations. Menon et at. (1995), reporting on an extended sample
from Barta's study, found a trend to a correlation between grey matter percent of the left
mid-portion of the STG and thought disorder, which was very strong if outliers were
excluded - although they also found a counter-intuitive association between larger left
posterior STG grey matter and higher delusion scores. The Milan group (Vita et at,
1995) have reported significant correlations between the volumes of the left and right
posterior STG and incoherence of speech and 'loss of goal' respectively, as well as
between abnormal STG asymmetry and thought disorder, although correlations were also
found between pre-frontal lobe volumes and various speech and language disorders. A
reduction in PT asymmetry has been found to correlate with thought disorder in two
studies (Rossi et at., 1994; Petty et al., 1995) but not in two others (DeLisi et at., 1994b;
Kleinschmidt et ah, 1994).
An alternative approach to the search for clinical relationships is to examine
symptom clusters or factors rather than individual features. For example, workers in
Philadelphia did not find any individual symptom-volume correlation, but did report that a
higher left hemisphere sulcal CSF volume, relative to the right, was associated with factor
of negative symptoms, and that increased ventricular: sulcal CSF was correlated with a
positive symptoms factor (Mozley et al., 1994). Wright et ah. (1995), in London, have
developed functional imaging methods for application to segmented structural scans and
reported that 'reality distortion' (hallucinations and delusions) was negatively correlated
with the grey matter volume in the STG, and that 'psychomotor poverty' (negative
symptoms) was associated with increased volume of grey and white matter in left temporal
regions, in male patients. Finally, results from the Philadelphia group have recently
suggested that MRI-clinical correlational patterns may differ between the sexes e.g. with
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increased frontal lobe volume being associated with less disorganisation in men but greater
disorganisation and suspiciousness in women (Cowell et al., 1996).
It is difficult to pull this disparate literature together, but it does appear that the
regional volume differences between patients with schizophrenia and normal controls are
not related to duration of illness or medication, that negative symptoms may be related to
cortical loss in the frontal lobes, and that positive symptoms are associated with deficits in
parts of the temporal lobes. Although a degree of consensus is evident from these reports,
there is more convincing evidence - as with CT - that MRI regional volumes are
associated with biological rather than clinical features.
(ii) Correlations with neuropsychological testing and other biological variables
Cognitive deficits in patients with schizophrenia have been found to be significantly
correlated with the areas of the cranium/cerebrum (DeMyer et al., 1988; Andreasen et al.,
1990), the temporal lobe (DiMichele et al., 1992) and the frontal lobe in one study
(Seidman et al., 1994) but not another (Raine et al., 1992). More reliably, the volumes of
temporal lobe structures have been linked to language deficits. DeLisi et al. (1991) found
that verbal memory task performance was inversely correlated with parahippocampal
gyrus volumes, particularly in first episode patients. The Harvard group also reported
strong associations between the same tests of verbal memory, abstraction and
categorisation with the parahippocampal and posterior superior temporal gyrus volumes
bilaterally (Nestor et al, 1993). Although the results from the Wechsler Memory Scale
did not correlate with temporal lobe or frontal lobe volumes in another study (Seidman et
al., 1994), this argues more against crude neuropsychological localisation than against the
previous results, and these workers subsequently found a relationship between contextual
word recall and frontal lobe volumes (Maher et al., 1995). Vita et al. (1995) reported that
the left and right posterior STG volumes were related to verbal fluency and object naming,
while the total ventricular volume was correlated with sentence generation complexity.
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The importance of examining small cortical regions that are associated with discrete
cognitive functions was re-inforced by Sullivan et al. (1996) when they reported that
lower scores on tests of executive function, short term and declarative memory, and motor
ability (individual and composite scores) were correlated with smaller total cortical grey
matter volume but not with broadly defined cortical regional volumes. Further, the finding
that hippocampal abnormalities are related to worse performance on tests usually
considered to be sensitive to the integrity of the frontal lobes (Bilder et al., 1994) suggests
that integrated ffonto-temporal function is disrupted in schizophrenia. Finally, patients
with prominent negative symptoms may perform particularly poorly on such frontal lobe
tests (Buchanan et al., 1994).
A number of research groups have also related MRI volumes to other biological
measures of brain function, such as the event-related potentials and cerebral blood flow or
metabolism. Blackwood et al. (1991) reported that increased P300 latency was inversely
correlated with the area of left and right anterior cingulate cortex, while other groups have
found that P3 amplitude reductions are associated with left temporal lobe and right
hippocampal areas as well as with positive symptoms (Egan et al., 1994), and volume
deficits in the left posterior STG and thought disorder - albeit in one-tailed significance
tests (McCarley et al., 1993). In an early attempt to relate structural volume to
metabolism, Guenther et al. (1989) suggested that reduced callosal area was associated
with less motor activation on PET. A series of studies from NIMH have produced results
of greater relevance to our current knowledge of schizophrenia and are a model for
integration of various findings. Having established that the hippocampus was smaller in
the affected twin of discordant pairs (Suddath et al., 1990), they went on to describe that
this deficit was associated with a failure to activate the pre-ffontal cortex during the
WCST (Weinberger et al., 1992) and that the degree of activation was correlated with
perseveration errors while the hippocampal volume reduction correlated with verbal
memory performance (Goldberg et al., 1994). This work is in keeping with their previous
ri -ffiW
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findings of a correlation between the VBR on CT and prefrontal activation during the
WCST, controlling for global blood flow (Berman et al., 1987). Although this has not
been exactly replicated (Ford et al., 1992), other groups have found an association
between enlarged ventricles and fissures on CT and lower global metabolism (Kling et al.,
1986) and between frontal sulcal prominence on CT and reduced resting normalised pre¬
frontal blood flow (Rubin et al., 1994). These suggestions of abnormal fronto-temporal
connectivity are supported by studies of the inter-correlations of structure volumes.
(iii) Inter-correlations of structure volumes on MRI
The total ventricular volume has been found to correlate with cerebral volume
(Kelsoe et al., 1988), the temporal lobes and hippocampi - corrected for frontal volume
(Suddath et al., 1989), and temporal horn volumes (Kawasaki et al., 1993). However, the
correlations are generally weak, some studies have not found such significant correlations
(e.g. Bogerts et al., 1990), and ventricular or cerebral volume may not be a true reflection
of a loss of brain substance in superficial gyri.
Studies of the relationship between the volumes of the frontal and temporal lobes
have also produced interesting results. Correlations have been reported between the right
prefrontal white matter and the amygdala-hippocampal complex, the pattern of which
were significantly different from controls (Breier et al., 1992); echoing the results from the
NIMH reports in discordant twin pairs. Wible et al. (1995) also reported a pattern of
regional inter-correlations within and between the left anterior temporal lobes and
prefrontal lobes, that was not so evident in controls. These results suggest an abnormal
excess of fronto-temporal communication, possibly associated with an increase in white
matter, that could be responsible for the pathognomic features of schizophrenia.
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1.2.4 CONCLUSIONS
The methodological difficulties encountered in studying the cerebral morphometry
of schizophrenia are evident from this review. Studies have suffered from small sample
size, varying slice thicknesses and boundary definitions; while non-systematic reviews have
placed undue emphasis on statistical significance rather than effect sizes (Chua &
McKenna, 1994). Nonetheless, methodological variation across studies appear to have
had relatively little influence on the main results - with the possible exception of the
differences between automated and serial slice measures of the CSF and frontal lobes.
Although studies covering only a few slices of the temporal lobes tend to find more
significant results than those of the whole lobe, this is probably attributable to greater
volume reductions in schizophrenia in anterior temporal lobe structures, and the
differences in matched variables or the exact posterior boundary does not seem to be
crucial. More evident is the contrasting findings of different groups, for example the
greater reductions in frontal lobes in patients in Iowa and the enlarged craniums in males
studied in Harvard.
It is clear from the foregoing quantitative review (see Table 1.5) that the brains of
patients with schizophrenia (as a group) are generally smaller than those of normal
controls, with more specific regional reductions in the temporal lobes and some of its
component parts and that the case-control percentage differences are most marked in
measures of the ventricular system. It is reassuring to note that these findings are very
much in keeping with those from post-mortem studies (Bogerts et al., 1985; Brown et al.,
1986; Shapiro et al., 1993), which also agree with the suggestion from this study that the
parahippocampal gyrus may be particularly affected. Moreoever, such abnormalities are -
at the very least - not so marked in other psychiatric disorders such as manic-depressive
psychosis (Johnstone et al., 1989b; Rossi et al., 1991; Harvey et al., 1994; Schlaepfer et
al., 1994). However, this review used the medians of percentage differences and therefore
does not take account of subject numbers or measurement variance and can not therefore
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determine whether the differences described are statistically significant. On the other
hand, this approach has the benefit of ease, comprehensibility, and is easily updated to
incorporate further studies. It is also possible to say what number of unpublished reports
or studies with alternative findings would reverse the apparent consensus, although this is
somewhat disquieting e.g. taking the results for the left amygdala in men - only three
studies finding no (0%) difference would reduce the median difference to zero. In
addition, this review method highlights suitable avenues for further research, such as more
thorough examination of the total head size (which may even be increased in men) and
altogether more studies in female patients - preferably using comparable methods to the
majority of previously published work so that, in time, a more thorough meta-analysis
would be a practical proposition. Further systematic work is also required on cerebral
asymmetry, changes over time and clinical correlations. Although studies that find a
lateralised difference in schizophrenia tend to do so on the left, there is little evidence from
the median figures of such leftward laterality except for the ventricular system. The
available data are most compatible with the present consensus that these changes are
developmental and non-progressive. It is therefore not particularly surprising that studies
attempting to relate volume reductions to clinical (state) features have produced
inconsistent findings, given that the former may only reflect risk factors for the
development of psychosis. In contrast, the relatively consistent associations with
cognitive deficits may reflect that these are trait markers.
The next generation ofMRI studies in schizophrenia should therefore concentrate
on specific populations (such as populations at high risk of developing psychosis), long
term follow-up and try to relate abnormalities to stable characteristics such as genetic
endowment. There is plenty of room for methodological refinement, as most ably
demonstrated by workers at NIMH (Kulynych et al., 1995 & 1996). Larger samples are
required, with more females, appropriately matched for age and laterality related variables
such as sex and handedness. If asymmetry is to be reliably addressed, any tilt should be
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corrected and volume raters should be blind to side (as well as diagnosis). Further
technical and methodological improvements will complement the functional capabilities of
MRI (see Chapter 4) and those of conventional functional imaging methods, which will
now be reviewed.
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1.3 FUNCTIONAL BRAIN IMAGING
The demonstration of structural brain abnormalities in schizophrenia adds weight
to arguments that it is a disease of the central nervous system, but has only provided
limited information as to its nature. Greater insights into such a relatively subtle
disturbance have been justifiably expected, and to a certain extent realised, from the
examination of functional indices such as cerebral perfusion and neuronal metabolism.
Seymour Kety and colleagues (1948) were the first to demonstrate putative 'metabolic
derangements' of the brain in schizophrenia and a feasible method of examination. They
used invasive measures with nitrous oxide (Kety & Schmidt, 1948), as a diffusible inert
index of arterial and venous blood flow (brain uptake being the difference between the
two), but could only examine global cerebral blood flow and oxygen consumption and did
not find any differences between acute or chronic schizophrenics and normal controls.
Many years were to pass before technological advances allowed a greater exploitation of
the potential of functional imaging in psychiatric disorders.
Such developments have lead to the two main techniques employed thus far:
Single Photon Emission (Computed) Tomography (SPE(C)T) and Positron Emission
Tomography (PET). SPET acquires functional (brain) images by detecting the single
photons emitted by an administered radio-isotope, while PET is sensitive to the two
positrons emitted by annihilation reactions. Although slightly different, both methods
depend upon the fact that administered tracers are distributed with regional cerebral blood
flow (rCBF) to active areas of the brain, and that such blood flow is tightly coupled to
brain metabolism (activity) by autoregulation in physiological and most pathological
conditions (Raichle et ah, 1976). This introductory review will now briefly describe, in
turn, these techniques and their associated problems, before a traditional narrative style
summary of the main studies that have been conducted to date. Other functional imaging
techniques, including the Electroencephalogram, and evoked potentials, will be briefly
discussed in Chapter 4.
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1.3.1 SINGLE PHOTON EMISSION TOMOGRAPHY - METHODOLOGY
Measurements of regional cerebral blood flow with collimators were first
conducted with radioactive Krypton, although this necessitated surgical brain exposure
and was soon replaced by the detection of Xenon (Xe) emitted gamma rays through the
intact skull (Glass & Harper, 1963). Improvements in scintillator detection probe
sensitivity and curve-fitting algorithms led to the possible use of inhaled or intravenous
rather than intra-arterial tracers. Almost co-temporaneously, methods for deriving three-
dimensional information form two-dimensional data (tomography) were being devised.
SPET systems were soon developed that could determine either the distribution of
statistically distributed radiotracers, such as 1^3 labelled compounds, or quantitative
measures of dynamic radio-pharmaceuticals such as Xe^3 (Devous, 1989).
In a SPET scanning session, subjects are first acclimatised to the imaging suite,
comfortably placed alongside or in the detector (gamma camera and collimator), given the
tracer substance with minimal environmental stimulation (sometimes with ears and eyes
patched) and asked to remain inactive during the equilibration period. With the original
tracer substance, IMP (1^3 labelled n-isopropyl p-iodoamphetamine), equilibration of the
3-5mCi (111-185 MBq) dose took 20 minutes, but this is no longer commercially available
(Van Heertum & Tikofsky, 1995). With the currently most widely used tracer, 10-20 mCi
(370-740 MBq) of ^^mTc-HMPAO (Technetium-hexamethylpropyleneamineoxime /
Exametazime) only 5 minutes is necessary for equilibration. The subjects' head is
positioned with reference to the orbito-meatal line (OML) to ensure that images are
acquired in a comparable way between subjects. During image acquisition, the subjects'
head is relatively immobilised, for example with a radiolucent head-holder and zygomatic
arch pressure pads, to avoid image degradation.
Early studies used a single detector that spun around the head, within a radius of
14cm, such as a cut-off detector head, long-bore fan beam collimation, or in frontal
tomography (Van Heertum & Tikofsky, 1989). Current machines use rotating gamma
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cameras, which offer an enhanced image resolution of as low as 10mm, or multiple
detector scanners with a resolution of 8-14mm depending on the number of detectors
(Kouris et al., 1991). Gamma cameras, also known as scintillation or Anger cameras, are
composed of a collimator and a crystal. The origin of the single gamma rays emitted by
the radiotracer is calculated from their trajectory through parallel holes in a lead
collimator. Gamma rays scintillate on contact with a sodium iodide crystal, the photons
then being concentrated by photomultiplier tubes and projected as a two-dimensional
image. In general, 64-128 projection times over 30-40 minutes are necessary to acquire
images that can be three-dimensionally reconstructed.
Detection systems (large bore collimators) for dynamic or diffusible tracers such as
Xel33 are sensitive and acquire the images very quickly, with a complete set of
projections every 10 seconds (sometimes called dynamic or D-SPECT), but suffer from
relatively poor resolution and give a limited number of brain slices as a consequence.
Nonetheless, as long as tracer input is measured, e.g. by scintillation over the lungs,
absolute quantitative rCBF values (in ml/min/lOOg brain tissue) can be generated. Static
or fixed-tracer tomography, with tracers such as IMP or HMPAO, is less sensitive and
takes longer to image the whole brain but has greater resolution. Rotating or multi-
detector gamma camera systems can generate contiguous brain sections and have the
ability to vary the number of slices and their orientation. Multiple detectors improve
energy sensitivity and resolution, but require servicing to ensure that the detectors are
aligned linearly and are uniform in sensitivity and can not be used for dynamic imaging,
whereas most rotating detector systems can be used for both Xe^3 and HMPAO
scanning as long as different collimators are available (Van Heertum & Tikofsky, 1995).
Radiopharmaceuticals for SPET scanning are of four main types. Firstly, diffusible
indicators, such as inhaled Xe*33 (lOmCi/minute), which are cheap, give absolute or
quantitative data and allow fast imaging time and 5-10 studies per patient lifetime.
However, their low energy (80keV) limits resolution, tends to overestimate high blood
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flows (especially in white matter), is insensitive to small activity differences at high
perfusion and gives limited grey/white matter distinction. Secondly, 7^23 labelled
lipophilics, such as IMP, generate high energy gamma rays (159 keV) and enhanced
photopeak detection and resolution, but may only accurately reflect rCBF for 60 minutes
after injection due to re-distribution and do not give absolute values without arterial
monitoring. They perform better at high rCBF than HMPAO but are no longer widely
used as iodination requires a cyclotron. Thirdly, 99™Tc labelled lipophilics, such as
HMPAO, are now widely available and extensively used as they have a similar distribution
and are less expensive than 1123 lipophilics. Dosimetry permits the use of 10-20mCi per
patient-procedure, which shortens imaging time but only allows three investigations in a
lifetime. The main problem with HMPAO is with pronounced back-diffusion in high flow
regions, which combined with higher extraction in low flow areas can result in poor
contrast (Moretti et al., 1995). Finally, 7^23 labelled neuroreceptor ligands - for
example, the muscarinic agonist 1123 Quinuclidinyl-iodobenzilate (Eckelman et al.,
1984), 1123 Iomazenil and 1123 Iodobenzamide (IBZM) - have only limited availability
and are expensive. There is no currently available SPET tracer for metabolism, until a
simple method of measuring input is devised, but regional blood volume (rCBV) can be
measured (albeit with 99mTc tagged red blood cells and a reference blood sample) and the
ratio of rCBF to rCBV is related to the oxygen extraction ratio (OER).
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1.3.2 SPET IMAGE ANALYSIS AND POTENTIAL ARTEFACTS
Image quality should be routinely measured at intervals throughout the procedure,
by closed loop cine or sinogram display, and positioning checked at regular intervals. The
detector photomultiplier tubes must be regularly calibrated, uniformity correction ensured
using count density correction maps, and detector head centre of rotation maintained, so
that acquisition artefacts such as detector non-uniformity ("ring-images") and rotation
errors are avoided. After acquisition and adequacy assessment, such as for any movement
artefact, the images are pre- or post-processed with a filtered back-projection technique.
Excessive or inadequate filtering will reduce image resolution. The rCBF is not easily
determined from pixel values with HMPAO or IMP and pixel sizing is crucial for
reconstruction, as the image sections should be at least one pixel-width thick (3-4mm) to
avoid distortion. Reconstructed axial sections can then be displayed, which gives
qualitative visual images, but further processing is necessary for quantitative analyses.
Visual inspection can reliably detect structural lesions, asymmetry, frontal lobe
abnormalities and activation effects provided multiple experienced raters are employed.
Quantitative rCBF data is usually derived by placing interactive regions of interest (ROI),
corresponding to anatomical areas, over the image. These can be automatic, derived from
a brain atlas, or drawn manually. ROI analysis proceeds by establishing the total tracer
count in that region, which is divided by the number of pixels to give an average pixel
tracer count per region - which can then be compared to other regions or the same regions
in other subjects.
Such comparisons must be 'normalised' to correct for whole brain or whole slice
blood flow. Regional tracer uptake results on SPET are usually normalised to the whole
slice (although this may obscure effects in regions contained within that slice) or occipital
regions (a good reference area, particularly if activation is controlled for with eye
patching); rather than to global uptake (which may not be known and diminishes regional
effects) or cerebellar uptake (which is difficult to fit to standard ROI's, can be irregularly
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shaped, and may itself be involved in many neuropsychiatric disorders (Steinberg et al.,
1995a)). However, as with ratio measures in structural scanning, it may be more reliable
to control for global CBF statistically, with an analysis of co-variance, rather than
normalise to whole brain or particular slices.
Methodological artefacts may arise as a result of differences in scanning protocol.
Even having the eyes open or closed may alter rCBF symmetry and reproducibility, in that
the more "physiological" condition of eyes open may give more reproducible results, with
less variability, as long as stimulation is minimised (Devous, 1989). Similarly,
administration of sedatives or anticholinergics to minimise movement may alter tracer
distribution. As with all imaging techniques, resolution and partial volume effects are
important considerations.
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1.3.3 SPET STUDIES IN NORMAL SUBJECTS
Neurophysiological studies with SPET were dependent on Xe^3 D-SPECT alone
until HMPAO became widely available in the past decade. Even the separate
measurement of rCBF in grey (70-90ml/min/100g) and white (20-30ml/min/100g) matter
has only been possible since the late 1960's, and methodological artefacts with Xenon
methods are a substantial concern. For example, inferior frontal regions can be
contaminated by inhaled gas in the nasal passages and cause a false 'hyperfrontality',
isotope scatter can lead to a potential overestimation problem - particularly in low flow
(white matter) areas - and the later Xe^3 tomography method gives higher white matter
flows of 60ml/min/100g. Nonetheless, there are several replicated reports of functional
activations with the Xe inhalation method that are in agreement with results from PET
(Devous, 1989; George et al., 1991). For example, attending to tasks or somatosensory
stimulation increases frontal blood flow (Devous, 1989), Broca's area is activated during
speech and visuospatial problems activate right parieto-occipital regions (Gur et al.,
1982), and the Stroop test produces activations of the mesial frontal region (Larrue et al.,
1994). Pharmacological activations have also been possible with Acetazolamide,
Arecoline and inhaled carbon dioxide (Devous, 1989). Such sensory, cognitive or
pharmacological stimulation in SPET (as in PET) produces activations in which the
magnitude of blood flow increases with stimulus complexity and rate, and the subjects'
attention.
Basic neurophysiological studies with SPET are perhaps of greatest interest to the
neuropsychiatrist as they can identify generally important determinants of rCBF that may
confound clinical studies. Females have been consistently shown to have increased
cerebral perfusion as compared to men, but the studies differ as to whether this is a global
effect (Gur et al., 1982) or one that is greatest in frontal regions (Mathew et al., 1986;
Daniel et al., 1988). This may even apply to men with high self ratings of femininity
(Daniel et al., 1988). Increasing age is associated with reductions in blood flow that are
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most marked anteriorly (Gur el ah, 1986; Mathew et ah, 1986), but cognitive activations
- at least to visuospatial tasks - can still provide the expected extent and pattern of rCBF
changes (Gur et ah, 1986). The extent of cerebral dominance, as measured with the
handedness, is associated with rCBF laterality but the effect is small - strong left handers
showing a 4% greater degree of the normal right sided increase in rCBF - and blood flow
to the hemispheres is highly correlated (Prohovnik et ah, 1980). Asymmetry is generally
minimal, perhaps with a difference of up to 3ml/min/100g, and generally increased rCBF
on the right side (Devous, 1989). Caffeine and nicotine appear to be global
vasoconstrictors (Mathew et ah, 1983) and vasodilators (Mathew et ah, 1986)
respectively. Anxiety can both increase and decrease rCBF depending on severity and
chronicity (Mathew & Wilson, 1990), while habituation to scan procedures will inevitably
reduce perfusion (Prohovnik et ah, 1980). Thus, although the Xenon inhalation method
may be relatively insensitive, it can nonetheless discriminate between whether the eyes are
open or closed during scanning, and is sensitive to the potentially confounding effects of
age, sex, handedness, anxiety, attention, time of the day, blood pressure and arterial
carbon dioxide levels (Devous, 1989).
The improved resolution with HMPAO might be expected to show even greater
effects of such variables, but few studies have examined these issues. Certainly, however,
it has been established that SPET with this tracer can reliably detect appropriate cortical
activations on sensory (Woods et ah, 1991; Crosson et ah, 1994), motor (Ebmeier et ah,
1992; Crosson et ah, 1994), cognitive (Shedlack et ah, 1991) and pharmacological
(Tiihonen et ah, 1994) stimulation. The lack of attention to studies of the determinants of
Exametazime measured rCBF in normal controls is disappointing, particularly as most of
the SPET studies in schizophrenia over the past five years have used this method. These
studies, and those employing Xenon inhalation, will now be reviewed, according to
whether they used resting or activated experimental conditions.
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1.3.4 SPET STUDIES IN SCHIZOPHRENIA
Functional imaging in schizophrenia research has primarily concentrated on so-
called 'hypofrontality'. Such a relative reduction in frontal rCBF was first suggested in a
series of studies by workers in Lund, Sweden. Using an intra-carotid injection ofXe*^
and 32 probes around the left hemisphere, they initially demonstrated that patients with
chronic schizophrenia had relatively low blood flow to frontal regions, that post-central
flow correlated with 'cognitive disturbance' (thought form and content), and that the most
'autistic' patients showed the least activation on a simple object naming test (Ingvar &
Franzen, 1974a). They took these observations forward by showing that symptoms of
indifference, inactivity and autism were negatively correlated with frontal flow (Ingvar &
Franzen, 1974b), and that hypofrontality persisted in schizophrenic subjects on cognitive
activation (Franzen & Ingvar, 1975). As the levels of medication did not correlate with
other findings, the authors concluded that there was evidence of defective neuro¬
transmission in the mediothalamic frontocortical projection bundle in chronic
schizophrenia.
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1.3.4.1 Xenon inhalation studies
Subsequent Xe^3 studies have used the less invasive inhalation method, with
cortical probes or SPECT, although this has a lower regional resolution. Mathew and
colleagues found no hypofrontality, but generalised rCBF reductions in patients with
schizophrenia, regardless of whether they were on medication or had been withdrawn for
one week, and hallucination severity was inversely correlated with postcentral blood flow
(Mathew et al., 1981 & 1982). Ariel et al.. (1983) did find reduced grey matter rCBF
values in frontal areas bilaterally, although this was only significant in the left hemisphere.
No significant reductions in resting rCBF were found by Pennsylvania researchers in either
medicated or unmedicated patients (Gur et al., 1983 & 1985), but these experiments were
conducted on only 15 and 19 subjects respectively and there is only one other Xe study
(also in small numbers) to find no such effect (Dousse et al., 1988). In contrast,
hypofrontality at rest was reported in several other early studies in medicated (Mubrin et
al., 1982; Kurachi et al., 1985; Mathew et al., 1988) and unmedicated patients
(Weinberger et al., 1986; Berman et al., 1986; Geraud el al., 1987), or both (Warkentin
et al., 1990). Kurachi et al.. (1985) also found a 'hyper-temporality' that was greatest on
the left in patients with auditory hallucinations, while Mathew et al. (1988) reported left
temporal rCBF reductions and that illness duration was related to hypofrontality.
The few resting Xe^3 D-SPECT studies have also reported hypofrontality in
medicated, unmedicated and first episode patients (Paulman et al., 1990; Sagawa et al.,
1990, Steinberg et al., 1995b). Moreover, medication effects appear, if anything, to
decrease rather than worsen the severity of hypofrontality (Matsuda et al., 1991).
Paulman and colleagues (1990) also found that reduced left frontal rCBF was associated
with neuropsychological impairment on the Wisconsin Card Sort Test (WCST) and that
increased hemispheric blood flow was correlated with positive symptoms.
More consistent differences between patients with schizophrenia and normal
controls have been found on various cognitive activations. In Philadelphia, medicated
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schizophrenic patients had aberrant hemispheric activation patterns, with left sided rCBF
increases on a spatial task and bilateral increases for a verbal task (Gur et al., 1983); a
pattern that was not substantially different in unmedicated patients (Gur et al., 1985). In
the first of an influential series of studies, workers at NIMH showed that medication-free
schizophrenic patients had smaller relative and absolute increases in dorso-lateral pre¬
frontal cortex (DLPFC) flow than controls while performing a slightly modified version of
the WCST, but not during a number-matching task, and that DLPFC rCBF correlated with
performance (Weinberger et al., 1986). They confirmed these findings in medicated
patients and established that DLPFC rCBF was not reduced on a visual continuous
performance test (Berman et al., 1986). This was employed as a baseline reference to
reduce resting rCBF variability and suggests that rCBF deficits were not simply
attributable to a generally poor performance or lack of attention to the task. Two later
studies reported a correlation between monoamine metabolite concentration and activated
DLPFC rCBF (Weinberger et al., 1988), and that Raven's Progressive Matrices
activations were post-central and no different between cases and controls (Berman et al.,
1988). Some support for the WCST related DLPFC deficit has been forthcoming
(Sagawa et al., 1990; Steinberg et al., 1996). The NIMH researchers have also refuted
evidence of abnormal lateralisation in schizophrenia beyond any task dependent increases
in left anterior and right posterior regions (Berman & Weinberger, 1990); and reported
WCST related DLPFC deficits in schizophrenics, but not their unaffected co-twins, that
were related to hippocampal volume (Berman et al., 1992; Weinberger et al., 1992).
Wood and Flowers (1990) reported hypofrontality and reduced activation of language
areas on verbal memory tasks in patients as compared to normal controls. Finally,
Andreasen et al.. (1992) studied never medicated and currently unmedicated patients
performing the Tower of London test. Activations were reduced in the left mesial frontal
cortex in both groups, particularly in those with negative symptoms, while neither
medication nor task performance were significantly associated with rCBF.
66
Chapter 1: Literature review
1.3.4.2 HMPAO studies
There are fewer studies using HMPAO as the tracer as it has only been widely
available for less than ten years. However, the enhanced resolution of grey/white matter
and ability to image subcortical structures with HMPAO has brought definite advances,
despite the somewhat reduced sensitivity with this technique as compared to Xenon
inhalation. The first study failed to detect hypoffontality (Bajc et al., 1989), as have some
other small studies (Kawasaki et al., 1992; Rubin et al., 1991 & 1994), but power issues
are paramount here as a combined analysis of the Rubin studies did find relative
hypoffontality (Rubin et al., 1994). Nonetheless, only a few other studies have detected
resting hypofrontality with HMPAO (Erbas et al., 1990; Dupont et al., 1994; Vita et al.,
1995) and some have actually reported 'hyperfrontality' in ummedicated patients with
acute illness (Ebmeier et al., 1993; Catafau et al., 1994; Parallada et al., 1994).
The main advantage of HMPAO has been in imaging specific anatomical regions
and thereby allowing meaningful clinical correlational analyses. Ebmeier et al. (1993)
found that negative symptoms were associated with resting reduced prefrontal rCBF and
that disorganisation was positively correlated with cingulate tracer uptake. Some studies
have reported 'hypotemporality' in medicated patients (Catafau et al., 1994; Dupont et al.,
1994), but Kawasaki and colleagues (1992) found increases in resting relative left
hippocampal and basal ganglia blood flow that were inversely correlated with negative
symptoms. This apparent discrepancy may be related to the levels of particular clinical
features in different patient groups - in a within-subjects follow-up study McGuire et al..
(1993) found that auditory hallucinations were associated with increased blood flow in
inferior frontal (Broca's area) and anterior cingulate cortex.
Activation experiments with HMPAO-SPECT have at least confirmed earlier
reports of hypofrontality. Lewis et al.. (1992) found reduced lateral and medial frontal
perfusion on a word fluency test, with negative symptoms being correlated with mesial
blood flow and performance with lateral rCBF. A failure of (usually left sided) lateral and
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medial pre-frontal cortex activation with the WCST has been replicated in unmedicated
and neuroleptic-naive subjects (Rubin et ah, 1991 & 1994; Kawasaki et ah, 1993;
Paralleda et ah, 1994; Catafau et ah, 1994). Workers at the Institute of Psychiatry have
tried to shed light on medial temporal lobe functioning in schizophrenia with verbal
memory testing. The first study identified generally greater rCBF increases in the left
medial temporal and anterior cingulate cortices (Busatto et ah, 1994), while the second
showed left basal ganglia hyperactivity in hallucinating patients that was not related to
medication levels (Busatto et ah, 1995). A previous resting study found a similar
association between hallucinations and subcortical blood flow (Musalek et ah, 1989), as
has another in which a failure of striatal suppression was evident during the WCST in
never medicated patients (Rubin et ah, 1991). Such a failure to deactivate the left
striatum might conceivably be related to postulated internal monitoring deficits in
schizophrenia.
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1.3.4.3 Other SPET studies
There are a handful of SPET reports using the tracer IMP or the dopamine ligand
IBZM in patients with schizophrenia. Resting IMP studies have shown both
hypoffontality (Suga et al., 1994) and hypotemporality (Cohen et ah, 1989a), while two
reports have described increased IMP uptake in left superior temporal regions during
active hallucinating (Matsuda et al., 1989; Suzuki et al., 1993) and factor analysis has
related negative symptoms to hypoffontality, disorganisation to the anterior cingulate
cortex and hallucinations to right sided rCBF increases (Yuasa et al., 1995).
IBZM is a highly specific D2-receptor ligand with relatively specific striatal uptake
and a long radioactive half-life, making it suitable for in vivo ligand studies. Pilowsky and
colleagues compared IBZM binding in patients on standard and atypical neuroleptics and
found that therapeutic response was not dependent upon D2 blockade (1992); and went
on to establish that there was no difference in striatal D2 receptor availability in typical
antipsychotic responders and non-responders (1993). Other researchers have largely
confirmed these findings (Volk et al., 1994; Klemm et al., 1996), while Sherer et al..
(1994) found that striatal receptor occupancy was related to extra-pyramidal side effects.
These studies not only challenge the simple dopamine model of schizophrenia, but also
suggest that such techniques could improve drug monitoring in clinical practice.
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1.3.5 CONCLUSIONS FROM SPET STUDIES IN SCHIZOPHRENIA
It is apparent that an 'absolute' hypofrontality, as measured with Xenon inhalation,
is a relatively robust finding in the studies of schizophrenia and that it does not appear to
be an artefact ofmedication exposure. The results are much less consistent with the tracer
HMPAO, but the enhanced spatial resolution it affords will allow the detection of more
specific areas of increased and decreased rCBF in further studies. Activation experiments
with both techniques reliably show hypofrontality - particularly with the WCST - which is,
if anything, improved with treatment. Although such impairment could simply reflect a
worse performance on the task, it can be seen that frontal lobe function is disturbed in
schizophrenia. The majority of clinical correlation studies show that such frontal rCBF
deficits are related to negative symptoms, while acute episodes tend to be associated with
increases in frontal perfusion. Auditory hallucinations appear to result from a
dysregulated neuronal circuit that includes cingulate, temporal and subcortical regions; and
whether perfusion is increased or decreased may depend on methodological factors such
as the reference region. However, few of these findings appear to be specific to
schizophrenia. Similar abnormalities, of general hypoperfusion (Mathew et al., 1980),
rCBF asymmetry (Gur et al., 1984), hypoffontality (Austin et al., 1992) and
hypertemporality (Zohar et al., 1989), have been reported in the affective disorders.
Berman et al. (1993) reported that WCST activated hypoffontality was not found in
depression, but they only included ten patients in the study. Future research should
concentrate on using larger samples of patients, novel activation paradigms, and determine
whether hypoffontality is attributable to structural tissue loss.
SPET does suffer ffom poorer resolution, worse (Compton) scatter and a greater
need for attenuation correction than PET, which can also give absolute values of rCBF or
substrate use and neuroreceptor density or occupancy. Ironically, however, improvements
in SPET technology have been hindered by the amount of attention given to PET scanning
(Rosenthal et al., 1995).
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1.4 POSITRON EMISSION TOMOGRAPHY (PET)
1.4.1 PET METHODOLOGY
PET is most commonly employed to measure the regional cerebral metabolic rate
in terms of glucose utilisation (rCMRgl). The PET scanner uses a ring of radiation
detectors to produce images of the distribution of radio-isotopes in the brain. The
isotopes are labelled with one of four radionuclides - ^C, ^N, '^O, and ' - which are
unstable, have an excess of protons and emit positrons during radioactive decay. The
positrons travel a certain distance (1-3mm) before losing kinetic energy and colliding with
a free electron, with the consequent emission of two 511 KeV gamma ray photons at 180
degrees to each other (Buchsbaum, 1987). (From the laws of energy and momentum
conservation, and E = mc^, 51 IKeV is the energy equivalent of the mass of a positron).
Gamma-sensitive radiation detectors, usually of either sodium iodide or bismuth
germinate crystals, scintillate in response to two simultaneous (within 5-20 nanoseconds)
photons at 180 degrees in a 'coincidence circuit'. The brain image is reconstructed from a
filtered-back projection algorithm of all these coincidence lines, with filtering ('smoothing')
chosen to balance propitious spatial resolution against statistical noise and edge effects.
Basic positron physics - the distance travelled ('positron range'), the difference in arrival
time ('time of flight'), and any momentum at collision leading to angular deviation from
180 degrees ('non-colinearity') - limit the ultimate resolution of PET to 2-3mm, although
technical developments could improve on the current resolutions of 5-10 mm
(Buchsbaum, 1987).
For quantitative analyses the photon count must be converted into true
radioactivity, with corrections for attenuation (as a result of photon energy loss or the
scattering by brain tissue, which is most marked in central tissues), finite resolution
(blurring of large structures), partial volume effects (underestimation of counts in small
structures due to dilution from surrounding tissue), random coincidences and the
inevitable statistical noise from radioactive decay. By comparison with the substrate
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concentration in the blood, together with a mathematical model of metabolism, the
metabolic rate of each element of the brain image is calculated (Holcomb et al., 1989).
PET measurements of metabolism depend on the observation that the functional capacity
of the adult brain is almost entirely dependent on oxidative glucose consumption, although
the usual tight coupling between rCBF and oxygen extraction is loosened in some acute
diseases and on acute physiological stimulation (Raichle et al., 1976; Fox & Raichle,
1986; Fox et al., 1988).
Particular nuclides are incorporated into specific compounds for use in different
techniques for determining metabolism. The rate of utilisation of ^O-labelled carbon
monoxide/oxygen/water are examples, but the half-life of only two minutes dictates that
steady state activity is more accurately measured than physiological changes in activity.
The latter requires a longer nuclide decay, to allow a sensitive and robust detection of
physiological processes, such as the fifteen minute half-life of ' ^C-labelled 2-deoxy-D-
glucose (2DG). 2DG is used rather than labelled glucose as it accumulates (for at least 40
minutes) as 2DG-6-phosphate after metabolism by hexokinase, rather than progressing
further along the glycolytic pathway, and is only slowly metabolised by phosphatase or
removed from the cell thereafter (Phelps et al., 1981a; Nelson et al., 1986). The most
commonly used nuclide is ^F-labelled 2DG (FDG) as this has a half-life of 110 minutes,
allowing multiple scans and sequential activations in the same session, with the possibility
of delineating specific functional anatomy in adjacent brain areas by appropriate
subtractions from baseline activity - which would otherwise demand multiple radio-isotope
dosing (Fox et al., 1986).
PET can also be employed to determine neurotransmitter turnover, by
administering a radioactive substrate (e.g. ^F-L-dopa), and receptor quantification by a
variety of techniques involving labelled ligands. In vivo receptor density measurement,
which is the more relevant technique to psychiatric research, can be undertaken by either
single-dose tracer kinetics or saturation analysis at equilibrium (Wagner et al., 1983;
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Sedvall et al., 1986). A ligand's retention by a receptor population (binding potential) is
the product of its tendency to dissociate from binding sites at equilibrium (Kd) and the
number of sites available (Bmax). Tracer activity in the caudate-putamen is curvilinear
and taken as a measure of total binding (especially if receptor numbers are low), whereas
that in the cerebellum is linear and reflects non-specific and free binding, the difference
between the two being specifically bound ligand (Wagner et al., 1983). Such calculations
can be facilitated (increasing signal to noise) by comparing the binding before and after the
administration of an unlabelled ligand such as haloperidol, which lowers the available
number of receptors. Kinetic studies use * 1C-3N-methylspiperone (NMSP) or one of its
analogues as the tracer, which are assumed to bind irreversibly and only require one pre-
treatment. Saturation experiments use ^C-raclopride and assume that brain tracer
metabolism is minimal, equilibrium is quickly attained, and that endogenous dopamine and
non-specific binding are negligible; as such, the cerebellar concentration essentially reflects
only free ligand, but this method requires larger doses of radioactivity due to sequential
imaging with different amounts of unlabelled raclopride (Sedvall et al., 1986). These
techniques can also be employed to estimate the receptor occupancy of different
medications as used in clinical practice, but all PET techniques are methodologically
complex and the results obtained are therefore subject to a number of possible artefacts.
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1.4.2 PET METHODOLOGICAL PROBLEMS AND POTENTIAL ARTEFACTS
Provided that the head is immobilised, the most important methodological concern
in PET studies is that the inter-subject variability in brain size and shape are controlled for
so that comparable functional localisations are possible. Head position must first be
standardised, usually by reference to inter-commissural line (the AC-PC plane), before
functional-structural image co-registration with CT/MRI or a pixel-by-pixel matching to a
standard template in stereotactic space, followed by 'redirected sampling' to allow for
measurements of regional brain tissue activity (Bench et al., 1990). Pixel matching must
be accurate as misalignment by as little as 3mm can substantially alter the activity detected,
especially where grey/white matter differences in isotope concentration can be as high as
100%. This sort of error might also compound, for example, the yield of artificially low
grey matter values (of 50-60 ml/lOOg) with water studies.
Unless the scanner covers the whole brain, there will be some 'dead space' where
portions of some structures - such as the basal ganglia - are not imaged. Such partial
volume effects increase measurement error and are most pronounced in small, thin or
wedge-shaped structures than larger spherical ones (Buchsbaum, 1987). The diameter of
a circle where the count rate is 50% of that at the centre is the full-width at half-maximum
(FWHM) value and approximates to the image resolution. A structure that is only as wide
as the FWHM will have a measured value diluted by about 70% (Buchsbaum, 1987),
while two activated structures separated by only the FWHM cannot be distinguished from
each other unless sequential activations are undertaken (Fox et al., 1986).
Statistical analysis faces the problem of numerous (highly correlated)
measurements in a relatively small number of subjects. These problems are reflected in the
use of at least seven different analytical strategies in the early PET literature (Holcomb et
al., 1989). Further difficulties in comparing studies arise from the lack of standardised
physio-behavioural test conditions, the high levels of inter-subject variance that are
compounded in studies of heterogeneous disorders, and uncertain inter-relations between
74
Chapter 1: Literature review
task activations in various patient groups. A within-subject test-retest design therefore has
maximal power and reliability; preferably with analysis by principal components structure
in the same subjects under multiple conditions.
Workers at the Hammersmith in London have developed more refined analysis
techniques than those in early use. Whereas researchers used to employ a region of
interest method in individual slices, Friston et al. (1990 & 1992a) have devised a Statistical
Parametric Mapping (SPM) programme which allows coverage of the whole brain.
Activated areas are identified by a conservative measure of statistical significance, with an
analysis of co-variance to control for global blood flow changes and a principal
components analysis to examine functional connectivity between discrete areas.
Finally, differences in subject groups are an important possible source of artifactual
results. Such subjects are inevitably selected on the basis that they can comply with the
immobilisation over a period of time demanded by the procedure. Differences in age, sex
distribution, anxiety levels or habitual amounts of drug consumption can systematically
confound the results obtained. There is an age related decline in blood flow to grey but
not white matter, which is not paralleled by a decline in oxygen metabolism (Bench et al.,
1990). While global metabolism may not differ between relatively young age groups,
relative frontal metabolism does appear to decrease from an early age (Wang el al., 1994)
and dopamine receptor numbers fall by approximately 10% per decade (Wong et al.,
1984). Females have greater glucose metabolism in all brain regions than men (an average
of 19%) which may vary across the menstrual cycle (Baxter et al., 1987). Finally, both
low levels of arousal/anxiety and acute administration of many drugs may increase rCBF
and metabolism, while severe anxiety and chronic drug abuse reduces these measures
(Mathew & Wilson, 1990 & 1991). The latter findings appear to apply to both normal
subjects and those with psychiatric disorders.
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1.4.3 PET STUDIES IN NORMAL SUBJECTS
A substantial body of experimental work has been performed with PET in normal
subjects, with activation by sensory, cognitive or pharmacological stimulation (Roland,
1993). Visual tasks result in 8% greater glucose use in the contralateral hemisphere with
hemi-field stimulation (Greenberg et al, 1981), bilateral increases of up to 50% with a
reversing checkerboard (Fox et al, 1986; Fox et al., 1988), and glucose use increases
further - by a factor of two - with an increasing complexity of visual stimuli (Phelps et ai,
1981a&b). Light stroking of the hand results in 9% greater contralateral metabolic
activity (Greenberg et al, 1991), while vibratory somatosensory stimulation focally
increases the rCBF in contralateral sensorimotor cortex by as much as 29% (Fox &
Raichle, 1986). Auditory stimulation experiments have demonstrated that glucose use
increases with attention to the stimulus, and that using an analytic strategy to remember a
sequence of tones results in greater left sided metabolism (especially of mesial temporal
lobe structures) whereas a non-analytic strategy increases right side use more (Mazziotta,
1985). Further evidence suggests that the hippocampus is particularly important in
memory function (Squire et al, 1992), although particular episodic or semantic memory
tasks selectively activate additional cortical regions (Paulesu et al, 1993; Shalliee et al,
1994). Such experiments are even beginning to shed light on the nature of consciousness
itselfwith, for example, demonstrations that multiple sensory representations of the body
exist in the brain that contribute to perception (Bottini et al, 1995) and that both random
and focused episodic memory activate medial frontal and limbic regions which may
underlie the experience of identity and self-awareness (Andreasen et al, 1995). It should
be borne in mind that such insights have been derived from sequential activation and
subtraction experiments, whereas the early research in schizophrenia was largely limited to
resting studies. This has undoubtedly contributed to increased measurement variance and
slowed the delivery of consensus regarding functional imaging findings in schizophrenia.
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1.4,4 PET STUDIES IN SCHIZOPHRENIA
1.4.4.1 Resting Studies
The first replicated finding with PET studies in schizophrenia was the
demonstration of "hypoffontality" and most subsequent studies have focused on this issue.
Buchsbaum and colleagues (1982) at NIMH were the first to demonstrate this, reporting
that the relative frontal: occipital FDG-CMRgl (and left central grey matter utilisation) at
rest was significantly reduced in 8 unmedicated patients as compared to 6 normal controls.
Subsequent resting FDG studies have reported relative (Farkas et al., 1984; DeLisi et al.,
1985a) or absolute (Wolkin et al., 1985) reductions in frontal:occipital metabolism, or
both (Wolkin et al., 1988; Siegel et al., 1993), and most of those to find neither (Kling et
al., 1986; Gur et al., 1987b; Tamminga et al., 1992) have still found non-significant
reductions. Although the subjects in these studies have either been medicated or only off
medication for about two weeks, medicated and unmedicated patients were no different in
one study (Farkas et al., 1984), and prospective studies have found that relative
hypofrontality persists after treatment despite a general improvement in glucose utilisation
(Farkas et al., 1984; DeLisi et al., 1985b; Wolkin et al., 1985) - although others have
found hypofrontality to be compounded in patients with prominent negative symptoms
(Buchsbaum et al., 1992; Wolkin et al., 1996). However, Cleghorn's group in Ontario
have reported relative hyper-frontality in both medicated (Szechtman et al., 1988) and
drug-naive patients with schizophrenia (Cleghora et al., 1989); and Gur et al. (1995) also
reported non-significant tendencies to increased frontal metabolism in first episode and
medication free patients.
FDG studies have also tended to report some extent of absolute or relatively
reduced glucose metabolism in the temporal lobes (Buchsbaum et al., 1982; Wolkin et
al., 1985; Gur et al., 1987b; Cohen et al., 1989b, Tamminga et al., 1992; Siegel et al.,
1993), although some have found 'hyper-temporality' (DeLisi et al., 1985b&e; Gur et al.,
1995) particularly on the left side. The other brain region to receive extensive study, the
77
Chapter 1: Literature review
basal ganglia, has been shown to have generally reduced absolute metabolism but less
consistently reduced relative CMRgl (Buchsbaum et al., 1982; Wolkin et al., 1985;
Buchsbaum et al., 1987; Gur et al., 1987b; Resnick et al., 1988; Szechtman et al.,
1988; Cohen et al., 1989b; Tamminga et al., 1992; Siegel et al., 1993; Gur et al.,
1995). A possible explanation of these inconsistencies is that metabolism is habitually
increased in both temporal lobes and the basal ganglia by antipsychotic medication
(Wolkin et al., 1985; DeLisi et al., 1985b; Buchsbaum et al., 1987; Holcomb et al.,
1996), so that the medication status of patients is particularly important when studying
these regions. Other statistically significant results of interest to be reported with FDG-
PET include 'hypo-parietality' (Cleghorn et al., 1989), an increased sub-cortical/cortical
gradient (Gur et a/., 1987b) and greater left-right asymmetry in unmedicated patients
(Gur etal., 1987b).
Some of these findings have been replicated by researchers using other radio¬
isotopes, such as carbon-11 labelled DG, in PET studies of schizophrenia. Volkow et al.
reported general hypermetabolism in unmedicated patients that did not alter substantially
after treatment (1986), and widespread hypometabolism but hyper-subcorticality in
medicated patients (1987). Other 'CDG' findings include hypofrontality and
hypoparietality in sub-groups of medicated patients (Kishimoto et al., 1987), and left
sided hypoffontality and hypotemporality in unmedicated patients (Wiesel et al., 1987a).
Two studies using the oxygen steady-state technique have failed to demonstrate
hypofrontality (Sheppard et al., 1983; Early et al., 1987). The former study included
medicated patients and found reduced basal ganglia activity and diminished left-right
asymmetry, while the latter (in never medicated patients) reported increased left globus
pallidus blood flow in never medicated patients. However, as with SPET, more consistent
results have been forthcoming in activation experiments.
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1.4.4.2 Activation experiments
The main advantage of activated measures ofmetabolism is that this is a relatively
straightforward method of controlling for inter-individual behavioural and physiological
differences. The first such study reported that patients with schizophrenia (and bipolar
affective disorder) showed a lower anteroposterior gradient and lesser lateralisation than
controls after unpleasant electrical stimulation to the right arm. However, this did not
necessarily mean reduced metabolism in frontal regions, as an increased posterior
utilisation was responsible for the reduced gradient (Buchsbaum et al., 1984). On
auditory vigilance tasks, schizophrenics have shown non-significant hypofrontality and
significant hypertemporality in one study where only six patients were examined (Jernigan
et al., 1985), and significantly reduced metabolism in the middle frontal and anterior
temporal lobes in a larger study of drug-free subjects (Cohen et al., 1987). Other FDG
activation experiments, employing visual continuous performance tests (CPT), have
reported relative hypofrontality, hypotemporality and diminished subcortical metabolism in
both ex-medicated (Buchsbaum et al., 1990) and never-medicated patients (Buchsbaum et
al., 1992), and in a large series of 83 subjects (Schroeder et al., 1994), although these
results have still to be independently replicated. The remaining FDG activated experiment
has found evidence of significantly reduced left temporal metabolism on amphetamine
challenge, which was associated with negative rather than positive symptoms (Wolkin et
al., 1994).
Various researchers have also used other PET techniques to measure activation
and some (in the case of the London group) have devised highly innovative cognitive
stimulation procedures. Guenther et al. (1994), using carbon-11, reported results
suggestive of an abnormal (hypoffontal-hypersubcortical) pattern on motor tasks that was
in keeping with their previous study (Guenther et al., 1989). The only other carbon-11
study examined the effects of an eye-tracking task in 18 medicated schizophrenics and
revealed marked hypoffontality both at rest and on activation (Volkow et al., 1987).
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Nakashima et al. (1994) also found a failure of frontal activation in medicated and
unmedicated patients whilst performing visually and memory guided saccades, although
H^-'O-rCBF was actually higher in all conditions in the patients.
Workers at the MRC Cyclotron Unit in London, using the F^-'O technique, have
particularly focused on the functional anatomy of auditory hallucinations as one of the
central features of the disorder. Following their demonstration of increased rCBF in
Broca's area during hallucinations (McGuire et al., 1993), they asked hallucinators and
non-hallucinators to imagine being spoken to in another person's voice. All groups,
including controls, exhibited a normal left frontal response but only the hallucinators had
reduced activation in the left middle temporal gyrus and rostral supplementary motor area
- suggesting that a predisposition to such phenomena is associated with a failure to
activate areas concerned with the monitoring of internal speech (McGuire et al., 1995).
In another experiment, with paced verbal fluency that matched for performance, chronic
patients showed (if anything) a greater spatial extent of activation in the DLPFC and a
convincing lack of rCBF reductions in the left superior temporal cortex as was found in
simple word repetition (Frith et al., 1995). These workers have also recently examined
the effect of dopaminergic (apomorphine) modulation of the neural response to paced
verbal fluency and found that the impaired activation of anterior cingulate was reversed
into a significantly augmented response as compared to normal controls (Dolan et al.,
1995). These findings not only provide a bridge between the putative
neuropharmacological and cognitive abnormalities in schizophrenia, but have also been
seen as evidence against simple hypoffontality and for hypotheses of abnormal ffonto-
temporal connectivity. The latter, in particular, has also been supported by some of the
findings from clinical correlational analyses ofPET data.
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1.4.4.3 Clinical and Biological correlations
Many workers have attempted to relate abnormalities of metabolism to the clinical
features of schizophrenia. There are, in particular, strong suggestions that hypoffontality
may be related to the presence of negative symptoms (Volkow et al., 1987; Wiesel et al.,
1987a; Tamminga et al., 1992; Wolkin et al., 1992; Schroder et al., 1996) or total
symptomatology (Siegel et al., 1993). Hypertemporality may be associated with both
positive and negative symptoms (Gur et al., 1995; Schroder et al., 1996), but Wiesel et
al., (1987a) found the relationship was with reduced temporal metabolism. The severity
of hallucinations has been positively correlated with anterior cingulate metabolism and
may also be associated with reduced metabolism in the auditory cortex and Broca's area
(Cleghorn et al., 1990 & 1992). The London group reported that auditory hallucinations
were associated with activation in limbic (hippocampus), paralimbic (parahippocampus)
and subcortical (thalamus) structures, as well as the right anterior cingulate, and also
found that the association cortices were activated in a single case with both visual and
auditory hallucinations (Silbersweig et al., 1996).
Following the lead of Liddle et al. (1992), other groups have shown a negative
symptoms factor ('psychomotor poverty') to be related to left DLPFC metabolism,
positive symptoms ('reality distortion') with right medial prefrontal cortex (and left
temporal) metabolism, and disorganisation with left superior temporal activity (Kaplan et
al., 1993; Schroder et al., 1996). Although the sign of these correlations, and their
precise location, differs in some of these studies this could be attributable to whether the
patients are fundamentally hypo- or hyper-frontal, and to activation or medication status
differences. Differences are also evident, for example, in the common symptom cluster in
medicated resting (Liddle et al., 1992) or un-medicated activated (Schroder et al., 1995)
patients, which has been located in the left parahippocampal gyrus (Friston et al., 1992b)
and the anterior cingulate respectively.
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Two groups have also examined the pattern of inter-regional correlations in
unmedicated patients; the first reporting more positive inter-correlations of CMRgl
between neo-, sub- and limbo-cortical regions in patients than in controls at rest (Wiesel et
al., 1987b), and the second finding fewer positive inter-correlations between frontal and
temporal cortex and subcortical structures whilst performing the CPT (Katz et al., 1996).
Finally, there have been attempts to link hypofrontality with CT structural measures, with
two studies found no association with CT rated cerebral atrophy (DeLisi et al., 1985a;
Wiesel et al., 1987a) but one reporting an association with ventriculomegaly and sylvian
fissure enlargement (Kling et al., 1986).
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1.4.4.4 Receptor binding studies
As already described, these studies can be used to quantify receptor numbers and
to image the effects of drugs in the brain. Seminal work in the 1970's had shown that the
potency of a drug in binding to dopamine receptors was very strongly correlated with the
dosage required in clinical practice (Seeman et al., 1976; Creese et al., 1976) - one of the
main pillars of the 'dopamine hypothesis of schizophrenia'. Subsequent PET studies have
shown that conventional doses of typical neuroleptics result in 70-90% D2 blockade, with
higher occupancy in those with extra-pyramidal side effects, while the atypical neuroleptic
clozapine is associated with only 40-60% occupancy (Farde et al., 1992). With the
development of more receptor ligands such studies may help in the rational development
of new treatments for schizophrenia, but they have already begun to shed light on the
pathophysiology of the disorder.
Post-mortem studies found increased densities (Bmax) of dopamine receptors in
deceased patients with schizophrenia (Lee et al., 1978; Owen et al., 1978; Seeman et al.,
1984) but these changes could have been attributable to antipsychotic medication effects
and in vivo PET studies have been able to examine this possibility. The ideal ligand needs
to be selective, saturable and bind with high affinity so as to give anatomical and
neurochemical specificity (Sedvall et al., 1986); such as the relatively selective (labelled)
dopamine binding drugs '' C-raclopride and ' 1C-3N-methylspiperone (NMSP). Wong et
al. (1986) reported 2-3 fold higher D2 receptor densities in the caudate nucleus of both
treated and untreated patient groups using NMSP. However, workers at the Karolinska
institute in Sweden used the much more selective dopamine blocker raclopride (Farde et
al., 1985) in a larger number of never-medicated patients and found no significant
difference in D2 receptor density on PET (Farde et al., 1987 & 1990). Subsequent studies
have failed to resolve these discrepancies. Although an independent raclopride study also
failed to find significant differences in schizophrenia (Hietala et al., 1994), and the NMSP
results have only been internally replicated - by Tune et al. (1993), but not by Nordstrom
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et al., (1995) - the Johns Hopkins group have suggested that Type II errors have hidden
an overall increase of 65% in dopamine receptor numbers across the five studies (Gjedde
et al., 1995). It has also been suggested that raclopride underestimates changes in D2
receptor density (Seeman et al., 1990) and that the NMSP studies may reflect an increase
in the recently discovered D4 receptor rather than D2 activity (Seeman et al., 1993).
Two other studies have widened this research agenda by suggesting pre-synaptic
abnormalities of increased fluorodopa uptake (Hietala et al., 1995) and elevated dopa
decarboxylase activity (Reith et al., 1994) in schizophrenia. Furthermore, increased D2
binding may also be found in bipolar disorder (Pearlson et al., 1995), which raises
important questions about the specificity of all the findings with PET in schizophrenia.
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1.4.5 ARE THE PET FINDINGS SPECIFIC TO SCHIZOPHRENIA?
Similar results (and inconsistencies) to those described above are apparent in the
neuro-imaging literature in other psychiatric disorders. Most work has been done on the
affective disorders, where hypofrontality has been reported by in unipolar depression
(Buchsbaum et al, 1984; Cohen et al., 1989b), bipolar affective disorder (Baxter et al.,
1985) or both (Baxter et al., 1989), and reduced metabolism in the caudate nucleus is a
fairly consistently finding in studies of depressed patients (Buchsbaum et al., 1984; Baxter
et al., 1985). In addition, increases in subcortical metabolism have been repeatedly
demonstrated in obsessive-compulsive disorder, which normalise after successful
behavioural treatment (Schwartz et al., 1996). Anxiety states are also associated with
PET scan changes with, for example, parahippocampal gyrus abnormalities in panic
disorder (Reiman et al., 1984, 1986 & 1989) and rCBF increases in limbic regions on
symptom provocation in phobias (Rauch et al., 1995) and post-traumatic disorder (Rauch
et al., 1996). Hypofrontality has also been described in anorexia nervosa (Delvenne et
al., 1995). Although these findings are nothing like as well replicated as in schizophrenia,
there are far fewer relevant studies. As well as questioning specificity, they raise
important methodological issues - such as the necessity to exclude co-morbid patients.
Moreover, given recent reports of mood induction leading to limbic and paralimbic
changes in metabolism (e.g. George et al., 1995), arousal or sadness during scanning are
likely to confound the results obtained - particularly in resting studies.
Finally, intriguing evidence for possible similarities in the neurobiology underlying
sub-types of the major psychoses has come from an opportunistic study from London -
where poverty of speech was associated with left sided hypofrontality independent of
diagnosis in 40 patients with depression and 30 with schizophrenia (Dolan et al., 1993).
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1.4.6 CONCLUSIONS FROM PET STUDIES IN SCHIZOPHRENIA
The resting PET studies, therefore, do generally report a hypoffontality in
schizophrenia that does not appear to be attributable to the effects of medication, while
putative abnormalities in other regions are less well replicated and more influenced by
medication status. Activation experiments, as with SPET, provide almost unanimous
support for functional abnormalities, although the exact direction and location of these
appears to critically depend on methodological factors such as the task employed,
scanning technique and clinical status of the subjects. Deficits in frontal and temporal
rCBF or metabolism seem to be linked to negative and positive symptoms respectively,
but there is a gradually increasing awareness that such neuroanatomical localisation is
simplistic and ignores likely abnormalities in the connectivity between these and other
brain regions. Receptor binding studies not only promise a clear clinical application of
neuroimaging - in drug development and monitoring - but also suggest a possible
pathophysiological mechanism of increased dopamine receptor activity in schizophrenia.
Inconsistent results in these research areas are understandable given the oft-cited
'heterogeneity' of the disease and its manifestations, and the small sample sizes in most
studies; but there is some evidence that putative abnormalities are not specific to
schizophrenia. Symptom based research has much to commend it, in terms of potentially
identifying the neural substrates of particular phenomena, but it should not be surprising if
it proves difficult to tease apart diagnostic groups on the basis of clinical features that are
similar across the 'functional' psychoses. Future studies must therefore concentrate on
these issues while remaining alert to the fact that the longitudinal course of schizophrenia
and the affective disorders was the original basis of their distinction and remains one of the
most reliable ways of clinically differentiating them. PET and SPET are less suitable
techniques for monitoring changes over time than some of the less invasive methods which
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2.1 INTRODUCTION
Kraepelin first distinguished the functional psychoses on the basis of outcome,
characterising Dementia Praecox as a progressively deteriorating condition, but came to
recognise that some patients - 13% of his own series - reached an apparently full recovery
(Kraepelin, 1919). Outcome predictors have been described since the seminal work of
Vaillant (1964), but many of the features associated with illnesses of a good outcome -
such as acute onset, older age, good pre-morbid psychosocial adjustment, clear
precipitants and affective features - also indicate an "atypical" nature to the psychosis
(Kasanin, 1933; Langfeldt, 1960). In the modern era, treatment response is a more
immediate concern than overall outcome; with repeated confirmations that medication has
a variable effect in schizophrenia. A substantial number of patients will make a virtually
complete symptomatic recovery (Jablensky et al., 1992), while repeated trials have found
that up to 25% of patients derive little and some 10% no benefit from typical neuroleptic
drug therapy (Davis, 1976), and 6-8% fail to respond to many months or years of
intensive antipsychotic treatment (MacMillan et al., 1986; May et al., 1988). Optimal
prediction of treatment response has an obvious relevance in the management of
schizophrenia.
The interplay between prognostic features of the illness and treatment response has
been little studied, and they may have differing influences on overall outcome in clinical
practice. For example, long-term outcome may relate more to the personal, social and
historical characteristics of individual sufferers (Vaillant, 1964), whereas treatment
response may be more dependent upon biological factors (Lieberman & Sobel, 1993).
The conventional view is that drug treatment can override, at least partly, the usual
prognostic effect of the static demographic variables (May & Goldberg, 1978). It is
therefore tempting to speculate that inter-individual differences in response - and the
pattern of its associations with other clinically and biologically relevant features of
schizophrenia - may reflect the heterogeneity of the underlying disease(s), serve as a
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means of identifying sub-types and shed light on the pathophysiology of the illness.
Recent developments in brain imaging and neuropsychological measures of brain function
have increased the possibilities for investigations in this area.
A number of research groups have made preliminary examinations of the biological
associations of outcome or treatment response. CT studies have used the relatively
insensitive area measure of the Ventricle-Brain Ratio (VBR), in 'good' and 'poor' patient
groups divided on an arbitrary basis, and delivered inconsistent results as to whether there
is a significant relationship between abnormal morphology and treatment response (e.g.
Weinberger et ah, 1980; Nasrallah et al., 1983a), or outcome (e.g. Kolakowska el ah,
1985; Losonczy et ah, 1986). MRI studies have occasionally described an association
between large lateral ventricles and poor outcome (Johnstone et ah, 1989b; DeLisi et ah,
1992), but usually as a post hoc correlation. Functional brain imaging techniques, such as
SPET and PET, have repeatedly demonstrated that higher negative symptom scores,
which may be indicative of a worse outcome, are commonly associated with hypofrontality
(e.g. Liddle et ah, 1992; Ebmeier et ah, 1993), particularly in chronic patients, but few
have specifically examined outcome or treatment response. Finally, several researchers
have identified cognitive deficits in schizophrenia, and found such impairments to be
associated with a poor outcome (Johnstone et ah, 1978; Golden et ah, 1980), although
this could be partly attributable to differences in motivation or concentration associated
with varying degrees of symptomatology or medication.
The purpose of this study was to use such techniques, in a priori dichotomised
patient groups, to identify the associations of treatment response. MRI, SPET and a
comprehensive neuropsychological test battery were employed to test the hypotheses that
treatment resistant patients would show more evidence of structural abnormality,
functional underactivity and cognitive deficit than treatment responsive patients.
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The specific hypotheses to be tested, and their justification, are as follows:
1. MRI - The previous literature, as reviewed in Chapter 1, suggests that the brain
regions most abnormal in schizophrenia are whole brain, the lateral and third
ventricles, left and right temporal lobes, and mesial temporal lobe structures such as
the amygdala and hippocampus. Greater degrees ofmorphological abnormality are
generally associated with more clinical disturbance. In particular, given that the
greatest changes are likely to be found in mesial temporal lobe structures, and that
these are most likely to be associated with the positive symptoms that
characteristically respond best to antipsychotic medication, the specific prediction is
that the hippocampus volume will be smaller in treatment resistant than responsive
patients.
2. SPET - Similarly, given that patients with schizophrenia are most commonly found to
be 'hypofrontal' as compared to normal controls, and that more severe symptoms are
generally associated with greater functional imaging abnormality, the specific
prediction is that frontal regions will show reduced tracer uptake in treatment resistant
as compared to responsive patients.
3. Neuropsychology - There is less of a literature on the neuropsychology of
schizophrenia and the association with symptoms, but the current consensus is that
deficits in attention and memory are most reliably detected beyond what would be
expected through general intellectual impairment. Accordingly, the best prediction is
that treatment resistant patients will show greater impairment on attention and
memory tasks - after taking global intellectual ability into account - than treatment
responsive subjects.
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2.2 METHODS
2.2.1 Subjects
Forty patients who satisfied DSM-III-R criteria (American Psychiatric Association,
1987) for Schizophrenia or Schizophreniform disorder were recruited from in- and out¬
patient populations at the Royal Edinburgh Hospital and associated hospitals. Two
dichotomous patient groups were sought, treatment responsive and treatment resistant,
according to the descriptive criteria for degree of Treatment Resistance proposed by May
et al. (1988). These criteria describe six levels of treatment resistance, varying between
"total remission within a week, whatever treatment is given (Level 1)" to "failure to
respond to any useful extent after six months' hospital treatment (Level 6)" (May et al,
1988). In practice, no patients were found to satisfy these extreme levels as remission did
not occur within one week in those satisfying criteria for schizophrenia and facilities to
measure plasma neuroleptic levels (as required for Level 6) were unavailable. The twenty
treatment responsive patients were those "...who respond well within one month...able to
return to the same social situation as before...with little if any residual scarring (Level 2)"
or, at worst, "patients who show a major reduction of symptoms within a month...(some)
residual schizophrenic disorder... able to return to earlier social existence... (but with)
reduced ability to study or work (Level 3)". The twenty patients designated as treatment
resistant all showed "psychotic symptoms or disturbed behaviour (that) does not
remit...such that they will remain for a long while in hospital or some alternative from of
caring milieu (Level 5)". Thus, there were no patients at level 4. The selection process
was designed to yield two groups of twenty patients each, who were matched for sex (ten
male and ten female in each group), age (within 6 years) and duration of illness (within 6
years). Patients were excluded if they suffered from any neurological condition, current
substance abuse or major depression, and all women had a pregnancy test before the
scans.
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2.2.2 Clinical Assessments
All 40 subjects underwent a detailed clinical examination including: a structured
psychiatric interview, the Present State Examination (Wing et al., 1974); a standardised
rating of current symptomatology, the Manchester Symptom Scale (Krawiecka et al.,
1977); and a brief neurological examination to detect evidence of dyskinesia on the
Abnormal Involuntary Movement Scale (AIMS) and the Targeting Abnormal Kinetic
Effects (TAKE) scale (Wojcik et al., 1980). This was supplemented by information from
the patients' psychiatric casenotes to complete the Schedule for Affective Disorders and
Schizophrenia - Lifetime Version (SADS-L; Spitzer & Endicott, 1978), for Research
Diagnostic Criteria (RDC; Feighner et al., 1972) and a modified version of the DHSS
Survey form (Johnstone, 1991).
These assessments gave a detailed record of the patients' psychiatric history - in
particular, of age at illness onset, duration of illness, number and duration of hospital
admissions - parental social class and a comprehensive account of medication exposure.
Age of onset was defined as the age at first contact with a psychiatrist who recorded
sufficient features to satisfy DSM-III-R diagnostic criteria for schizophrenia; the duration
of illness taken from this date until the beginning of the investigation in January 1992.
Exposure to psychotropic medication, in particular to antipsychotic and anticholinergic
agents, was recorded as the current dose in chlorpromazine and procyclidene equivalents.
Additional measurements of illness outcome were made from interview and
casenote information. Social outcome, in terms of self care, employment and acceptability
of behaviour, was assessed on the rating scale devised by Cooper (1961), while global
outcome was measured on the McGlashan cross-sectional and follow-up scales
(McGlashan, 1984).
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2.2.3 Magnetic Resonance Imaging
2.2.3.1 Image Acquisition
All 40 patients underwent MRI scanning on a 1.0 tesla Siemens (Erlangen,
Germany) scanner. Mid-line sagittal localisation was followed by two sequences to image
the whole brain. A "Turboflash" sequence, a 3D-FLASH collection 500ms after a spin
inversion (TI = 500ms), with a relaxation delay of one second, was employed to acquire
an image that could be reconstructed in three dimensions. A Spin Echo (SE) dual-echo
scan was also conducted, with a repetition time of 3565ms, and echo times of 20ms to
obtain a proton density weighted image and 90ms for a T2-weighted image (SE 3565/20-
90). The 3D-FLASH sequence was collected as 128 contiguous 1.56mm thick coronal
slices; with flip angle 10 degrees, repetition time 10ms, echo time 4ms, field of view
255mm, and a relaxation delay of one second. The SE scan generated 31 contiguous 5mm
thick axial slices in the Talairach plane; with flip angle 90 degrees and field of view 250
mm. The scans had acquisition matrices of 130 x 256 and 192 x 256 pixels respectively;
both being interpolated to 256 x 256 on transfer to a Sun work station. Thus, the voxel
size was 0.996 x 0.996 x 1.56 mm on the 3D-FLASH image and 0.976 x 0.976 x 5 mm on
the SE image. Regular phantom measurements over the fifteen months of the study
ensured that these sequences remained reliable.
2.2.3.2 Visual Assessment
A clinical neuroradiologist (CGS - see acknowledgements) examined the MRI
scans for structural abnormalities and motion artefact. Two female subjects, both
treatment responsive, were excluded from the study due to a previously undiagnosed
pituitary tumour and left hemisphere infarct respectively, and two additional patients
recruited. One male subject was re-scanned as his first scan was severely degraded by
movement. A standardised clinical assessment was made of the severity of cerebral
atrophy, an "atrophy score", on a seven-point scale (0 to 6), as indicated by the degree of
92
Chapter 2 - MRI, SPET, Neuropsychology and Treatment Response in Schizophrenia
sulcal widening, ventricular size and shape, the relative size of the brain to the cranium,
and the patients' age. High Intensity Signal (HIS) lesions were coded as present or absent,
and their location and numbers noted - being distinguished from Virchow-Robin spaces by
comparison between the proton density and T2 weighted images.
2.2.3.3 Volumetric measurements
Image processing was carried out on Sun Microsystems workstations using the
software package "Analyze" (Mayo Foundation, Rochester, USA) to outline and compute
volumes of the neuroanatomical structures of interest. Structures were identified with the
assistance of a MRI atlas (Duvernoy, 1991), and volumes were calculated by summing
voxels over all slices included. Specific regions of interest were selected a priori as: pre¬
frontal lobes (left and right), temporal lobes (left and right), hippocampi (left and right),
whole brain, intracranial cerebrospinal fluid (CSF), lateral ventricles (left and right), and
third and fourth ventricles.
The pre-ffontal lobes were defined as extending from the frontal pole to the last
slice before the appearance of the fibres of the genu of the corpus callosum (after Suddath
et al., 1990); the temporal lobes defined as extending from temporal pole to the last slice
containing fibres of the crux of the fornix, and the hippocampi defined as extending from
the appearance of the temporal stem to the last slice containing the fornix crux fibres (after
Shenton et al., 1992). The remaining regions of interest were outlined using naturalistic
boundaries (after Suddath et al., 1990). The third and fourth ventricle volumes were
estimated in combination, together with the cerebral aqueduct, as it was difficult to reliably
distinguish their posterior boundaries from the suprapineal and cerebellar cisterns
respectively. The 3D-FLASH scans were used for all measurements, except the whole
brain and intracranial CSF volumes which were calculated from the SE 3565/20-90 scans
after ensuring that the whole brain volumes were closely related by both techniques (inter-
scan correlation r = 0.96; mean difference 30.8 cc, standard deviation (sd) 32.3).
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Comparisons of structure volumes between groups were made both uncorrected and
corrected (as a ratio) for whole brain volume, to control for variations in head size.
2,2.3,4 Inter-Rater Reliability
The assistance of two trained medics was enlisted to conduct the volumetric
measurements, as this took approximately six hours for each brain analysed. All three
volume raters remained blind to group membership. The author (SML) calculated all
ventricular volumes, another rater (GTI) all whole brain and intracranial CSF volumes,
and the third (CGS) the hippocampi, while two raters (SML and GTI) estimated pre¬
frontal and temporal volumes. All three raters examined ten pre-frontal and temporal
lobes to determine inter-rater reliabilities (inter-rater correlation SML-GTI r = 0.93, mean
difference 1.07cc, sd 4.7; SML-CGS r=0.90, mean difference 1.95cc, sd 3.7).
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2.2.4 Single Photon Emission Tomography
SPET imaging was performed on a head dedicated SME-Neuro 900 12-detector
Strichman scanner, using 99mjC-Exametazime (HMPAO) to measure regional cerebral
perfusion. Tracer uptake was measured as count density on slices at 5mm intervals,
extending the full length of the brain, a total of 14 to 18 slices per subject. Three slices
were used in this study: at the mid-ventricular level (including the basal ganglia) 4cm
above the orbito-meatal line (OML), and 6cm and 8cm above the OML. A standardised
brain template, derived from a brain atlas (Talairach et al., 1988), was symmetrically and
linearly transformed to fit the outline of the brain defined by 40% of the images' intensity
spectrum, by a physicist blinded to scan identity and indifferent to the experimental result.
Although this method does not take inter-individual anatomical differences into account, it
leaves the relative relationship of regions of interest to one another intact and provides a
reliable method for determining relative uptake patterns (Ebmeier et al., 1991). Regional
count densities were reconstructed with Neuro-900 software (version 2.66) and analysed
using the Statistical Package for the Social Sciences (SPSS) for Apple Mac, version 4.0.
Group comparisons were conducted after normalising both for whole slice and occipital
uptake; the 36 regions of interest (18 left and right) examined are shown with the results.
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2.2.5 Neuropsvcholoeical Test Battery
Comprehensive testing was undertaken with a wide variety of tasks chosen for
ease of application. Pen and paper tasks included: a measure of pre-morbid intellectual
ability, the National Adult Reading Test (NART; Nelson, 1982); a measure of current IQ,
the Quick Test (Amnions & Ammons, 1962); the Mini-Mental State Examination, as a
measure of global intellectual functioning (MMSE; Folstein et al., 1975); an assessment
of attention/working memory, the Digit Span (forwards and backwards - Randt memory
battery version A) and of psychomotor speed, Digit Symbol Substitution, from the
Wechsler Adult Intelligence Scale - Revised (WAIS-R; Wechsler, 1981). Tests of
executive functioning included: Verbal Fluency, or word production, for animals (Animal
Naming Set Test, Isaacs & Kennie, 1973) and for words beginning with the letter 'A'
(Controlled Word Association Test, Benton, 1978) in 60 seconds; the Stroop test (Stroop,
1935); and Trails 'A' and 'B' (Reitan, 1958). The Annett scale was chosen to measure
handedness (Annett, 1970). The Rivermead Behavioural Memory Test (RBMT; Wilson et
at, 1985) was used as an index of episodic memory. Selected measures from the
Cambridge Neuropsychological Testing Automated Battery (CANTAB; Owen et al.,
1990) were also employed: Spatial and Pattern Recognition, and the Delayed Matching to
Sample tasks as tests of memory, and the Continuous Performance Test as a measure of
sustained attention. Finally, the tester rated the patients attention and co-operation on two
five-point scales (after Shakow, 1981).
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2.2.6 Timing of Investigations and Data Analysis
Once the diagnosis was confirmed and group membership assigned, the usual
sequence of investigation was from MRI to SPET to neuropsychology to clinical
assessment. The SPET scan generally followed MRI within one week (median interval =
6 days). The neuropsychological and clinical assessments were usually completed on the
same day, in two sittings, within a few days of the SPET scan (median interval = 6 days).
The results were largely analysed by SPSS for Mac 4.0. As age, sex and duration
of illness were matched between groups at the design stage, the effects of these variables
were not examined. In order to estimate the probability that the pattern of structural and
functional group differences had arisen by chance a multivariate analysis of variance was
conducted treating the 11 MRI regional volumes and 36 SPET regional tracer uptake
ratios as repeated measures. MRI statistical analyses were conducted on both absolute
and corrected (for whole brain) volumes, while SPET analyses were conducted on
corrected (to whole slice and occipital) uptake ratios. The effects of laterality and region
on structure volumes were examined as two "within subjects' factors", in addition to the
primary comparison "between subjects" of treatment response group membership. This
was followed by a post hoc t-test for individual regions of interest in both the MRI and
SPET scans. Effect sizes were calculated for between group differences in MRI volumes,
by dividing the volume difference by the larger of the two standard deviation (Gore &
Altman, 1982).
Neuropsychological test results were compared between the response groups by
analysis of variance (ANOVA); possible confounders being controlled for with an analysis
of co-variance (ANCOVA).
The subjective atrophy score ratings and HIS lesion numbers were compared with
the Mantel-Haenszel test for linear association. They were then coded as present or
absent to allow examination of this association by univariate logistic regression. Spearman
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correlation coefficients were computed between these anomaly scores and the symptom
ratings, regional MRI volumes and neuropsychology results.
Associations between clinical and outcome variables, with neuropsychological
variables and regional volumes, were also examined by two-tailed Spearman rank
correlation coefficients. To conduct correlations between numerous
clinical/neuropsychological results and the large number of SPET (and MRI) variables, the
former were factor analysed. A principal components analysis identified initial factors, a
varimax rotation was performed, and factor scores were calculated by regression. These
factors were then correlated, by the Spearman rank method, with the SPET and MRI
results.
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2.3 RESULTS
2.3.1 Subjects, demographics and clinical characteristics
Approximately three patients were approached for each one who was suitable and
consented to participate. This limited the dichotomy of treatment response between
groups further, as very poor responders were often too unwell to comply with the detailed
assessments, while very good responders were sometimes not under active follow-up and
reluctant to return to the hospital.
Of those who agreed to participate, the DSM-III-R diagnostic categories were:
Schizophreniform Psychosis (N=2) and Schizophrenia (N—38). Sub-categories of
Schizophrenia were: Paranoid (N=19), Undifferentiated (N=T0), Disorganised (N=8), and
Catatonic (N=T), and 36 suffered from DSM-III-R Chronic Schizophrenia. Thirty-five
patients also satisfied RDC criteria for Schizophrenia, the others being Schizoaffective
(N=3) or Schizophreniform (N=2). The patients were clinically stable at the time of the
investigations, so that the effects of acute relapse and/or large doses of medication were
minimised. Table 2.1 (overleaf) describes the patients by their demographics, relevant
historical details and current medication levels. The matching of patients for sex, age and
illness duration was satisfactory, although treatment resistant patients were slightly
younger and yet had been ill for longer, indicating an earlier age at onset in this group. As
would be expected, the mean number of admissions, total time spent in hospital and
current medication dosage were substantially higher in treatment resistant patients. Table
2.2 (two pages overleaf) details the clinical picture at the time of testing, by measures of
symptom severity, outcome and abnormal movements. The patient groups differed
substantially on most individual symptom measures and the total scores, and all outcome
measures. In addition, 14 of the responsive patients were employed or full-time students
(and a further three were active housewives) as compared to none of the resistant subjects.
Statistically significant differences were found between the response groups on the AIMS
(Mann-Whitney U=103.5, P=0.006), but not the TAKE (U=139.5, P=0 1).
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Table 2.1 - Clinical characteristics of treatment responsive and treatment resistant
patients with schizophrenia (means and standard deviations)





















YEARS IN EDUCATION 14.0 (2.8) 10.9 (1.2) P < 0.001
df = 38, t = 4.4
PATERNAL OCCUPATION
(Social Class I-VI)
2.6 (0.8) 2.9 (0.5) P = 0.4
Likelihood ratio =
1.8
NUMBER of ADMISSIONS 4.9 (4.7) 10.4 (6.5) P < 0.005
df = 38, t = -3.1
HOSPITALISATION TIME
(months)
6.6 (7.1) 57.1 (87.4) P < 0.002
df = 38, t = -2.6
ANTIPSYCHOTIC DOSAGE
(Chlorpromazine equivalents)
268 (274) 902 (669) P < 0.001
df = 38, t = -3.8
ANTICHOLINERGIC DOSE
(Procyclidine equivalents)
3.0 (6.4) 3.3 (4.7) P = 0.9 1
df = 38, t = -0.2
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Table 2.2 - Symptom and outcome measure scores in treatment responsive and
treatment resistant patients with schizophrenia (means and standard deviations)
RESPONSIVE RESISTANT
KRAWIECKA
TOTAL SCORES 3.9 (3.3) 11.8 (5.1)
KRAWIECKA
DEPRESSION 0.5 (0.6) 1.0 (0.9)
KRAWIECKA
ANXIETY 0.8 (0.9) 1.1 (1.1)
KRAWIECKA
DELUSIONS 0.6 (1.0) 3.4 (1.1)
KRAWIECKA
HALLUCINATIONS 0.2 (0.8) 2.5 (1.8)
KRAWIECKA
SPEECH IRRELEVANCE 0.3 (0.5) 0.8 (1.2)
KRAWIECKA
POVERTY of SPEECH 0.2 (0.5) 0.4 (0.6)
KRAWIECKA
FLAT AFFECT 0.6 (0.9) 1.2(1.1)
KRAWIECKA
INCONGRUITY 0.4 (0.9) 0.7 (1.2)
KRAWIECKA
RETARDATION 0.2 (0.5) 0.6 (0.8)
POSITIVE SYMPTOMS
TOTAL SCORE 0.4 (0.6) 1.8 (0.9)
NEGATIVE SYMPTOMS
TOTAL SCORE 0.5 (0.4) 0.9 (0.5)
COOPER'S
OUTCOME SCALE 4.8 (0.8) 1.8 (0.5)
McGLASHAN'S
Cross-Sectional Outcome 15.4 (2.6) 5.6 (2.1)
McGLASHAN'S
Follow-Up Outcome 15.4 (2.0) 6.0 (2.2)
AIMS 1.0 (1.7) 2.8 (2.4)
TAKE 2.2 (2.1) 3.4 (2.0)
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2.3.2 MR1 Results
2.3.2.1 MRI Volumetric Measurements
The hippocampi could not be reliably measured in two male cases due to
movement artefact, but the remaining structures were thought to be reliably identifiable in
all scans. The mean height of the resistant patients, at 167.8 cm, was lower but not
significantly different from that of the responsive patients, at 169.4cm (P=0.6). Analysis
between response groups by MANOVA found no significant differences in the volumes of
any measured structure, comparing either raw volumes (Fj 35=1.1, P=0.3), or those
normalised to whole brain volume (F135=0.2, P=0.9). Table 2.3 (overleaf) shows the
absolute volumes of the structures measured, together with effect sizes of the differences
between response groups. Almost all structures are smaller in the treatment resistant
group, with only minor exceptions of the left pre-ffontal lobe and the third/fourth
ventricles. There was no interaction between response and lobe (Fj 35=2.0, P=0.2), but a
tendency to one between response and side (Fj 35=3.0, P=0.09). Examining table 2.3 this
interaction is likely to reflect the smaller difference between the left and right volumes of
the lateral ventricles, temporal lobes and particularly pre-firontal lobes in the resistant as
compared to the responsive patients; but this possible effect was not examined statistically
as no tilt correction was employed prior to image analysis.
Post hoc paired t-tests, across all subjects, revealed smaller left than right sided
hippocampi (two-tailed t=3.03, P=0.004) and temporal lobes (two-tailed t=1.93, P=0.06).
Left handed subjects (N=4), were found to have lower volumes of all structures than the
right-handers (N=35; 1 ambidextrous), but this difference was only statistically significant
in the left temporal lobe (raw volumes 68.2 versus 76.6 cc; two-tailed t=3.26, P=0.01), for
both raw and corrected volumes.
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Table 2.3 - Raw volumes fee) on MRI in treatment responsive and treatment
resistant patients with schizophrenia (means and standard deviations),
and effect sizes tin standard deviation units).
RESPONSIVE RESISTANT EFFECT SIZE
WHOLE BRAIN 1196.3(113.7) 1142.8 (131.2) 0.41
INTRACRANIAL CSF 218.8 (44.2) 207.0 (77.6) 0.15
LEFT TEMPORAL LOBE 77.4 (8.2) 73.4 (10.8) 0.37
RIGHT TEMPORAL LOBE 80.3 (10.2) 75.5 (10.5) 0.46
LEFT HIPPOCAMPUS 5.3 (0.7) 5.1 (0.7)* 0.29
RIGHT HIPPOCAMPUS 5.5 (0.6) 5.3 (0.7)* 0.29
LEFT PRE FRONTAL LOBE 61.0 (8.3) 61.2(11.8) -0.02
RIGHT PRE FRONTAL LOBE 63.7 (8.2) 61.8(11.1) 0.17
LEFT LATERAL VENTRICLE 9.1 (4.5) 8.5 (3.5) 0.17
RIGHT LATERAL VENTRICLE 8.8 (4.0) 8.0 (3.2) 0.25
THIRD & FOURTH VENTRICLES 4.1 (1.3) 4.2 (1.3) -0.08
*N=18 as two male hippocampi excluded due to motion artefact.
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2.3.2.2 MRI Visual Assessment
Thirty-three (82%) of the patients showed some ('none-mild' or greater) degree of
generalised cerebral atrophy, which was at least 'mild' (score of 2 or more) in 21 (52%).
Almost all (95%) of the treatment-resistant patients had some atrophy, as compared to 14
(60%) of the responsive cases, but this difference was not statistically significant (M-H
value = 1.6, P=0.2). However, using the more powerful statistical technique of logistic
regression with atrophy dichotomised into none or some, a strong tendency was found to
an association between treatment response and atrophy (P=0.06) with the resistant
patients having a substantially elevated risk (odds ratio = 2.85, 95% confidence interval
0.94-8.69).
Fifteen (38%) of the patients had at least one HIS lesion (range 0-4). These were
widely and bilaterally distributed, in the cortex, deep white matter, periventricular region
and subcortical areas. They were identified in 9 (45%) resistant and 6 (30%) responsive
patients, with no suggestion of a significant difference by chi-square (M-H value = 0.7,
P=0.4) or logistic regression (OR=1.4, P=0.3) analyses with dichotomisation around none
or at least one lesion. However, 5 (25%) of the resistant patients had at least three HIS
lesions, as compared to 2 (10%) of the responsive patients.
Finally, an unexpected observation from visual assessment of the scans was the
frequency of appearances suggesting inflammation of the lining of the paranasal sinuses.
The ethmoid sinus was affected in 72%, the maxillary sinus in 20%, the frontal sinus in
18% and the sphenoidal sinus in 10%. However, the prevalence of sinusitis was identical
in both treatment resistant and responsive patients, at 90%, and is probably related to the
fact that 33 (82%) of the patients were current cigarette smokers.
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2.3.3 SPET scan results
The overall effect of treatment response on regional uptake ratios failed to reach
statistical significance by MANOVA, whether uptake was normalised to the whole slice
(Fi 3g=0.98, P=0.5) or occipital uptake (F] 33=2.06, P=0.3). Table 2.4 (overleaf) gives
the uptake ratios, corrected for whole slice uptake, in the 36 regions of interest from the
three slices chosen for analysis in this study.
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Table 2.4 - SPET regional uptake of 99mTe-Exametazime. normalised to the whole
slice, in treatment responsive and treatment resistant patients with schizophrenia
(means and standard deviations!.
LEFT RIGHT
RESPONSIVE RESISTANT RESPONSIVE RESISTANT
Lower Slice
(4cm above OML)
Frontal 0.96 (.04) 0.95 (.05) 0.99 (.03) 0.97 (.05)
Anterior Temporal 1.03 (.06) 1.02 (.07) 1.09 (.05) 1.06 (.06)
Posterior Temporal 1.04 (.06) 1.03 (.04) 1.07 (.04) 1.06 (.06)
Occipital 1.02 (.04) 1.02 (.06) 1.03 (.04) 1.02 (.05)
Calcarine 1.17 (.08) 1.19 (.09) 1.18 (.06) 1.19 (.08)
Anterior Cingulate 1.02 (.09) 1.01 (.08) 1.08 (.08) 1.05 (.08)
Posterior Cingulate 0.91 (.08) 0.95 (.08) 0.96 (.11) 0.98 (.10)
Caudate 0.90 (.09) 0.92 (.12) 0.95 (.11) 0.94 (.08)
Putamen 1.10 (.06) 1.08 (.06) 1.08 (.07) 1.06 (.06)
Thalamus 1.04 (.04) 1.03 (.06) 1.04 (.05) 1.05 (.06)
Middle Slice
(6cm above OML)
Frontal 0.95 (.04) 0.94 (.04) 0.97 (.04) 0.96 (.04)
Parietal 1.00 (.04) 1.01 (.04) 1.03 (.04) 1.02 (.03)
Occipital 1.04 (.06) 1.04 (.06) 1.06 (.07) 1.04 (.06)
Anterior Cingulate 1.08 (.08) 1.05 (.06) 1.09 (.06) 1.05 (.07)
Posterior Cingulate 1.21 (.10) 1.24 (.07) 1.22 (.06) 1.25 (.06)
Upper Slice
(8cm above OML)
Frontal 0.87 (.05) 0.89 (.03) 0.88 (.06) 0.91 (.04)
Parietal 0.92 (.06) 0.95 (.06) 0.96 (.05) 0.97 (.04)
Occipital 0.96 (.06) 1.00 (.06) 0.98 (.07) 1.01 (.05)
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2.3.4 Neuropsychology test results
Some patients did not complete all the testing, but only one refused to do all the
tests. The detailed results are presented in three tables on consecutive pages overleaf,
according to whether the tests primarily measured global (Table 2.4), executive (2.5) or
memory functioning (2.6). As shown in these tables, several statistically significant
differences emerged between the two response groups, indicating poorer functioning in
the resistant patient group. However, these deficits could be attributable to clinical
differences between the resistant and responsive patients, such as in pre-morbid
functioning and neuroleptic exposure. To control for the former, all the differentiating
tests were re-analysed co-varying for the number of years spent in full time education and
only one measure remained which clearly distinguished, at a high level of statistical
significance, between responsive and resistant patients - the Rivermead Behavioural
Memory Test - Profile Score (RPS, Fj35=9.7, P=0.004). This test showed a statistically
significant difference between the groups, even when current IQ (Fj 36=9.5, P=0.005),
global intellectual functioning (^35=8.5, P=0.007), and current antipsychotic medication
levels (Fj 36=11.8, P=0.002) were taken into account; and the current dose of
anticholinergic drugs were very similar in the responsive and resistant subjects. Table 2.7
(four pages overleaf) shows the differentiating neuropsychological test results, and the
between group differences before and after controlling for years spent in education to
show the magnitude of the effect.
107
Chapter 2 - MRI, SPET, Neuropsychology and Treatment Response in Schizophrenia
Table 2.4 - Global intellectual functioning in treatment responsive and treatment
resistant patients with schizophrenia (means and standard deviations)
RESPONSIVE RESISTANT F value P value
NART IQ
(WAIS equivalent) 114.5(10.3) 101.2 (9.5) F,37 = 17.6 P < 0.001
QUICK IQ
107.4 (18.0) 89.1 (14.9) Fij? — 12.0 P = 0.001
IQ DECLINE
7.0 (13.0) 12.1 (10.2) Fl37 = L3 P = 0.2
MINI-MENTAL
STATE EXAM 28.3 (1.8) 25.1 (3.7) FO7 — 10.0 P = 0.003
DIGIT SYMBOL
SUBSTITUTION 8.6 (2.4) 6.4 (2.0) Fl.35 ~ 8.9 P = 0.005
ATTENTION 4.7 (0.6) 3.9 (1.1) Fu7 = 8.3 P = 0.006
CO-OPERATION 4.5 (0.5) 4.2 (0.8) Fo7 = 9.1 P = 0.005
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Table 2.5 - Executive functioning in treatment responsive and treatment resistant
patients with schizophrenia (means and standard deviations)
RESPONSIVE RESISTANT F value P value
CONTINUOUS
PERFORMANCE
TEST - F (failed
response, omissions)






1.0 (1.4) 3.3 (3.3) F133 = 6.6 P = 0.015
STROOP TEST W-C
(word-colour, errors)
16.7 (17.9) 41.0 (19.5) FU3 = 14.7 P = 0.001
TRAILS TESTS B-A
(thinking time)
49.8 (25.6) 60.4 (36.5) F133 = 1*0 '■tf II o w
VERBAL FLUENCY
- letter 'A'
13.4 (7.5) 9.6 (5.3) Ft33 = 3.0 P = 0.09
VERBAL FLUENCY
- animals
20.2 (8.7) 14.2 (7.1) Fl,33 = 4.9 P = 0.03
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Table 2.6 - Memory functioning in treatment responsive and treatment resistant
patients with schizophrenia (means and standard deviations)




















6.7 (1.7) 5.6 (1.9) Fi,36 = 4.0 P = 0.053
PATTERN
RECOGNITION
19.3 (4.1) 17.8 (3.0) F136=1.5 ii o
SPATIAL
RECOGNITION
15.4 (2.3) 13.6 (3.0) Fi,36 = 4.5 P = 0.04
DIGIT SPAN -
FORWARDS
7.5 (1.4) 7.3 (1.2) Fl,36 = 0.4 P = 0.5
DIGIT SPAN -
BACKWARDS




21.7 (1.9) 17.3 (3.8) F136 = 20.3 P < 0.001
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2.3.5 Clinical and Biological Correlations
Exploratory correlational analyses were performed between the clinical and
biological data in all 40 subjects. As shown in Table 2.8 (overleaf), Spearman rank
correlations between clinical and MRI variables were fairly strong and negative between
delusion ratings and temporal lobe volumes, hallucinations and the hippocampi, anxiety
and the lateral ventricles; with fairly strong positive correlations between retardation and
flat affect ratings and the lateral ventricle volumes. All outcome measures consistently and
positively correlated with the temporal lobe volumes. Differentiating neuropsychological
test variables were consistently negatively correlated with delusion and hallucination
symptom scores on the Krawiecka Scale, as well as strongly and positively with the
outcome measures. Notably, the clinical correlations with the Rivermead Profile Score
(RPS) score were slightly higher than for other test results.
As shown in Table 2.9 (two pages overleaf), Spearman correlations between the
MRI and neuropsychological variables were strongest for whole brain, left pre-frontal lobe
and particularly the temporal lobe (both left and right) volumes. Measures of global
intellectual functioning were generally more strongly related to MRI volumes than were
the memory tests; indeed, correlations with RPS were often lower than those of both
global and executive tests.
Spearman correlations between the qualitative MRI anomaly ratings and other
variables of interest were rarely statistically significant. No significant correlations were
found between atrophy or HIS lesion number and Krawiecka positive or negative
syndrome scores, nor with the neuropsychology results. The only significant correlations
with regional volumes were between atrophy and the volumes of the left (r=.36, P<0.05)
and right (r=.32, P<0.05) ventricular volumes, and between the number ofHIS lesions and
the volumes of these same structures (r=.33 and .39 respectively). Of particular note,
were very weak correlations between atrophy and the whole brain (r=.10) or intracranial
CSF (r=-.04) volumes.
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Factor analysing the Krawiecka symptom ratings and the neuropsychological tests
which distinguished between the patient groups, identified five factors within eight
iterations:
(1) a "reality distortion - neuropsychological differences" factor, explaining 33% of the
variance, with hallucinations (-.37), delusions (-.45), and all cognitive tests (.46 to .88);
(2) a "psychomotor poverty" factor, explaining 15.5% of the variance, with flat affect
(.77), poverty of speech (.80) and psychomotor retardation (.88), together with the RPS (-
•34);
(3) an "affective factor", 10 .9% of the variance, with depression ( .80) and anxiety (.89);
(4) a "positive symptoms" factor, explaining 8.5% of the variance, including incoherent
speech (.90) and the CPT-I error score (.57); and
(5) a final "disorganisation" factor, explaining 6.7% of the variance, of inappropriate affect
(.73), with the MMSE (.42) and Verbal Fluency (-.44).
Table 2.10 (overleaf) shows Spearman-rank correlations between tracer uptake on
SPET, normalised to occipital uptake, and MRI volumes, with these five factors. Only
seven, relatively weak, correlations were found with SPET uptake, out of 140
comparisons. However, some consistent positive and strong correlations were found with
MRI volumes: between Factor 1 and the left and right temporal lobes (i.e. larger temporal
lobes, fewer positive symptoms and better cognitive function) and between Factor 2 and
the volumes of the left and right lateral ventricles (i.e. larger ventricles, more negative
symptoms and worse performance on the RPS).
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Table 2.10 - Spearman rank correlations between the five factors, derived from
symptom ratings and the distinguishing neuropsychological tests, and regional
SPET tracer uptake (normalised to the occipital uptake and MRI regional volumes
FACTOR 1 FACTOR 2 FACTOR 3 FACTOR4 FACTOR 5
Left Anterior Cingulate (+4cm) -.16 -.35* .01 .02 -.15
Left Anterior Cingulate (+6cm) .01 -.05 .14 -.07 -.14
Left Caudate (+4cm) .03 -.17 .15 .07 -.04
Left Frontal (+4cm) .15 -.04 -.07 .04 -.21
Left Frontal (+6cm) -.09 -.05 .01 -.05 -.06
Left Frontal (+8cm) -.09 .03 -.05 -.19 -.13
Left Anterior Temporal (+4cm) .09 -.33 .16 .20 -.10
Left Parietal (+6cm) -.13 -.14 -.16 .17 -.23
Left Parietal (+8cm) -.13 .16 -.18 -.07 -.09
Left Posterior Cingulate (+4cm) -.21 .01 -.15 .18 -.04
Left Posterior Cingulate (+6cm) .00 .10 -.26 .14 -.07
Left Putamen (+4cm) -.01 -.25 -.21 -.15 -.08
Left Posterior Temporal (+4cm) .12 -.22 .04 .19 -.10
Left Thalamus (+4cm) .12 -.38* .38* .09 .08
Right Anterior Cingulate (+4cm) -.17 -.39* -.14 .05 -.16
Right Anterior Cingulate (+6cm) .04 -.01 .16 -.11 -.12
Right Caudate (+4cm) .07 -.25 -.07 .17 .04
Right Frontal (+4cm) .13 -.03 .04 -.09 .03
Right Frontal (+6cm) -.01 -.18 -.40* -.21 -.01
Right Frontal (+8cm) -.13 .14 -.06 -.30 .14
Right Anterior Temporal (+4cm) -.03 -.35* -.11 -.13 .07
Right Parietal (+6cm) -.04 -.33 -.20 -.22 -.18
Right Parietal (+8cm) -.06 .16 -.27 -.27 .30
Right Posterior Cingulate (+4cm) -.17 -.09 -.35* .17 .19
Right Posterior Cingulate (+6cm) -.13 -.01 -.30 .20 -.25
Right Putamen (+4cm) .04 -.30 -.14 -.08 .15
Right Superior Temporal (+4cm) .24 -.29 -.05 -.02 .19
Right Thalamus (+4cm) .09 -.19 -.04 .06 -.20
Whole Brain Volume .41* -.05 -.13 .02 .25
Intracranial CSF .17 .01 -.09 -.05 .05
Left Temporal Lobe .68*** -.01 -.06 .11 .19
Right Temporal Lobe .55** -.17 -.33 -.00 .11
Left Hippocampus -.05 -.17 -.07 -.02 -.00
Right Hippocampus -.07 -.22 .06 -.01 .10
Left Pre-Frontal Lobe .34* .02 .08 .11 .08
Right Pre-Frontal Lobe .24 -.18 -.06 -.17 .15
Left Lateral Ventricle .15 .40* -.24 -.20 -.03
Right Lateral Ventricle .10 .49** -.07 -.24 .00
Third & Fourth Ventricles -.05 .25 -.22 -.31 .32
KEY: FACTOR 1 "Reality Distortion-Neuropsychological Differences"; FACTOR 2 "Psychomotor
Poverty"; FACTOR 3 "Affective"; FACTOR 4 "Positive Symptoms"; FACTOR 5 "Disorganisation".
PROBABILITY: *P<0.05, **P<0.01, ***P<0.001.
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2.4 DISCUSSION
The main finding of this study is that patients with treatment resistant
schizophrenia do not have a statistically significant lower volume of brain structures on
MRI or reduced tracer uptake on SPET as compared to treatment responsive patients.
However, several differences were found between the groups on neuropsychological
testing, and the RPS remained significant after controlling for several possible
confounders. Possible reasons for the negative findings on the brain scans include: the
patient groups were not sufficiently dichotomised, the study was not sufficiently powerful
to detect statistically significant differences, the heterogeneity inherent in schizophrenia
masks any differences between sub-types, and/or that such biological differences do not
exist between such patient groups.
Firstly, it is clear from the available clinical information on the patient groups that
they were markedly different in terms of their medication response, most symptom levels,
measures of abnormal movements, social and global outcomes, and occupational levels.
While practical considerations limited the dichotomy, the groups were certainly different
by clinical comparisons and were sufficiently so as to detect differences in cognitive
performance. The patient groups in this study differed markedly in terms of "positive
symptoms" or indices of "reality distortion" (hallucinations and delusions), but less so in
what have been labelled "disorganisation" symptoms (thought disorder, incongruity,
irrelevance of speech), and hardly differed at all in the levels of "negative symptoms" or
"psychomotor poverty" syndrome (Crow, 1980; Liddle et al, 1992). These symptoms
have been linked to pathological processes predominantly affecting neuronal networks in
left-sided temporo-limbic structures, the right ventro-lateral pre-frontal cortex and the left
dorso-lateral pre-frontal lobe respectively (Liddle et al, 1992; Ebmeier et al, 1993).
Further, MRI studies have demonstrated reduced superior temporal gyral volume in
hallucinating schizophrenics as compared to controls (Barta et al, 1990; Shenton et al,
1992). Although not significantly so, the volumes of temporal lobes and hippocampi were
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substantially lower in the more severely hallucinating (treatment resistant) patients in this
study, and these measures were fairly strongly correlated. The similarities between the
patient groups on other symptom measures may account for the less marked group
differences in the putatively important other brain areas.
Secondly, although there was no consistent relationship between SPET uptake and
treatment response, it is noteworthy that almost all structures on MRI were smaller in
resistant patients. This is compatible with a neurodevelopmental model of schizophrenia,
where the more profound the cerebral aberration, the greater the effect on brain size, age
at onset and clinical outcome (Weinberger, 1987). If this model is accurate the main
problem in detecting subtle differences between patient groups is one of study power. For
example, taking the best reproduced abnormalities between schizophrenics and controls,
relative enlargement of the lateral ventricles, and assuming that the difference between
outcome sub-groups of schizophrenic patients is as high as 30% (Johnstone et al., 1989b)
- as compared to approximately 10% in this study - the variability of this measure in
schizophrenics is such that study groups of 100 members each would be necessary to
detect a statistically significant difference (Gore & Altman, 1982). Similarly, considering
the largest effect size (or standardised difference) between response groups in this study,
that of 0.46 for right temporal lobe volume differences, two study groups of 80 members
each would be needed for this to be statistically significant (Gore & Altman, 1982).
Thirdly, and more generally, outcome in schizophrenia can be influenced by a
variety of factors which need not be directly illness related, such as the effects of
medication and aspects of care, or other individual and external factors (May & Goldberg,
1978). Moreover, although the clinical course is usually established relatively early in the
illness, some individuals may be misclassified and a sub-group of initially responsive
patients may relapse within two years of maintenance treatment and remain refractory to
further treatment thereafter (Kane & Lieberman, 1987). However, the patients in this
study, although selected for differing treatment response, were different on all the
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outcome measures employed, and there are no indications, thus far, that any of the 40
patients were misclassified. Such plentiful sources of confounding might obscure an
association between MRI or SPET and treatment response, yet it could be argued that a
substantial biologically or clinically important effect should be detectable above such
'noise'.
The results from CT studies examining the relationship between morphological
abnormalities, usually lateral ventricular enlargement, and treatment response have been
conflicting. In the studies directly addressing this question, two main approaches are
discernible. Firstly, schizophrenic patients are selected for a particularly high VBR
(usually two standard deviations above a control group mean) or not, prior to
administering treatment; those with large ventricles generally (Weinberger et al., 1980;
Schulz et al., 1983b; Luchins et al., 1984), but not always (Nasrallah et al., 1983a;
Nimgaonkar et al., 1988), respond less well to neuroleptics, in terms of symptomatic
improvement. Alternatively, individual patients, assigned to relatively good or bad
outcome on a post hoc basis, have had their symptom improvement scores correlated with
VBR; an approach that has sometimes shown a strong negative correlation (Smith &
Maser, 1983; Smith et al., 1983; Kolakowska et al., 1985; Pandurangi et al., 1989;
Schroder et al., 1993), or no relationship (Williams et al., 1985; Nimgaonkar et al.,
1988), but more often found a paradoxical association between a high VBR and a trend
towards better neuroleptic response (Smith et al., 1985; Boronow et al., 1985; Losonczy
et al., 1986; Wilms et al., 1992; Bersani et al., 1995). The latter technique has also
found a relationship between "delayed" neuroleptic response and third ventricle size in one
study (Kaplan et al., 1990), but not another (Boronow et al., 1986), and no relationship
with a number of global morphological measures (Smith et al., 1987a). Clearly, there is
no consistent linear relationship between ventricular enlargement and treatment response,
at least on CT, as was confirmed in a recent meta-analysis of these studies (Friedman et
al., 1992).
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A volumetric rather than area approach, using the relatively sensitive MRI rather
than CT, on specifically selected patients, might better elucidate the relationship between
neuroanatomy and outcome or treatment response. Certainly, previous MRI studies
suggest an association between increased ventricular size and poor outcome (DeLisi et al,
1992), or more negative symptoms (Young et al., 1991; Gur et al, 1994), and between
reduced mesiotemporal volumes and more severe psychopathology (Bogerts et al, 1993);
similar to the correlations between Krawiecka scores and outcome measures with
structure volumes in this study. However, very few other relevant MRI studies have been
conducted. A group of outpatients have been dichotomised on a scale of deficit (negative)
symptoms and studied with MRI (Buchanan et al, 1993), but the patient group with
more symptoms had larger volumes of all structures measured, approximating to those of
a normal comparison group. Similarly, no cerebral volume differences were found
between schizophrenics with favourable, intermediate or poor outcomes in another MRI
study (Harvey et al, 1993). These results support the findings of this study that there is
no simple relationship between brain structure volumes and outcome or treatment
response.
However, a tendency was found to an association between 'atrophy' and treatment
response in the current study. Although this was only manifest in one of two analyses,
both were planned comparisons. Previous studies of the relationship between treatment
response and cerebral atrophy on CT have provided inconsistent results. Although
treatment resistance has been related to general (Gattaz et al, 1988) or frontal atrophy
(Kaiya et al, 1989; Friedman et al, 1991) in some reports, others have found a
curvilinear relationship with symptom improvement (Smith et al, 1983) and the most
frequent finding is of no significant association (Nasrallah et al, 1983b; Boronow et al,
1985; Smith et al, 1987a; Nimgaonkar et al, 1988, McCreadie et al, 1989; Friedman et
al, 1992). Nonetheless, there are suggestions from the few relevant MRI studies of such
a relationship. Jewart et al (1991) found an excess of qualitatively abnormal scans in
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patients who were resistant as opposed to responsive to clozapine, and Lieberman et al.
(1992) reported a tendency to greater qualitative abnormalities in chronic multi-episode
cases as compared to first episode subjects. One possible reconciliation of these
discrepant findings is that cortical atrophy, or a loss of grey matter, represents a different
disease process to the loss of white matter responsible for ventricular enlargement. This
interpretation is supported by previous CT studies which failed to find a correlation
between these measures (Weinberger et al., 1989; Smith et al., 1983; Boronow el al.,
1985), but in this and another MRI study (Lieberman el al., 1992) a significant
correlation - albeit weak - has been found. By contrast, no correlation was found in this
study between atrophy and whole brain or CSF volumes. These quantitative measures are
inevitably determined by the size of the head, which is highly variable, difficult to control
for satisfactorily and subject to partial volume artefact. Qualitative ratings may
automatically control for the former and is perhaps less subject to the latter. Thus, a
standardised assessment of the degree of generalised loss of cerebral substance may be
more sensitive to clinically relevant cortical atrophy than volumetric measurements of the
whole brain. However, a further note of caution in the interpretation of this weak finding
is that only one rater was used and there is therefore no guarantee of the reliability of this
measure in the current study.
Previous SPET or PET studies of treatment response have also failed to identify
definite associations with tracer uptake or receptor occupancy. There is only one
comparable study to the current one, which employed PET. Buchsbaum et al. (1992)
reported that a low metabolic rate in the caudate and putamen in 25 unmedicated patients
predicted their subsequent response to haloperidol. Moreover, among responders,
haloperidol 'normalised' striatal metabolism, while in non-responders it tended to
exacerbate hypofrontality. The differences between these two studies could be
attributable to the greater power of the Buchsbaum study - with a prospective within-
subject design - or that they standardised the medication regimes of the patients during the
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experiment. However, the rCBF values in responsive and resistant patients show no
consistent pattern that would suggest a power problem in the present study and other
functional imaging studies have established that poor clinical response to neuroleptics is
not simply attributable to inadequate dopamine receptor blockade (Wolkin et al., 1989;
Coppens et al., 1991; Pilowsky et al., 1993).
The possibility remains that a sub-group of treatment resistant schizophrenic
patients with marked structural brain changes could be delineated. This would be
compatible with the great variability in MRI volumes within the patient groups in this
study, which was more marked in the resistant group. In addition, the schizophrenic
subjects with a particularly high number of HIS lesions tended to be those with a poor
response in both this study and one other (Harvey et al., 1993). As already discussed,
previous CT studies of patients with ventricular:brain areas two standard deviations above
a control mean have generally identified a group of patients with a poor treatment
response (Weinberger et al., 1980; Schulz et al., 1983; Luchins et al., 1984). However,
these are findings in highly selected patient groups, and meta-analyses of the VBR in
schizophrenia have failed to find any evidence for a bi-modal distribution (Raz & Raz,
1990; Daniel et al., 1991b). This suggests that ventricular enlargement is not a marker
for a specific sub-type of schizophrenia. Greater accuracy in predicting treatment
response and outcome on an individual or group basis may be possible if additional factors
are considered with brain structure, such as the many other biological variables that have
been linked to treatment response (May & Goldberg, 1978; Lieberman & Sobel, 1993).
In this study, although imaging variables did not distinguish the patient groups, the
cognitive testing did - particularly long-term episodic memory functioning (RPS). The
relative selectivity of this finding argues against it being attributable to symptomatology,
attention or co-operation; and it withstood controlling for intelligence or global
functioning, pre-morbid education and medication levels. The RPS is determined over a
comparatively lengthy and complex series of sub-tests (but no more so than, for example,
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the delayed matching task) that were devised to measure aspects of memory in everyday
use (Wilson et al., 1985). Several previous studies have shown that schizophrenic
subjects have cognitive deficits, primarily of memory, learning and concept formation, as
compared to controls (Goldberg et al., 1990; Saykin et al., 1991; Frith et al, 1991).
Indeed, further evidence suggests that schizophrenics exhibit a relatively specific pattern of
neuropsychological abnormality - primarily that of impaired long-term memory - akin to a
dysmnesic syndrome (Tamlyn et al., 1992; Goldberg et al., 1993), and that these deficits
are related to symptom and outcome measures (Goldberg et al., 1990; Frith et al., 1991).
Although there are also reports of deficits in executive tasks (Shallice et al., 1991), as in
this study, the results replicate findings of particular deficits in memory, and suggest that
these are strongly related to treatment response (and outcome). In general, cognitive
deficits are associated with negative symptoms, ventricular enlargement and a poor
outcome (Johnstone et al., 1976 & 1978; Golden et al., 1980 & 1982; Kemali et al.,
1985), and the few previous studies of treatment response tend to find stronger
correlations with attention rather than memory (Smith et al., 1992; Goldman et al., 1993)
but the RPS is a more sensitive test of memory functions that are important in the daily
lives of patients. This is supported by the observation that the RPS correlated more
strongly with clinical variables than the other, more traditional, cognitive tests.
The correlations between the RPS with both positive and negative symptoms, and
with both the "reality distortion" and "psychomotor poverty" factors, is in keeping with
previous findings (Goldberg et al., 1990; Tamlyn et al., 1992), and suggests that memory
dysfunction is intrinsic to schizophrenia, rather than to any one aspect of it. While it is
perhaps unsurprising that the distinguishing neuropsychology tests correlated with the
differentiating clinical measures, the pattern of associations with the five clinical factors
argues that different but related pathological processes are responsible for these
relationships (c.f. Frith et al., 1991; Liddleetal, 1992). Further support for this assertion
comes from the fact that the RPS correlated equally strongly with whole brain, pre-frontal
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and temporal MRI volumes, suggesting that global processes are important determinants
of memory function. Indeed, all the cognitive tests showed remarkably consistent
correlations with pre-frontal, temporal and whole brain volumes; arguing against crude
structural localisation of neuropsychological functioning. The few previous MRI-
neuropsychology correlational studies in schizophrenia describe a similar picture; an
association between cerebral area and performance on the Stroop test (Andreasen et al.,
1986), a relationship between memory dysfunction and reduced temporal lobe area
(Michele et al., 1992) or cerebral volume (Kareken et al., 1995), and strong correlations
between executive or memory tasks and pre-frontal areas (Seidman et al., 1994). Thus,
such neuropsychological deficits probably reflect generalised brain dysfunction, but this
may be most pronounced in temporal regions and on memory tasks.
Here, as in previous studies, poor outcome and more severe symptomatology has
been related to neuropsychological impairment, although almost all of the psychological
tests which distinguished the patient groups were no longer significant after taking
account of years of education. Thus, the neuropsychological abnormalities appear to
reflect a process that begins relatively early in life and has effects before the advent of
psychotic symptoms. As such, it could be argued that controlling for years of education is
not justifiable when this may be affected by the early manifestations of the illness itself,
particularly in those who develop it at a young age. However, given that performance on
nearly all neuropsychological tests is related to general abilities and educational
attainment, some attempt must be made to control for these factors. The fact that the
RPS remained robust, although not unaffected, to controlling for several possible
confounders indicates the central importance of memory in schizophrenia, and suggests
that poor memory functioning may predict a poor prognosis. For example, memory
impairment may adversely affect treatment compliance, or hinder abilities on several
everyday tasks.
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2.5 CONCLUSIONS
In conclusion, the ability of episodic memory testing to distinguish sub-groups of
patients with schizophrenia may mean that memory functioning is an important
determinant of outcome in the disease. If a specific association with treatment response is
independently confirmed, this would imply a biological relationship and possibly one of
pathophysiological importance. Quantifiable differences are therefore detectable between
treatment responsive and resistant patient groups, but it does not seem possible to reliably
differentiate them using neuroimaging techniques. Neuropsychological tests, perhaps in
association with other clinical and biological measures, might be able to delineate
prognostic and possibly even aetiological sub-types of schizophrenia. There may be a sub¬
type of schizophrenia that is associated with grossly abnormal cerebral morphology and a
poor outcome, but the findings of this and other studies suggest that illness outcome - or
even treatment response - is too diverse an issue, and confounded by too many variables,
to be predicted by currently available imaging techniques. The variability in other illness
factors in schizophrenia appears to be greater than that related to outcome or treatment
response.
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3.1 INTRODUCTION
Although differences in 99mTc-Exametazime uptake were not found between the
two groups ofpatients with schizophrenia, the 40 SPET scans constituted a substantial
resource for further study. Normal control subjects were not included in the MRI and
SPET study of treatment response but a normal comparison group was available from the
MRC Brain Metabolism Unit control bank who had been scanned with identical methods.
Results were also available for a group of 20 unmedicated schizophrenic patients and a
further 10 patients with other non-organic non-affective psychoses (i.e. schizoaffective,
brief reactive, paranoid and not otherwise specified psychoses) who had also not received
any oral neuroleptics for at least two weeks or depot for at least two months. It was
therefore decided to investigate previous but conflicting findings regarding frontal tracer
uptake or neuronal metabolism on functional imaging in schizophrenia. The large group
of patients available made it possible to increase the power of any statistical comparisons,
to examine the effects of medication in the 60 schizophrenic or schizophreniform patients,
and to conduct a preliminary investigation of the diagnostic specificity of any
abnormalities identified. Moreover, the high resolution SPET technique employed in all
70 patients allowed a particular focus on distinguishing tracer uptake in lateral as opposed
to medial frontal cortex, as the lumping together of these regions is one potential reason
for conflicting results from earlier studies. Twenty controls were therefore selected from
the MRC bank, who were balanced for age and sex with the 70 patients. The SPET scans
of all 90 subjects were examined on just two regions of interest (frontal and cingulate) on
three slices (4, 6 and 8 cm above the OML) to limit the possibility of Type I error. Mean
tracer uptake was examined relative to occipital uptake as this part of the brain is least
affected by any ventricular enlargement. Hyperfrontality was identified in lateral frontal
regions in all unmedicated patients as compared with controls, but reduced left cingulate
(and mesial frontal cortex) uptake was a common finding in all patients with schizophrenia
- regardless ofmedication status (Ebmeier et al., 1995).
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This investigation therefore dissociated medial and lateral prefrontal cortical tracer
uptake in psychosis and schizophrenia. Very similar results have also been reported from
two other research groups using FDG-PET (Tamminga et al., 1992; Siegal et al., 1993).
Tamminga and colleagues examined 12 actively psychotic patients with schizophrenia,
who had been unmedicated for at least one month, and found significantly reduced
regional cerebral glucose metabolism in the anterior cingulate and hippocampus as
compared to normal controls. Moreover, these reductions were common to both deficit
and non-deficit patient subgroups, whereas neocortical hypometabolism was only found in
the patients with deficit schizophrenia (Tamminga et al., 1992). Siegal and co-workers
reported their findings in 70 unmedicated patients and 30 controls, all of whom were male,
who were scanned whilst performing a version of the Continuous Performance Test
(CPT). Relative hypofrontality was found in the schizophrenia subjects, which was more
marked in medial than lateral frontal regions and on the right rather than left side, and
negatively correlated with both positive and negative symptom scores (Siegal et al.,
1993).
These studies consistently point to anterior cingulate deficits as characteristic of
all patients with schizophrenia. They are in agreement with the few previous functional
imaging research reports that have attempted to distinguish between frontal and cingulate
metabolism, which have found reduced activity in anterior cingulate cortex (Andreason et
al., 1992; Lewis et al., 1992; Kawasaki et al., 1992) and increased metabolism in lateral
prefrontal regions (Wiesel et al., 1987a; Ebmeier et al., 1993). Further support and a
possible pathophysiological basis for these findings has come from neuropathological
research.
In a series of experiments, Benes and co-workers at Harvard have described a
number of relevant abnormalities in the post-mortem brains of patients with schizophrenia.
A blind quantitative analysis confirmed previous uncontrolled findings of reduced neuronal
density in prefrontal, anterior cingulate and motor cortices (Benes et al., 1986). Neuronal
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aggregates were smaller and separated by wider distances in cingulate regions, particularly
in layer II (Benes & Bird, 1987); accompanied by increased numbers of long vertical
axons in layers II and III (Benes et al., 1987). These findings were shown to be
attributable to a reduction in the numbers of small neurones (interneurones) in most layers
of the prefrontal and cingulate cortices, but most marked in layer II of the cingulate cortex
(Benes et al., 1991). Pyramidal neurone numbers were not significantly different between
patients and controls, other than an increase in layer V of the prefrontal cortex in
schizophrenic patients (Benes et al., 1991). Moreover, the differences found were not
attributable to the effects of potential confounders such as age, postmortem interval, or
duration of specimen fixation; and were also noted in patients who were neuroleptic naive.
This body ofwork suggested that gaba-ergic interneurones (basket cells) were reduced in
number in the pre-frontal and cingulate cortical regions and predicted that this would be
accompanied by a compensatory up-regulation ofGABA-A receptors. The hypothesis
was confirmed in a receptor binding experiment, where a preferential increase in
bicucilline-sensitive ^H-muscimol binding was identified in the superficial layers of
cingulate cortex in 6 patients as compared to 8 controls (Benes et al., 1992). Similar
results, also implicating gaba-ergic abnormalities in schizophrenic patients, have also been
reported by a number ofworkers examining both frontal and temporal areas with similar
techniques.
Kiuchi and colleagues described an increase in ^H-flunitrazepam receptor binding
in 13 patients with schizophrenia, localised to medial and orbito-frontal cortex, temporal
cortex and putamen, but not to other cortical areas such as the hippocampus (Kiuchi et
al., 1989). In addition, pre-synaptic GABA re-uptake sites have been shown to be
reduced in left temporal areas by two research groups (Simpson et al., 1989; Reynolds et
al., 1990). These neuropathological studies suggest that gaba-ergic abnormalities may be
found in patients with schizophrenia. Modern in vivo imaging techniques do not suffer
from artefacts related to retrospective design, cause of death (agonal) or post-mortem
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related changes in the brain. It was therefore decided to conduct a neuro-imaging
investigation of gaba-ergic functioning using the specific benzodiazepine receptor ligand
1123-Iomazenil (ethyl 7-iodo-5,6-dihydro-5 -methyl-6-oxo-4H-imidazo[ 1,5a][ 1,4]-benzo-
diazepine-3-carboxylate). Iomazenil can be used with SPET (Schubinger et al., 1991),
labels the same site as the more established PET ligand Flumazenil but with ten-fold higher
affinity (Johnson et al., 1990), and together with its longer in situ availability may
therefore be superior to Flumazenil as an in vivo imaging agent (Woods et al., 1991). A
sub-group of the patients from Study I who had already been SPET scanned with
Exametazime were selected to test the hypotheses that patients with schizophrenia would
have increased Iomazenil binding in frontal and cingulate regions as compared to normal
controls, and that low Exametazime tracer uptake would be associated with a relatively
high Iomazenil binding in within patient comparisons.
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3.2 METHODS
3.2.1. Subjects
Ten patients with DSM-III-R schizophrenia were selected - an equal number
having had relatively high or low anterior cingulate Exametazime binding. Their mean
duration of illness was 13.9 years (s.d. 10.3), with a mean current antipsychotic dosage of
380.5 chlorpromazine equivalents (s.d. 483.7). Patients were excluded if they were
currently receiving benzodiazepine medication, and none of the subjects received any such
treatment for two weeks before the scan. Ten controls were also recruited. There were 6
men and 4 women in each group, but the mean age of patients (36.7, s.d. 9.7) was
substantially higher than that of the normal subjects (mean 26.1, s.d. 7.4).
3.2.2. Scanning procedure
The ten patients, and one of the controls, were studied with the Neuro-900 high
resolution multi-detector NeuroSPECT (Strichman Medical Equipment Inc., USA) system
located in the MRC Brain Metabolism Unit at the Royal Edinburgh Hospital. This imager
has 572-hole collimators, which give an in-slice resolution of 7.5mm (full width at half
maximum); the sensitivity of the instrument has been measured at 520 counts per second
in a head sized phantom filled with 1 kBq of 99mTc per ml (Ebmeier etal., 1991). Images
were reconstructed in middle resolution mode with two iterations using dedicated
software (Strichman Medical Equipment Inc. version 2.86b, 1993).
The remaining nine controls were examined with an identical scanner and
reconstruction protocol at the Department ofNuclear Medicine, University ofAmsterdam.
However, 800-hole collimators were used, which give a spatial resolution of 6mm and a
sensitivity of 315-520 counts per second with a phantom filled with 1 kBq of 99mTc per
ml (Verhoeff et a/., 1993).
Prophylactic thyroid blocking was carried out with potassium iodide or iodate
respectively. Subjects were scanned at rest, lying on the imaging table, with eyes patched
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and background noise minimised. SPET scan studies were conducted using mean
intravenous 11 ^-^-Iomazenil at doses of 161.5 MBq (s.d. 13.0) in patients and 120.8 MBq
(s.d. 27.0) in controls.
3.2.3 Image and Statistical analysis
Mid-ventricular slices containing the basal ganglia, parallel to the OML plane
(approximately +4cm.), were successively acquired between the time of injection and 250
minutes later. Data were available up to 185.4 (s.d. 7.4) minutes in patients and up to
153.0 (s.d. 50.0) in controls; and were taken from 73.3 (s.d. 2.2) minutes post-injection
(i.e. after peak values) in the patients, and from 80.8 (s.d. 16.6) minutes in the controls. In
patients, an average of 8.6 (s.d. 1.3) slices could be used; in controls an average of 10.1
(s.d. 5.3) slices.
Templates originally drawn from a neuroanatomical atlas (Talairach et al., 1988)
were fitted to the trans-axial slice by aligning the outer border of the template with the
outer border of the cortex, which was determined visually as the 20% isocontour line of
the activity map. The inter-rater error for cortical count densities is, in most cases, less
than 5% (Ebmeier et al., 1991; Verhoeffel al., 1993). The template contained ten regions
of interest on both sides (shown with results).
Two estimates of specific receptor binding capacity were derived from the non¬
linear (single exponential) regression of regional activity over time. Only estimates of
regressions accounting for more than 50% of the variable variance were used. If the
variance explained was less than 50%, this was attributable to increased noise rather than
to a better fit of other non-linear models. The first measure was the regional elimination
half-life computed from regional washout curves after 70 minutes (i.e. after regional peak
measures), which has been shown to share a substantial amount of variance with estimates
of specific binding capacity (Wood et al., 1992). Secondly, regional Iomazenil uptake,
extrapolated to the time of injection from measures after 70 minutes, was taken to
133
Chapter 3: Iomazenil binding in schizophrenia
represent early delivery by regional perfusion and specific binding, as regional perfusion is
known to affect the cerebral distribution of Iomazenil mainly at the early stages (Al-Tikriti
et ciL, 1994; Verhoeffet al., 1993). In order to remove between-subject variability,
extrapolated Iomazenil activity and half-lives were standardised to occipital regions of
interest. Figure 3.1 (overleaf) shows the Iomazenil binding in selected regions of interest
over the time of the experiment.
All ten patients had also been examined with 99mTc-Exametazime perfusion SPET
an average of 16.9 months (s.d. 5.2) before the Iomazenil scan. These scans were
acquired with a very similar protocol to the one used for Iomazenil (with injection at rest,
eyes patched, and minimal background noise), and were re-analysed with the templates for
this study to make the two imaging modes comparable.
Differences in receptor binding capacity, as measured by elimination half-lives,
between the patients and controls were examined with Mann-Whitney U-tests corrected
for multiple comparisons. Effect sizes for these comparisons were computed to predict
the approximate group sizes required to demonstrate any such effects at statistically
significant levels. Occipital uptake ratios of perfusion, receptor ligand binding and
standardised elimination half-lives were compared within-patients with non-parametric
statistical tests - using Friedman-Analysis of Variance followed by theWilcoxon Matched-
Pairs Signed-Rank Test. Estimates of specific receptor binding capacity were then
correlated with perfusion measures from the Exametazime scans, using the Spearman
Rank method, to determine the contribution of cerebral blood flow patterns to Iomazenil
binding. This was done for both individual regional measures and across regions using
group averages.
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3.3 RESULTS
3.3.1 Iomazenil binding in patients and controls
The regional elimination half-lives of Iomazenil, in patients with schizophrenia and
controls, are shown in Figures 3.2 and 3.3 (overleaf) and the values given in Tables 3.1
and 3.2 (on subsequent pages), on the left and right sides respectively. The values are
within the range of previously published results (Woods et a/., 1992). On the left,
Iomazenil binding was significantly increased in the patients in only the posterior cingulate
region of interest (P=0.01), which was not in the predicted region and did not meet the
level of significance required after Bonferroni correction (P<0.0025). Similarly, on the
right side, the activity in the caudate was significantly elevated (P=0.03) and showed a
tendency to be so in the posterior cingulate (P=0.09) but not to the extent required with
control for multiple comparisons. In each of these regions the average number of slices
available per patient was less than ten, as the proportion of variance explained in the non¬
linear regression was less than 50% in the remainder - meaning that those values were
rejected. Tables 3.1 and 3.2 also show the effect sizes for these group comparisons of
uptake ratios and standardised wash-out half-lives. With 10 subjects in each group, an
effect size of at least 1.2 standard deviation units would be required to have a power of
0.8 to detect a statistically significant difference in planned comparisons. This translates to
an overlap of at most one-third in the frequency distributions of the subject groups, and
would give a clinically meaningful separation (Cohen, 1988) - whereas the effect sizes in
the left and right anterior cingulate cortex were 0.5 and 0.4 respectively.
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3.3.2 Retrional perfusion and Iomazenil binding in patients with schizophrenia
Tables 3.3 and 3.4 (overleaf) show the perfusion, extrapolated uptake and
elimination half-lives on the left and right sides respectively in the ten patients with
schizophrenia. In some of the small cingulate regions ofapriori interest, values were
excluded where the non-linear regression equation accounted for less than 50% of the
overall variance. The only statistically significant differences between perfusion, uptake
and elimination were in the left and right basal ganglia regions (see Tables). Although
these differences were robust to controlling for multiple comparisons, the measures of
receptor binding capacity were relatively lower than those of perfusion. In the only region
of interest to show a tendency to the expected increase in binding (as measured with
elimination half-life) - the right frontal cortex - the level of significance did not meet that
required after Bonferroni correction (P<0.003).
These results are also shown in Figures 3.4 and 3.5 (on pages 144 and 145) to
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Figure 3.4 - Occipital ratios of regional perfusion (rCBFk extrapolated Iomazenil
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Figure 3.5 - Occipital ratios of regional perfusion (rCBF), extrapolated Iomazenil
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3.3.3 Correlations between perfusion and extrapolated lomazenil binding
As a final test of the hypothesis, Spearman rank correlation's were performed
between Exametazime measured cerebral perfusion and Iomazenil receptor binding
extrapolated to time zero. These are shown in Table 3.5 overleaf. Significant positive
correlations indicate receptor binding potential commensurate with cell numbers and
activity, absent correlations imply a lack of co-variance due measurement error or a
change in perfusion between scans, and significant negative correlations suggest - as
predicted - an inverse relationship between receptor binding and perfusion (i.e. a relative
benzodiazepine receptor supersensitivity).
After Bonferroni correction for multiple comparisons, requiring a significance level
ofP<0.003, only one significant correlation in the left anterior temporal region (r=.83,
P=0.003) and one trend in the left posterior temporal region (r=.80, P=0.009) remained.
Between-subjects correlations in the other cortical regions also tended to be positive, but
did not meet the required level of significance.
When group means were examined across regions of interest, cerebral perfusion
was significantly and positively correlated with extrapolated receptor binding for the ten
cortical areas (r=.74, P=0.01).
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k
Table 3.5 - Spearman rank correlations between regional perfusion and extrapolated
Iomazenil binding (normalised to the occipital cortex)
REGION RHO P VALUE*
Left Frontal .50 0.1
Left Anterior Temporal .83 0.003
Left Posterior Temporal .77 0.009
Left Anterior Cingulate .14 0.7
Left Posterior Cingulate .54 0.2
Left Caudate -.36 0.3
Left Putamen .02 1.0
Left Thalamus -.47 0.2
Right Frontal .50 0.1
Right Anterior Temporal .44 0.2
Right Posterior Temporal .10 0.8
Right Anterior Cingulate .38 0.3
Right Posterior Cingulate .70 0.04
Right Caudate -.25 0.5
Right Putamen .58 0.08
Right Thalamus -.10 0.78
* significance level required after Bonferroni correction P<0.003
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3.4 DISCUSSION
In essence, the hypothesis of increased benzodiazepine receptor binding in the
anterior cingulate and frontal cortex in schizophrenia suggested by the post-mortem
literature was not confirmed. Although significant differences were found, in within
patient comparisons, of regional elimination half-lives of Iomazenil as compared to
Exametazime uptake in the basal ganglia, binding was significantly lower than perfusion
estimates in these regions and the correlations between these measures were generally
positive.
The potential explanations for the essentially negative results in the case-control
experiment include the possibilities ofType II error due to inadequate power or
methodological failings, or that the null hypothesis is correct and that the post-mortem
studies have been subject to Type I error. Unfortunately, the design of the current study
does not allow much certainty in accepting the null hypothesis. Using two groups of ten
subjects each gave sufficient power to identify clinically significant effect sizes of at least
1.2 standard deviation units in 80 out of 100 planned comparisons (Cohen, 1988), and the
estimated effect size from one anatomical study was of 2.0 (Benes et ah, 1992). The
effect sizes for differences in the anterior cingulate identified here were only of the order
of 0.5, which would demand approximately 60 subjects in each group to detect a
statistically significant difference (Cohen, 1988). Thus, although the study was planned
with sufficient numbers, based on the pre-existing literature, the relatively small effect
observed could be attributable to differences between in vitro and in vivo approaches - for
example, the potential confounding of anxiety or current medications in studying live
subjects - or to some methodological problems in the present study that may have
increased measurement variance or 'noise'.
An obvious methodological problem is the large difference in ages between the
patients and controls. Even in the relatively young age groups examined, increasing age is
associated with reductions in cerebral perfusion (Gur et ah, 1986) and receptor binding
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capacity (Wong et al„ 1984). Thus, the patients' more advanced age may have led to a
systematic underestimation of Iomazenil binding in comparison to the younger controls
and Type II error; although, in the absence of specific information of the effects of age on
Iomazenil binding, it might be expected that these age effects would be balanced by
parallel decrements in cerebral perfusion. The patients are also more likely to have been
treated with benzodiazepines in the past than the controls, although none were treated
within two weeks of the scan and the effect ofprevious treatment is likely to be relatively
small (Sybirska et al., 1993). Neuroleptic drugs reduce GABA levels (Lichtshtein et at,
1978) and would therefore have exaggerated any tendency to increased receptor
sensitivity and binding. It might be argued that the patients were receiving their second
scan and may have been less anxious about the procedure than the controls, but
endogenous gaba-ergic compounds do not substantially modulate Iomazenil binding (Innis
et ciL, 1991).
More particularly, there are several differences between the scanning protocols in
the patients and controls that could have materially affected the results obtained. This is
largely attributable to the fact that the patients were scanned in one centre and most of the
controls in another, which was attempted because Iomazenil is an expensive ligand with
limited availability. The lesser resolution of the scanner used in the patients (in Edinburgh)
will have led to greater partial volume effects and reduced the likelihood of finding
increases in binding in relatively small regions like the anterior cingulate. Similarly, the
slightly shorter average time to image acquisition in the patients could have reduced group
differences, as the predicted receptor supersensitivity in regions with low perfusion would
have become more noticeable with time, but this was controlled for by extrapolating back
to binding at time zero. Alternatively, the higher average dose of ligand administered in
the patients, would have tended to produce a positive rather than a negative result.
Lastly, the large variance of almost all measures, particularly in the controls, would have
reduced the chances of finding significant differences in receptor binding.
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An assumption of the analysis is that activity after approximately 70 minutes
mainly reflects specific receptor binding capacity. This ifjustified because displacement
studies in primates showed that the non-specific binding of Iomazenil was only about 10%
at 120-330 minutes after injection of the radiotracer (Innis et al., 1991). Moreover, from
between 20 and 60 minutes after injection of the ligand onwards, the regional distribution
of Iomazenil remains constant (Innis et al., 1991), and has been shown to be very similar
to that of labelled Flumazenil in PET experiments (Verhoeffet al., 1993).
A final methodological issue of concern is that all the methods of estimation were
relative (to the occipital region), so that global differences in receptor binding capacity
would not have been detected. In the absence of arterial measures of free parent ligand, a
quantitative modelling procedure was not employed, so that conclusions about absolute
receptor binding are not possible (Abi-Dargham et al., 1994). Using a bolus injection
method and examining subjects after the respective regional peak densities meant that no
true equilibrium was established at the time of scanning, so that non-receptor related
factors such as ligand delivery to the brain (regional perfusion) and rate of disappearance
from plasma could have differentially affected group measures. However, experience with
metabolic and cerebral blood flow imaging suggests that quantitative modelling may
actually increase noise and make it more difficult to discover regional abnormalities
(George et al., 1991). The possibility remains that any group differences in the reference
region could have confounded the result, particularly as Iomazenil uptake is greatest in
occipital regions (Innis et al., 1991; Woods etal., 1992). Putatively greater structural
tissue losses in frontal than occipital regions in schizophrenia (see Chapter 1) are relevant
considerations here, but the work ofBenes (1991) - on which this study is based -
suggests that any such losses are limited in nature and extent. Further, and perhaps most
importantly, two other Iomazenil-SPET studies in schizophrenia have also failed to find
any evidence of gaba-ergic upregulation (Busatto et al., 1995; Schroder et al., 1995b).
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All in all, although inconclusive, the results presented here do not support
suggestions from the post-mortem studies of gaba-ergic abnormalities in frontal regions
and raise issues of possible confounding in those experiments. In this regard, the finding
of increased muscimol binding in pre-frontal cortex (Hanada et al., 1987) has been
attributed to differences in the numbers of patients and controls who suffered sudden
deaths or prolonged terminal illnesses (Shapiro, 1993). Moreover, the report of increased
flunitrazepam binding (Kiuchi et al., 1989) has been contradicted by Squires et al. (1993)
who found widespread reductions in that same measure. It should be noted that the Benes
studies describing an apparent loss of inter-neurones have not been independently
replicated, were conducted on small numbers of subjects and that the patients with
schizophrenia had 'prominent affective disturbance' (Benes et al., 1991). Akbarian et al.
(1995) reported no significant cell loss in any layer of the pre-frontal cortex in the brains
of ten chronic schizophrenics who had no affective disturbance, and there is even the
possibility of an increased neuronal density in this area (Selemon et al., 1995). Indeed,
Squires et al. (1993) have suggested that the loss of small cells described by Benes and
colleagues may have actually been attributable to deficits in the numbers of small
pyramidal neurones, which could have been mistaken for basket cells. They went on to
suggest that other interpretations of the increased binding of ^H-muscimol (Benes et al.,
1992) are plausible - including a hyperinnervation by gaba-ergic neurones on larger
pyramidal cells or an intrinsically larger number ofhigh affinity GABA-A receptors in
schizophrenia - which may better fit the findings from post-mortem neurochemistry studies
and the results from the present study.
The reduction in Iomazenil binding as compared to Exametazime measured
perfusion of the thalamus, caudate and putamen within the patients with schizophrenia
must be treated cautiously for several reasons. It was not expected and should therefore
be regarded as a post hoc result. Almost 18 months, on average, elapsed between the
scans and a progressive reduction in perfusion and binding cannot be ruled out. Partial
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volume effects, reducing measured perfusion/binding, are most marked in such small
regions, especially those closer to the centre of the brain. Finally, Iomazenil uptake is
lower and clearance higher in the thalamus and basal ganglia as compared to cortical
regions (Beer et al, 1990; Innis et al., 1991; Woods et al, 1992) and follows the known
distribution ofGABA receptors with least reliability in the thalamus (Beer et al, 1990).
Nonetheless, the size of the differences detected in the current study demands an
examination of the relevant post-mortem studies.
The results are clearly compatible with those of reduced muscimol binding in the
caudate (Hanada et al., 1987) and reduced flunitrazepam binding in the globus pallidus
(Squires et al., 1993), but not with an increase of the latter in the putamen (Kiuchi et al.,
1989). At first sight, putative reductions in the numbers ofGABA re-uptake sites in the
putamen, caudate and lateral pallidum (Simpson et al., 1992) would be expected to be
associated with receptor supersensitivity, but similar findings in the left temporal cortex
have not been shown to be accompanied by post-synaptic up-regulation (Simpson et al.,
1989; Reynolds et al., 1990 & 1993). These findings, could conceivably be attributable to
an excess of gaba-ergic transmission that may be localised to the basal ganglia (although a
more generalised effect as suggested by Squires et al. (1993) would not be compatible
with the results from the present study). Moreover, such an interpretation could be
supported by functional neuro-imaging findings of a reduction in basal ganglia metabolism
that is normalised by antipsychotic medication (see Chapter 1).
However, the status of any 'gaba-ergic hypothesis of schizophrenia', and
particularly that of an increase in activity, has received at best inconsistent support from
the literature. Early reports suggested that GABA levels were reduced in the nucleus
accumbens and thalamus (Perry et al., 1979) or amygdala (Spokes et al., 1980), or only in
the posterior hippocampus (Toru et al., 1988). These have been challenged (Cross et al.,
1979), but there is no support for any increases in GABA concentrations. Similarly, CSF
and plasma levels ofGABA are generally normal, and have not been consistently related
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to any particular illness characteristic (van Kammen & Gelernter, 1987). It could be
claimed that the effects of antipsychotic drugs, in reducing GABA levels (Lichtshtein et
ah, 1978), may account for these findings. However, if gaba-ergic activity in the brain
were excessive, a parallel increase in the levels of the activity dependent Glutamic Acid
Decarboxylase (GAD) would be expected, and while Hanada et al. (1987) described no
such effect, Sherman et al. (1993) found a decrease, and a recent study has actually
reported a reduction in GAD gene expression in the pre-ffontal cortex (Akbarian et al.,
1995). These GAD activity results are the most consistent findings in this literature and
are strong evidence against excessive gaba-ergic activity in patients with schizophrenia.
This literature review therefore strongly suggests that the findings of reduced
Iomazenil binding in the thalamus and basal ganglia are methodological artefacts. Indeed,
the only indisputable findings from the current study are ofpositive correlations between
perfusion and receptor binding in left temporal cortex, which - given that structural
abnormalities in schizophrenia are probably most marked in this region - is strong evidence
that any benzodiazepine receptor deficits have little role in their aetiology. Some of the
inconsistencies in previous studies could be attributable to regionally selective
abnormalities in GABA levels and activity. Certainly, glutamatergic theories of
schizophrenia, which are currently receiving intense interest, are based on similarly
variable findings - although they do generally suggest an increase in activity in frontal
regions and a reduction in temporal cortex and basal ganglia (e.g. Deakin et al., 1989;
Simpson et al., 1992). Such findings have led to influential theories about glutamate
function in schizophrenia (Carlson & Carlson, 1990; Olney & Farber, 1995), which have
been modified to incorporate gaba-ergic components (Benes, 1993 & 1995) but it is
difficult to advance a strong case that the latter are fundamental. Given that many
neuropeptides are co-localised in neuronal populations, it is possible that many apparent
deficits in gaba-ergic functioning are associated with and possibly attributable to
glutamatergic abnormalities. Indeed, Squires et al. (1993) interpreted their findings of
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reduced ^H-flunitrazepam binding in the hippocampus as evidence of a loss of
glutamatergic pyramidal cells because these normally outnumber gaba-ergic neurones in
the cortex and would therefore be expected to have the greatest concentration of
benzodiazepine binding sites. A putative disturbance in the afferent projections to the
frontal cortex is suggested by glutamatergic hyperinnervation (Deakin el al., 1989), and is
also compatible with the original Harvard report of an increase in vertical axons in the
cingulate (Benes etal., 1986).
Finally, clinical observations and treatment trials do not support views that GABA
activity is fundamentally disturbed in schizophrenia. Gaba-ergic drugs, such as baclofen,
have occasionally been found to exacerbate psychotic symptoms, while benzodiazepines
have at most small effects (van Kammen & Gelernter, 1987; Wolkowitz & Pickar, 1991).
On the other hand, there are suggestions that excitatory amino-acids, such as glycine, may
have a beneficial effect in negative symptoms at least (Javitt el ah, 1994), although
replication is still required.
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3.5 CONCLUSIONS
The main results from the present Iomazenil binding study do not support
suggestions ofan up-regulation in GABA receptors in the pre-ffontal cortex ofpatients
with schizophrenia. Rather, these findings and the inconsistencies in the previous
literature go against the view that any disturbance ofGABA functioning in schizophrenia
is substantial or ofprimary importance. Unfortunately, the deficiencies of the present
study demonstrate the many methodological factors that can confound neuro-imaging
experiments and highlight the difficulties in conducting multi-centre research in this area.
Nonetheless, the combination ofperfusion images with receptor binding scans is an
exciting new experimental tool in brain imaging research, and one whose scope will
increase with the development of other ligands of relevance to neuropsychiatric disorders.
In vivo studies are complimentary to post-mortem experiments and do not suffer from
artefacts related to agonal events and post-mortem or fixation intervals. If such
technological advances are to be translated into important findings that will increase our
knowledge of schizophrenia, researchers must carefully formulate hypotheses that can be
tested in sufficiently large numbers of subjects to allow confidence in both positive and
negative results. The following, final, chapter in this thesis will briefly discuss these issues.
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THE FUTURE OF BRAIN IMAGING IN SCHIZOPHRENIA
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4.1 INTRODUCTION
What developments in neuroimaging approaches to the study of schizophrenia and
other neuropsychiatric disorders are likely in the foreseeable future? This question must
be answered in terms ofwhat is feasible as well as desirable, and cover likely advances in
both technical and theoretical areas. These are important current issues for schizophrenia
researchers as the initial enthusiasm accompanying new discoveries is gradually giving way
to a more realistic appreciation of what has been achieved thus far. The neuroimaging
findings have helped to demonstrate that schizophrenia is a disease of the brain, but have
failed to consistently tie the pathognomic features of the illness to particular abnormalities.
Without this, the deficits could be seen as nothing more than epiphenomena, especially as
many workers have shown very similar abnormalities in a variety of other psychiatric
disorders. This does not, of course, invalidate the findings but does pose very real
questions about their specificity, and behoves researchers to harness the available
technology to consistently demonstrate links between brain structure and function, as well
as differences in these relationships between the major diagnostic groupings, symptom
complexes and individual symptoms.
In these regards, technological developments promise to increase the sensitivity of
the various measures of structure and function, but the simple application of such technical
advances will not be sufficient to substantially increase knowledge about the
pathophysiology of neuropsychiatric conditions. This will require new questions, framed
as testable hypotheses, which can be addressed in such a way as to ensure confidence in
both positive and negative answers. This chapter will briefly consider the likely
technological advances, in both structural and functional neuro-imaging, over the next few
years; before discussing desirable developments in theoretical and experimental
approaches to the study of schizophrenia.
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4.2 TECHNICAL DEVELOPMENTS
4.2.1 Structural imaging
Most MRI scanners now offer anatomical resolution as good as 1 -2 mm. Further
technical improvements are possible - which could reduce partial volume effects and other
artefacts - but the main advances are likely to be in more reliable and automated
volumetric assessments. Serial slice techniques, with internal anatomical boundaries, are
prone to slice positioning artefacts, partial volume effects, parallax errors due to
uncorrected rotation, and difficulties with naturally variable gyral boundaries. Surface
rendering techniques can minimise these problems and provide more reliable volume
estimations (Kulynych et al., 1995 & 1996). Other methods to control for inter-subject
variations in brain size and shape include linear transformation into a defined 'bounding
box' (Andreasen el al., 1994b), spatial normalisation to a template in stereotactic space
(Collins et al., 1994; Wright et al., 1995) and landmark-based ('spline') deformations
(DeQuardo el al., 1996). Such methods may reduce measurement variability, which is
usually most marked in patients, and might therefore be particularly useful when
considering small differences between patient sub-populations and in cohorts over time.
Automatic volumetric programmes, which substantially reduce image processing time, are
already available for whole brain estimations, segmentation into grey and white matter and
correcting tilt (e.g. Kohn et al., 1991), but are unlikely to be able to discriminate particular
lobes ofgyri of interest.
The main technical advances in MRI are, in contrast, new developments in
functional imaging techniques that are already rivalling PET and SPET, and may soon
prove to surpass them, in terms of resolution, availability and safety.
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4.2.2 Functional imaging
4 2.2.1 - PET and SPET
Future developments in PET, such as progressively smaller crystals and more
powerful photomultiplier tubes for signal amplification, could substantially improve on the
usual current spatial resolution of about 5mm - but basic positron physics limit the
ultimate resolution to 2-3mm (Buchsbaum, 1987). Indeed, the need for an on-site
cyclotron to manufacture radionuclides, and the ensuing expense and limited availability of
the technique, mean that PET may have a relatively limited future as a neuroimaging
method. Its main current advantage, of a wide range of radiopharmaceuticals with good
biochemical sensitivity, will allow perhaps 5-10 more years of profitable experimentation -
particularly in mapping the localisation of increasing refined neuropsychological tasks
(after Petersen et al., 1988) and in behavioural pharmacology of cognitive activations (e.g.
Dolan et al., 1995) - but advances in SPET and particularly functional MRI are likely to
eventually make PET an expensive and unnecessary research tool.
Recent developments in SPET imaging include software improvements to allow
sequential acquisitions (to discard movement degraded images), multiple angle imaging,
dynamic filtering, surface variable attenuation correction and three dimensional display.
Such instrumentation has brought SPET to the stage of rivalling PET for resolution and
sensitivity. Workers in Edinburgh have now successfully adapted SPM for SPET, which
will allow whole brain coverage and analysis of'functional connectivity' (see below). New
receptor ligands and a possible glucose analogue are being developed, which will allow
relevant studies in large subject groups as a result of the relative inexpensiveness of SPET.
In particular, improvements in energy resolution hold the promise of Dual Isotope
Imaging, where 140 keV (^^mTc) emissions could be distinguished from tracers of 159
keV (1^23) an(j absolute rCBF could be measured at the same time as ligand binding or
rCBV (Devous, 1995). However, even SPET is unlikely to be able to compete with the
major advantages of functional MRI.
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4.2.2.2 Functional 7V1RI
MRI hardware has already been adapted for functional studies of biochemical
metabolism in Magnetic Resonance Spectroscopy (MRS), which can measure the
concentration of metabolites as long as they contain paramagnetic nuclei such as
phosphorus-31 (in ADP, ATP and phospho-esters), hydrogen-1 (in aspartate) and carbon-
13 (in choline and fat). Although MRS studies in schizophrenia have suffered from poor
resolution until very recently, there is some emerging consensus of reduced
phosphomonoesters and inorganic phosphate in frontal cortex (Deicken et al., 1994;
Stanley et al., 1995) and of reduced N-acetyl aspartate in temporal structures (Renshaw et
al., 1995; Maier et al., 1995), which may reflect increased breakdown of neuronal
membranes in schizophrenia. These studies promise to be able to examine similar
measures of neuronal functioning as post-mortem receptor binding experiments, but
without the confounding effects of old age and cause of death.
Another technique, still in infancy, is that of functional MRI (fMRI) which
promises to revolutionise functional neuro-imaging. It measures activation increases in
rCBF through a reduction in paramagnetic blood deoxyhaemoglobin content, without the
need for radioactive contrast agents, and can therefore be employed in multiple scans over
time with easy co-registration with structural MRI. Experience thus far in schizophrenia
research is very limited, but preliminary studies have shown that such experiments can be
done and have already highlighted reduced and less lateralised motor activations (Wenz et
al., 1995), a greater response to photic stimulation (Renshaw et al., 1994), and reduced
left frontal but increased left temporal activation during a word fluency task (Yurgelun-
Todd et al., 1996). Both MRS and fMRI are best conducted with larger field strength
magnets, allowing fast imaging and improved resolution, but reliable results can be
obtained with the more widely available clinical scanners. They offer spatial resolution in
the millimetre range, and the concomitant use of electrophysiological techniques in 'multi¬
modal' imaging could provide complementary temporal resolution.
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4.2.2.3 Electrophysiologv
The main techniques used to date are those of Electoencephalography (EEG),
Event Related Potentials (ERP's), and Brain Electrical Activity Mapping (BEAM); while
recent technical developments include Magneto-encephalography and Transcranial
Magnetic Stimulation (TMS). Their main advantage is of high temporal resolution, in the
millisecond range, which is substantially greater than any currently available alternative
techniques, and the lack of any exposure to radioactivity or X-rays. Their main problem,
however, is the poor spatial resolution they offer, which may account for the somewhat
inconsistent results obtained to date and their apparent lack of specificity (see Blackwood
et al., 1994). In general, brain activity recordings are made from overlying scalp
electrodes and are therefore an indirect measure which can be affected by conduction
through brain tissue and bone and movement artefact, particularly from eye muscles. For
quantitative analysis, electrode placement has to be corrected for skull size, and signals
have to averaged over many trials to be detectable above background noise. Nonetheless,
some of these techniques are widely available and relatively cheap, so that more typical
clinical populations can be examined outside the major centres.
The temporal information they provide about neural synchrony and network
interactions bring interesting possibilities in correlating electrophysiology with other brain
imaging techniques as composite measures of the sites and timings of putative
abnormalities. For example, ERP amplitude reductions have been correlated with left
temporal lobe measures and positive symptoms (McCarley et al., 1993; Egan et al., 1994),
while latency may correlate with SPET tracer uptake in frontal and parietal cortex
(Blackwood et al., 1994).
It is apparent that functional and structural imaging methods are complementary
and that their combined potential may substantially expand our knowledge of
schizophrenia, but this will also depend on accompanying advances in our theoretical
approaches to the disease.
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4.3 THEORETICAL DEVELOPMENTS
4.3.1 Aetiological theories
What do we know about the cause(s) of schizophrenia, and what hypotheses does
such knowledge generate that can be usefully tested in future studies?
Given that we can state with a fair degree of certainty that genetic factors account
for 50-70% of the variance in liability to develop schizophrenia (McGufFin el al., 1995),
and that other risk factors such as obstetric complications (Geddes & Lawrie, 1995) and
drug abuse (Andreasson et al., 1987) are well recognised, psychiatric researchers have
relatively few theories of how these variables may interact pathophysiological^ and lead
to the development of the classical clinical picture. This is presumably related to the
conceptual difficulty in formulating plausible links from aetiological factors, to biological
abnormalities (ofbrain structure and function), to symptoms and signs. Three main 'grand'
hypotheses have been advanced in recent years, two of which have been found wanting
(Crow, 1980; Murray et al., 1985) and the third has yet to be bettered, possibly due to its
lack of specific predictions (Weinberger, 1987; Murray & Lewis, 1987).
Other theories have been proposed, concentrating on neurochemical disturbances
such as in dopaminergic neurotransmission (e.g. Davis et al., 1991) or localised structural
deficits in the left hemisphere (McCarley et al., 1993) or the heteromodal association
cortex (Schlaepfer et al., 1994), but these have been limited in scope rather than
attempting to link known abnormalities at other levels. Those models that have
incorporated findings in several research fields are essentially modifications of the
neurodevelopmental schema (e.g. Stevens, 1992; Keshavan et al., 1994).
Crow's suggestion of two separate disease processes, mediated largely by
dopaminergic overactivity and brain damage respectively (1980), has suffered the same
fate as attempting to draw a distinction between familial and sporadic associations of
aetiological factors (Murray et al., 1985) - in research as well as clinical samples, these
processes and factors do not conveniently dissociate from one another. It appears, rather,
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that all are widely distributed amongst the patient population. The neurodevelopmental
hypothesis, on the other hand, accommodates all these variables as predictive of
schizophrenia - once triggered by biological and psychological events around puberty -
with only subtle manifestations of a fixed lesion up until that point (Weinberger, 1987;
Murray & Lewis, 1987). This 'hypothesis' is therefore more accurately referred to as a
'model', synthesising the available facts rather than delivering concrete refutable
predictions. For example, if the current consensus that the structural brain changes in
schizophrenia do not progress was seriously challenged by well executed studies, this
would be incorporated into the model rather than requiring an abandonment of the
hypothesis.
However, it is not the case that this model is therefore scientifically useless,
according to Popper's falsifiability criterion. As an explanatory scheme it has much to
commend it, in a similar way to Darwin's evolutionary ideas and in stark contrast with
Freud's psychoanalysis - because they are or are not, respectively, based on empirical
observations. Moreover, it is possible to induce testable propositions from the
neurodevelopmental model if one is more specific about the period of development that is
referred to and the putative processes involved at that time. Such an scheme has been
suggested by Lyon & Barr (1991), who proposed that first trimester effects will lead to
small brains, second trimester events to ventricular enlargement, and third trimester or
perinatal factors to hypoxia and multi-site abnormalities.
The neurodevelopmental model has, of course, been built largely upon the findings
of the neuroimaging literature in schizophrenia. Ironically, then, the fact that similar
abnormalities have been found in structural, functional, and receptor binding experiments
on subjects with affective disorders (see Chapter 1) - that may differ only in degree -
argues that this model may equally apply to other psychotic disorders. Indeed, a
'continuum of psychosis' is also suggested by the overlap in symptomatology, treatment
response and outcome (Crow, 1990), and recent demonstrations that neurodevelopmental
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aberrations may also be found in patients with affective disorders (Sands & Harrow, 1995;
Vocisano et al., 1996). This suggests that these variables - which presumably reflect
underlying commonalties in disease processes, whether integral to psychosis per se or
merely as markers of severity - should be regarded as widely distributed in psychotic (and
possibly all) populations for the purposes of both theorising and experimentation (see
below).
This conceptual approach has been favoured by geneticists for some time
(McGuffin et al., 1995). Schizophrenia is regarded as the product of several genes
(polygenic) that interact with each other and environmental factors (multifactorial) to
increase or decrease the liability to the condition. It is important to recognise that
apparent environmental effects, such as obstetric complications or drug abuse, may
themselves be genetically mediated or the product of gene-environment interactions.
Moreover, particular constellations of risk factors within individuals and over time could
account for the co-existence of schizophrenia and affective psychoses within some
families, the existence of schizo-affective psychoses, and individual diagnostic changes
over time. Similar arguments, have been advanced for the relationship between anxiety
and depression; where genetic factors may be essentially the same, but with phenotypic
expression altered by environmental events (Kendler et al., 1995). For example, certain
genes may predispose to life events and the experience of 'stress' or maladaptive coping
mechanisms (in anxiety or depression), and different genes to the substance abuse that can
precipitate onset or relapse (in psychosis). An epidemiological, risk factor approach is
necessary to provide empirical support or refutation of these possible interactions - as has
been recognised for years in other multifactorial diseases e.g. ischaemic heart disease.
Unfortunately, very few studies have employed such an approach in studying
schizophrenia, let alone psychosis more generally. Previously, researchers have tried to
find neat but artificial distinctions between aetiological (Murray & Lewis, 1985) or
pathophysiological factors (Crow, 1980), with little observable success. This is
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unsurprising when one considers that 'abnormal' genes (and other risk factors) may be
quite common in the general population (Harrison & Geddes, 1996). In the absence of a
defined genetic abnormality, and a screening test for it, it is methodologically impossible to
distinguish those at or not at genetic risk. (The family history is an unreliable proxy, and
there may be different genes with differing effects within particular families.)
Heterogeneity has been commonly invoked to explain such negative results, without
distinguishing between genetic and phenotypic variance or testing the 'heterogeneity
hypothesis' (see below). However, subtle refinements of these early theories, with explicit
consideration of possible explanations of heterogeneity, have been recently proposed.
For example, Lewis (1989) and particularly Castle & Murray (1991) have suggested a
pathophysiological model that incorporates sex differences in onset and course of
schizophrenia as well as a possible psychotic continuum. It remains to be seen whether
such age at onset differences reflect different disease processes or are primarily
manifestations of differing degrees of severity.
Other contemporary theories linking aetiological factors and pathophysiological
processes are few and far between. Crow (1990) has again been one of the few to suggest
a possible association between specific genetic and structural abnormalities; in postulating
that anomalous cerebral asymmetry was of aetiological importance, as well as suggesting
that a single 'asymmetry gene' was responsible for both brain development and psychosis.
While the first part of this hypothesis has received some tentative empirical support, with
demonstrations of a loss of asymmetry in schizophrenia and in those who apparently carry
the gene (Bilder el al, 1994; Honer el al, 1995), it is extremely doubtful that only one
gene is involved. Moreover, Crow's latest refinement of this theory - that links differential
age at onset in the sexes to mating behaviour, and an equal worldwide prevalence to
language and social intelligence and other species-specific behaviour (Crow, 1994) - is
unlikely to find much scientific support given its vague nature, absence of logical steps and
apparent lack of specific testable hypotheses. Indeed, it is difficult to see how any
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language/social deficits that may be identified would favour his rather than the
neurodevelopmental model. Although Crow's theory draws attention to our ignorance of
the normal development of the human brain, it is all too easy to weave disparate threads of
evidence into a model of some sort. This has been amusingly demonstrated by Birley
(1993), who linked schizophrenia to other essentially human characteristics such as the
phenomenon of sole heterosexuality, love, practising sex for pleasure and the
disproportionately large size of the penis as compared to other primates. These
speculative theories have the superficial attraction of apparently incorporating such
important findings as the reduced emotional depth and sensitivity, decreased fertility and
social deficits in schizophrenia - but, crucially, in an unfocused and untestable way. Small
specific theories have greater scientific value than big vague ideas.
Neurochemical theories of schizophrenia, particularly the 'dopamine hypothesis',
have substantial empirical support and potential links to genetic, structural and functional
findings, but these have rarely been formulated in such a way as to be able to state that
dopaminergic abnormalities are or are not associated with other specific biological
disturbances (see Davis et al., 1991). It has become clear that schizophrenia is not simply
a hyperdopaminergic state and that a variety of other neurochemical abnormalities are
likely to be involved. The best recent evidence of neuropharmacological disruption in
schizophrenia has been realised from studies of glutamate receptors and a number of
workers have proposed 'glutamate hypotheses' of the disorder (e.g. Carlsson & Olney,
1995). This accommodates known biological and clinical features of schizophrenia, such
as structural changes and age at onset, as well as dopamine involvement. Moreover, it
suggests some neurodegenerative component to the condition, through glutamate
mediated excitotoxic neuronal damage, which challenges the simple neurodevelopmental
conceptualisation of schizophrenia and is also compatible with observations that some
cognitive impairments in schizophrenia show an apparent progression in the first five years
of the illness (Bilder et al., 1992). Excitotoxicity could account for poor prognosis in
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many patients with schizophrenia, particularly those with the deficit syndrome, while its
absence could explain the generally good outcome in affective disorders. This hypothesis
has the advantage of a definite prediction - i.e. some degree of progressive volume
reduction in some brain structures, particularly in the early stages of the illness
Psychological theories of schizophrenia have been largely discredited by the
advances in our neuroscientific knowledge about schizophrenia. Latter day attributional
explanations of psychotic phenomena (e.g. Roberts, 1992) are inherently mentalistic, but
given our ignorance about mind-body relationships and the possibility that applications of
such conceptualisation may have practical benefits for patients these should not be
dismissed. The recent resurgence of interest in neuropsychology is of more immediate
interest to neuroscientists conducting schizophrenia research as this has brought some
definite conceptual advances, even though these have only rarely been tied to specific
biological abnormalities. The new 'cognitive neuropsychology' is functionally oriented
rather than lesion based, which is desirable given the latter's implications of specific
cortical region involvement, but assumes that mental faculties are essentially modular - a
proposition that may not be valid (see below). Nonetheless, genes may well code for
cognitive processing tendencies - whether of modular capabilities or inferential
propensities. Frith (1992) has perhaps made the greatest theoretical contributions in this
area, in proposing abnormalities of 'self-monitoring' (leading to positive symptoms), 'self-
generation' (negative symptoms), and 'suppression of inappropriate responses' (thought
disorder and mood incongruence). These cognitive processes have also been neatly tied to
particular patterns of regional brain metabolism (Liddle et al., 1992), which might
themselves be possible to trace back to structural brain changes. Although somewhat
redolent of Kraepelin's three syndromes, which do not conveniently differentiate patient
groups, they may represent different disease processes and provoke interesting questions -
of general importance - as to whether such abnormalities reflect state or trait abnormalities
and about their specificity and relationship with aetiological risk factors.
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Frith (1992) has also borrowed the concept of abnormal 'theory of mind' from
autism researchers to try and explain social deficits in schizophrenia. This has less intrinsic
appeal, given the consensus that there are no substantive links between the two conditions
and that social intelligence or cognition may be more accurate descriptions of the
processes affected in schizophrenia researchers, but may ultimately prove of value if some
association with underlying cerebral abnormalities (whether similar or different in
schizophrenia and autism) can be found.
In summary, contemporary schizophrenia research seems to operate largely in a
theoretical vacuum. Grand explanatory models are desirable in synthesising knowledge
from disparate fields of research and in highlighting areas of potential interest, but must be
accompanied by smaller, more specific and definite hypotheses. In many ways, a
hypothesis that proves to be incorrect is as scientifically valuable than one which is right -
we need more falsifiable theories rather than less. There is a need to link together known
aetiological risk factors (genetic transmission, obstetric complications, drug abuse, and
possibly schizotypy and social stressors), whether these act as predisposing or
precipitating causes, with biological abnormalities (of brain structure and function) and
thence to the cognitive deficits and characteristic clinical features of schizophrenia. It
should be borne in mind that many of these aetiological variables are prevalent and widely
distributed in the general and psychiatric populations. In many ways, however, our
theorising about schizophrenia is constrained by our ignorance about how these agents
may exert their pathophysiological effects and the possible interactions between them.
Advances in our understanding of schizophrenia, therefore, will also be dependent on
implementing new practical approaches to examining these possible effects. Given that
we, broadly, know what causes schizophrenia, it should be possible to devise and conduct
experiments that will further an integrated neuroscientific understanding of schizophrenia.
A recent example of such an experimental approach is the series of studies conducted by
Cannon et al. (e.g. 1989), which found that a large part of the variance in the propensity
169
Chapter 4: The future of brain imaging in schizophrenia
to develop schizophrenia (in high risk individuals) was attributable to family history and
obstetric complications, and demonstrated an interaction between levels of genetic risk
and delivery complications with distinctive relations to ventriculomegaly and atrophy.
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4.3.2 Experimental approaches
The main practical issue for schizophrenia researchers is how we can apply what
we already know about the illness to realise further increases in our knowledge. It is clear
that future studies will need to employ the best available epidemiological and
neuroscientific techniques to answer important questions in such a way as to give
confidence in the answers. The following pages briefly consider topical issues in
epidemiological, psychopathological and neuroimaging approaches to schizophrenia;
highlighting what studies are currently needed in each area.
4,3.2.1. Epidemiology
Epidemiology is narrowly defined as the study of the associations of disease in a
population, but is also concerned with fundamental issues of study design and analysis.
Much progress has been made in recent years in identifying risk factors for the
development of schizophrenia (Cannon & Jones, 1996), and studies of gene-environment
interactions are now required. Rutter has suggested that key questions include whether
schizophrenia with neurodevelopmental precursors is any different from schizophrenia
without them, and whether these factors primarily reflect genetic or environmental causes
(Rutter, 1995). In seeking to answer these questions, researchers must consider the
distribution of such risk factors in the general population as well as schizophrenic and
other psychiatric patients.
Most research into schizophrenia is, understandably, conducted as case-control
studies on clinical populations in large tertiary referral centres. The problem with this is
that it is difficult to be certain that any abnormalities found are generalisable to all patients
with schizophrenia or whether they are only representative of a sub-population. Patients
in tertiary care are often the worst affected cases, raising the possibility that any findings
are markers of severity rather than disease per se. Possible selection biases are difficult to
overcome in small studies and the only reasonable alternatives are to conduct large
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collaborative multi-centre studies or to identify cohorts of patients and controls from the
general population. Multi-centre studies are laborious, expensive and do not bring
prestige to individual researchers or departments; moreover, they may not be possible in
high-tech areas such as neuro-imaging where different scanning protocols may confound
results (as demonstrated in Study 2 of this thesis). Population based projects are probably
therefore the best approach, with their advantage of generally representative patients and
controls. Moreover, the large number of cases identified substantially increase statistical
power.
Many neuro-imaging studies, as with much schizophrenia and medical research
generally, are completed with relatively small numbers of subjects. Negative results (the
null hypothesis) are therefore difficult to accept, given the likelihood of Type II error.
Positive results, on the other hand, are generally accepted as they - with little if any
consideration of possible Type I errors or confounding by case-control differences in small
samples. Publication bias favours positive results and multiple significance testing ('data-
dredging') for them. It is obvious that we need studies that are at least an order of
magnitude larger than most previous research, with explicit prior hypotheses and
multivariate statistical techniques to examine interactions and potential confounding, so
that negative results can be accorded the same value as positive findings.
Negative findings are often attributed to 'heterogeneity', without further
consideration of other possibilities or the nature of the apparent heterogeneity. Such
assertions are of little scientific value, whereas it is possible to test for the existence of
such variance and whether it is primarily genotypic or phenotypic (Carpenter et al., 1993).
For example, the extent of clinical differences within and between concordant
monozygotic twin pairs identifies the source of such differences (Bailey et ah, 1996).
The use of these strategies, together with a generally greater awareness of epidemiological
issues, are desirable goals for future research into the causes of schizophrenia.
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4.3.2.2. Psvchopathologv
The difficulty in finding consistent clinical correlates of the biological abnormalities
in schizophrenia has prompted experimental approaches designed to reduce heterogeneity.
The most frequent method is to examine patients with and without a particular
phenomenon of interest, which has been most widely used in the study of auditory
hallucinations. These are, perhaps unsurprisingly, localised largely to language areas of
the cortex (e.g. McGuire et al., 1993 & 1995) in functional imaging experiments.
However, localisation - regardless of accuracy - is not explanation: one could confidently
predict that visual hallucinations reflect dysfunction in the occipital lobes without
understanding why they occur. This approach does have value in seeking to link
abnormalities of brain structure and function to cognitive and clinical findings (Mortimer
& McKenna, 1994), but does not explain the characteristic form and content of auditory
hallucinations in schizophrenia. Similar phenomena are also found in 10-15% of cases
with severe affective disorders and the symptomatic approach may therefore tell us more
about temporal lobe pathology generally than in any particular disease. Future studies
should therefore focus on differences in form and content, within and between different
disorders, and try to establish the modulation of these experiences as patients develop
insight and the experiences become 'pseudohallucinations'. Functional MRI could be a
valuable technique in the long-term follow-up studies required.
Similar elucidation is required of the possibly similar biological basis of negative
symptoms in schizophrenia and depressive retardation (Dolan et al., 1993). Studies of the
objective behavioural concomitants of these problems may be illuminating; but it is clear
that a purely symptomatic approach has limitations. This is likely to be particularly so
where symptoms of illness are not qualitatively distinguishable from normal experience.
For example, the remaining characteristic symptoms of schizophrenia - 'bizarre' delusions
- clearly merge into partial delusions, which merge into overvalued ideas (such as anorexic
'fatness' and hypochondriacal disease conviction) and normal beliefs. Cultural
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compatibility and the strength of conviction are the conventional discriminators, but these
are arbitrary clinical judgements rather than objective differentials. Nonetheless, there is
some potential in seeking to explain delusions as, for example, irregularities in access to
and storage ofparticular memories (McKenna, 1991).
The symptom based approach necessarily precludes study of individuals without
frank psychosis, whereas a number of schizophrenia related personality disorders
aggregate in the families of affected individuals and may be risk factors for the condition.
It will be important to examine how the childhood precursors and biological associations
of schizophrenia relate to these forms of psychopathology. Clearly, a purely symptom
based approach has some value but there is a need for sub-syndrome based (e.g. Liddle et
al., 1992) and disorder based research studies, with their differing but complementary
capabilities.
4,3.2.3. Neuroimaging
Structural neuroimaging studies have provided valuable information about
morphological abnormalities in schizophrenia, but has not as yet established the extent to
which different parts of the brain are affected and how these changes relate to aetiological
factors and clinical features. For example, do the loss of brain substance,
ventriculomegaly, and asymmetry abnormalities reflect different disease processes related
to particular genetic and environmental effects? This issue needs to be pursued in family
and high risk studies, such as those by Cannon and colleagues (1989). In studying related
individuals with and without psychosis, genetic heterogeneity related measurement
variance is reduced and meaningful clinical correlations of biological abnormalities may be
evident that would otherwise be obscured. Is the apparent reversal or loss or exaggeration
of cerebral asymmetry meaningful or does it just reflect generalised reductions in brain
volume? More studies need to examine these possibilities - with better control of tilt or
rotation and blindness to side. To what extent are these structural changes purely trait
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markers for the propensity to develop psychosis in the presence of other risk factors? By
excluding schizophrenics with head injuries or those who are substance abusers, do we mis
the opportunity to study the effects of these possible precipitants in those most likely to
have brain changes?
Establishing reliable answers to these questions demands an epidemiological
approach to both subject selection and data analysis i.e. large groups of population based
patients and controls, with multiple regression analyses to control for confounders and co-
variates (particularly head and whole brain size) and their interactions. The effects of
medication, and a host of other possible confounders, cannot be adequately examined by
simply ignoring them if they are not 'statistically significantly' different between study
groups. These relationships need to be examined, as does the possibility of a degenerative
component to schizophrenia, with knowledge of general population norms and it is only
comparatively recently that some groups have started this endeavour (Gur et al., 1991;
Pfefferbaum et al., 1994; Schlaepfer et al, 1995; Murphy et al., 1996). Perhaps most
importantly, encouraging the use of standardised techniques between research centres will
facilitate reliable comparisons between studies and allow the use of meta-analyses to
examine larger numbers of subjects for weak but relevant associations.
Similar issues and questions are pertinent to the other main methods of brain
imaging - functional mapping and neuropsychology - except these have the potential to
discriminate state and trait abnormalities. However, conflating the two may account for
some inconsistencies in the literature. Repeated studies over time, as possible with
functional MRI, would clarify these effects and could examine for possible 'excitotoxic'
decrements, but the test-retest reliabilities of functional imaging methods are largely
unknown. More generally, we do not know enough about normal patterns of
neuroreceptor binding patterns and metabolic profiles in different mental states. The
physiological basis of the signals measured with various techniques requires further
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elucidation: particularly as cerebral blood flow and metabolism are heavily influenced by
levels of arousal and many psychoactive drugs (Mathew & Wilson, 1990 & 1991).
The physiological basis of activity related changes in regional cerebral perfusion or
metabolism is also poorly understood. They two are assumed to be linear, but this
assertion has limited empirical support at rest and some physiologic activations may
actually uncouple perfusion and oxidative metabolism (Fox & Raichle, 1986); as could
some pathological processes. Although much attention has been given to functional
activations on cognitive tasks in normal subjects, particularly on PET (e.g. Petersen et al.,
1988), the standard 'subtraction method' may fail to reveal a region involved at both rest
and activation, can sometimes indicate activation when there is no participation in a
particular task and has difficulties interpreting reductions in metabolism (Horwitz &
Sporns, 1994). Some of these problems may be attributable to variations in the resting
state between subjects and have prompted greater interest in correlational data analysis
strategies (Friston et al., 1992a). Such analysis has the potential to examine the
'functional connectivity', or the temporal relationship between spatially remote
neurophysiological events, of particular tasks. This explicitly acknowledges and measures
activity in distributed neural networks, as probably underlies most cerebral activity, and is
of considerable interest to neuroscientists generally.
A fundamental problem with the functional mapping of cognitive processes is the
underlying assumption that such activity is essentially modular in nature. While this
convenient, and therefore scientifically justifiable, it may not be valid. An obvious likely
example of an exception to this rule is general intelligence (Anderson, 1990). This
modular view of cognitive processing is partly a throwback to the original purposes of
neuropsychology in lesion localisation, while the search for discrete impairments in
schizophrenia has proved largely fruitless. As demonstrated in Study 1 of this thesis,
conventional tests have limited ability to distinguish between sub-groups of schizophrenia
whereas tests ofmore everyday functions may do so. It has been argued that the ability of
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neuropsychological tests to identify abnormalities of brain structure and function or to act
as specific cognitive probes has been exaggerated, while their utility in developing
individually tailored treatments and in predicting outcome has been underestimated
(Keefe, 1995). Apparently specific performance deficits could be attributable to not
attending to the task or increasing task difficulty; while reductions in brain activation in
patients and controls may simply reflect impaired concentration or the use of different
strategies. Further progress in these areas is likely to require more use of paced cognitive
testing and simple everyday measures of faculties such as memory and attention.
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4.4 CONCLUSIONS
Twenty years of neuro-imaging research in schizophrenia has provided substantial
gains in our knowledge and understanding of the disorder. Continuing technological
developments have led to an increasing array of sensitive and complementary techniques
to examine neuropsychiatry disorders, but these advances must be harnessed to test
similarly evolving specific hypotheses in increasingly sophisticated experiments, rather
than simply lead to explorative uses ofnew methods in old research paradigms.
Practically, a greater appreciation is required of the essentially normal distribution
of most variables of interest to schizophrenia researchers. Each new generation of
researchers applying the latest technological advances seem to have to re-discover that
there are no neat dichotomies between schizophrenia and normal controls, let alone other
disorders. This appears to be linked to the predominance of 'tertiary care' research rather
than population based studies. We need more explicit theories, informed by a greater
awareness of normal and abnormal brain development and degeneration, devised by those
in a position to test them in large samples with multivariate statistical techniques.
A number of questions about schizophrenia stand out as both important and
testable: the interactions between various risk factors at different time periods; any
possible progression in biological abnormalities, particularly in the first five years of the
illness; can distinct neurodevelopmental processes, rather than sub-types, be identified; and
how specific are any such processes to schizophrenia, particularly as compared to other
psychoses. Structural imaging experiments need to include more women in general,
clarify issues about the size of the head and brain and possible asymmetry anomalies in
schizophrenia, and examine the course of such abnormalities in long-term follow-up
studies. Functional imaging, particularly fMRI, could establish if there are any identifiable
traits predisposing to schizophrenia and, given that course may be the best discriminator
between schizophrenia and affective psychoses, study changes over time.
Neuropsychology studies would benefit from a greater use of measures of everyday
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functioning, rather than tests derived from lesion studies, and trying to link deficits in them
to the clinical characteristics of particular disorders. Recently proposed animal models of
schizophrenia, of the effects of phencyclidene, could help to increase knowledge in each of
these core areas. New strategies, such as examining the objective behaviour
accompanying phenomena rather than just the symptoms themselves, may also be valuable.
Older paradigms, largely overlooked in these days of 'biological psychiatry', such as the
link between social stressors and relapse in schizophrenia, should not be forgotten.
With the combination of increasing sophisticated and sensitive neuro-imaging
methods, novel theorising and rigorous hypothesis testing, within an integrated
neuroscientific approach to neuropsychiatric disorders and brain-behaviour relationships
(after Damasio, 1994), it is likely that substantial advances will be made in the near future
in identifying the causes of schizophrenia.
179
REFERENCES
Abi-Dargham A, Laruelle M, Seibyl J, et al. (1994). SPECT measurement of
benzodiazepine receptors in human brain with I-123-iomazenil: kinetic and
equilibrium paradigms. Journal ofNuclearMedicine, 35: 228-238.
Akbarian S, Kim JJ, Potkin SG, el al. (1995). Gene expression for Glutamic Acid
Decarboxylase is reduced without loss of neurons in prefrontal cortex of
schizophrenics. Archives ofGeneral Psychiatry, 52: 258-266.
Al-Tikriti MS, Dey HM, Zoghbi SS, Baldwin RM, Zea-Ponce Y, Innis RB (1994). Dual-
isotope autoradiographic measurement of regional blood flow and benzodiazepine
receptor availability following unilateral middle cerebral artery occlusion.
European Journal ofNuclearMedicine, 21: 196-202.
American Psychiatric Association. Diagnostic and StatisticalManual ofMental
Disorders - third edition, revised (DSM-II1-R). Washington,DC: American
Psychiatric Association 1987.
AndersonM (1992). Intelligence andDevelopment: a Cognitive Theory. Blackwell:
Oxford.
Andreasen NC (1989). Nuclear Magnetic Resonance Imaging. In: Brain Imaging -
Applications in Psychiatry (Ed: NC Andreasen). APA:Washington. Pp 67-121.
Andreasen NC, Nasrallah HA, Dunn V, et al. (1986). Structural abnormalities in the
frontal system in schizophrenia: a MRI study. Archives ofGeneral Psychiatry, 43:
136-144.
Andreasen NC, Ehrhardt JC, Swayze VW, el al. (1990). Magnetic Resonance Imaging of
the Brain in Schizophrenia. The Pathophysiological Significance of Structural
Abnormalities. Archives of General Psychiatry 47: 35-44
Andreasen NC, Ehrhardt JC, Swayze VW, et al. (1991). T1 and T2 relaxation times in
schizophrenia as measured with MRI. Schizophrenia Research, 5: 223-232.
Andreasen NC, Rezai K, Allinger R, et al. (1992). Hypofrontality in neuroleptic-naive
patients and in patients with chronic schizophrenia Archives ofGeneral
Psychiatry, 49: 943-958.
Andreasen NC, Flashman L, Flaum M, et al. (1994a). Regional Brain Abnormalities in
Schizophrenia Measured With Magnetic Resonance Imaging. Journal of the
American MedicalAssociation 272: 1763-1769.
Andreasen NC, Arndt S, Swayze V, et al. (1994b). Thalamic Abnormalities in
Schizophrenia Visualized Through Magnetic Resonance Image Averaging.
Science 226: 294-298.
Andreasen NC, O'Leary DS, Cizadlo T, et al. (1995). Remembering the past: two facets
of episodic memory explored with positron emission tomoraphy. American
Journal ofPsychiatry, 152: 1576-1585.
Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987). Cannabis and schizophrenia.
Lancet, ii: 1483-6.
Ammons RB, Ammons CH (1962). The Quick Test (QT): Suggestions for
administration, scoring and interpretation of the QT. PsychologicalReporter 11:
111-161.
Annett M (1970). A classification of hand preference by association analysis. British
Journal ofPsychol, 61: 303 -321.
Ariel RN, Golden CH, Berg RA, et al. (1983). Regional cerebral blood flow in
schizophrenics: tests using the Xenon-133 inhalation method. Archives ofGeneral
Psychiatry 40: 258-63.
Austin MP, Dougall N, Ross M, Murray C, O'Carroll RE, MofToot A, Ebmeier KP,
Goodwin GM (1992). SPET with 99mTc-Exametazime in major depression and
the pattern ofbrain activity underlying the psychotic/neurotic continuum. Journal
ofAffective Disorders, 25: 31-44.
181
Aylward EH, Reiss A, Barta PE, et al. (1994). MRI measurement of posterior fossa
structures in schizophrenia. American Journal ofPsychiatry, 151: 1448-1452.
Bailey A, Phillips W, Rutter M (1996). Autism: towards an integration of clinical, genetic,
neuropsychological and neurobiological perspectives. Journal ofChild
Psychology andPsychiatry, 37: 89-126.
Bajc M, Medved V, Basic M, Topuzovic N, Babic D (1989). Cerebral perfusion
inhomogeneities in schizophrenia demonstrated with single-photon emission
computed tomography and Tc99m-hexamethylpropylene-amineoxime. Acta
Psychaitrica Scandincn'ica, 80: 427-433.
Barta PE, Pearlson GD, Powers RE, Richards SS, Tune LE (1990). Auditory
hallucinations and smaller superior temporal gyral volume in schizophrenia.
Amerian Journal ofPsychiatiy 147: 1457-62.
Barta PE, Petty RG, McGilchrist I, et al. (1995). Asymmetry of the planum temporale:
methodological considerations and clinical associations. Psychiatry Research:
Neuroimaging, 61: 137-150.
Baxter LR, Mazziotta JC, Phelps ME, et al. (1987). Cerebral glucose metabolic rates in
normal human females versus human males. Psychiatry Research, 21: 237-45.
Baxter LR, Phelps ME, Mazziotta JC, et al. (1985). Cerebral metabolic rates for glucose
in mood disorders. Archives ofGeneral Psychiatry, 42: 441-447.
Baxter LR Schwartz JM, Phelps ME, et al. (1990). Reduction of prefrontal cortex
glucose metabolism common to three types of depression. Archives ofGeneral
Psychiatiy, 46: 243-250.
182
Becker T, Elmer K, Mechla B, et al. (1990). MRI Findings in Medial Lobe
Structures in Schizophrenia. European Neuropsychopharmacology, 1: 83-86
Beer H-F, Blauenstein PA, Hasler PH, et al. (1990). In vitro and in vivo evaluation of I-
123-Ro 16-0154: a new imaging agent for SPECT investigations of
benzodiazepine receptors. Journal ofNuclearMedicine, 31: 1007-1014.
Bench CJ, Dolan RJ, Friston KJ, Frackowiak RSJ (1990). PET in the study of brain
metabolism. British Journal ofPsychiatry, 157 (supplement 9): 82-95.
Benes FM (1993). Neurobiological investigations in cingulate cortex of schizophrenic
brain. Schizophrenia Bidletin, 19: 537-549.
Benes FM (1995). Altered glutamatergic and GABAergic mechanisms in the cingulate
cortex of the schizophrenic brain. Archives ofGeneral Psychiatry, 52: 1015-1018.
Benes FM, Bird ED (1987). An analysis of the arrangement of neurons in the cingulate
cortex of schizophrenic patients. Archives ofGeneral Psychiatry, 44: 608-616.
Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL (1991). Deficits in small
interneurons in prefrontal and cingulate cortices of schizophrenic and
schizoaffective patients. Archives ofGeneral Psychiatry, 48: 996-1001.
Benes FM, Vincent SL, Aisterberg G, Bird ED, SanGiovanni JP (1992). Increased
GABA-A receptor binding in superficial layers of cingulate cortex in schiophrenics.
Journal ofNeuroscience, 12: 924-929.
Benton AL. The measurement of aphasic disorders. In Aspectospatologicos del
lenguege, ed. Velasquez AC, Lima: Centro Neuropsicologico 1978.
Bentson JR, Reza M, Winter J, et al. (1978). Steroids and apparent cerebral atrophy on
CT scans. Journal ofComputer Assisted Tomography,!: 16-19.
Berman KF, Illowsky BP, Weinberger DR (1988). Physiologic dysfunction of dorsolateral
pre-frontal cortex in schizophrenia, IV: further evidence for regional and
behavioural specificity. Archives ofGeneral Psychiatry, 45: 616-622.
183
Berman KF & Weinberger DR (1990). Lateralisation of cortical function during cognitive
tasks: regional cerebral blood flow studies of normal individuals and patients with
schizophrenia. Journal ofNeurology, Neurosurgery and Psychiatry, 53:150-160.
Berman KF, Torrey EF, Daniel DG, Weinberger DR (1992). Regional cerebral blood
flow in monozygotic twins discordant and concordant for schizophrenia. Archives
ofGeneral Psychiatry, 49: 927-934.
Berman KF, Doran AR, Pickar D, Weinberger DR (1993). Is the mechansm of prefrontal
hypofunction in depression the same as in schizophrenia? British Journal of
Psychiatry, 162: 183-192.
Berman KF, Weinberger DR, Shelton RC, Zee RF (1987). A relationship between
anatomical and physiological brain pathology in schizophrenia: lateral cerebral
ventricular size predicts cortical blood flow. American Journal ofPsychiatry,
144: 1277-1282.
Berman KF, Zee RF, Weinberger DR (1986). Physiologic dysfunction of dorsolateral pre¬
frontal cortex in schizophrenia, II: role of neuroleptic treatment, attention, and
mental effort. Archives ofGeneralPsychiatry, 43: 126-135.
Bersani G, Venturi P, Tanfani G, Pancheri P (1995). Cerebral ventricular enlargement and
neuroleptic response in chronic schizophrenia: preliminary findings with
risperidone. Human Psychopharmacology, 10: 53-58.
Besson JAO, Corrigan FM, Cherryman GR, Smith FW (1987). Nuclear magentic
resonance brain imaging in chronic schizophrenia. British Journal ofPsychiatry,
150: 161-163.
Bilder RM, Lipschutz-Broch L, Reiter G, et al (1992). Intellectual deficits in first-episode
schizophrenia: evidence for progressive deterioration. Schizophrenia Bulletin, 18:
437-449.
184
Bilder RM, Wu H, Bogerts B, et al. (1994). Absence of Regional Hemispheric
Volumes Asymmetries in First-Episode Schizophrenia American Journal of
Psychiatry 151: 1437-1447.
Bilder RM, Bogerts B, Ashtari M, et al (1995). Anterior hippocampal volume reductions
predict frontal lobe dysfunction in first episode schizophrenia Schizophrenia
Research, 17: 47-58.
Birley JLT (1993). Pair bonding, language and the origins of schizophrenia. Annual
Meeting of the Royal College ofPsychiatrists, abstract book pagel5.
Blackwood DHR, Young AH, McQueen JK, et al. (1991). MRI in schizophrenia: altered
brain morphology associated with P300 abnormalities and eye tracking
dysfunction. Biological Psychiatry, 30: 753-769.
Blackwood DHR Ebmeier KP, Muir WJ, et al. (1994). Correlation of regional CBF
equivalents measured by SPECT with P300 latency and eye movement abnormality
in schizophrenia. Acta Psychiatrica Scandanavica, 90: 157-166.
Bogerts B, Meertz E, Schonfeldt-Bausch R (1985). Basal ganglia and limbic system
pathology in schizophrenia. Archives ofGeneral Psychiatry, 42: 784-791.
Bogerts B, Ashtari M, DegreefG, et al. (1990). Reduced Temporal Limbic
Structure Volumes on Magnetic Resonance Images in First Episode
Schizophrenia. Psychiatric Research: Neuroimaging 35: 1-13.
Bogerts B, Lieberman JA, Ashtari M, et al. (1993). Hippocampus-Amygdala Volumes and
Psychopathology in Chronic Schizophrenia. Biological Psychiatry 33: 236-246.
Boronow J, Pickar D, Ninan PT, et al. (1985). Atrophy limited to the third ventricle in
chronic schizophrenic patients. Archives ofGeneral Psychiatry, 42: 266-71.
Bottini G, Paulesu E, Sterzl R, et al. (1995). Modulation of conscious experience by
peripheral sensory stimuli. Nature, 376: 778-781.
185
Breier A, Buchanan RW, ElkashefA, et al. (1992). A Magnetic Resonance imaging Study
of Limbic, Prefrontal Cortex, and Caudate Structrures. Archives of General
Psychiatry 49: 921-926.
Brown R, Colter N, Corsellis N, et al. (1986). Postmortem evidence of structural brain
changes in schizophrenia. Archives ofGeneral Psychiatry, 43: 36-42.
Buchanan RW, Breier A, Kirkpatrick B, et al. (1993). Structural Abnormalities in Deficit
and Nondeficit Schizophrenia. American Journal of Psychiatry 150: 59-65.
Buchanan RW, Strauss ME, Kirkpatrick B, et al. (1994). Neuropsychological
impairments in deficit vs non-deficit forms of schizophrenia. Archives ofGeneral
Psychiatry, 51: 804-811.
Buchsbaum MS (1987). PET in schizophrenia In: Psychopaharmaocoloy: the third
eneration ofprogress (EdMeltzer HY) pp783-792. Raven Press: New York.
Buchsbaum MS, Ingvar DEI, Kessler R, et al. (1982). Cerebral glucography with positron
tomography: use in normal subjects and in patients with schizophrenia. Archives
ofGeneral Psychiatiy 39: 251-259.
Buchsbaum MS, DeLisi LE, Holcomb HH, et al. (1984). Anteroposterior gradients in
cerebral glucose use in schizophrenia and affective disorders. Archives ofGeneral
Psychiatry 41: 1159-66.
Buchsbaum MS, Wu JC, DeLisi LE, et al. (1987). PET studies of basal ganglia and
somatosensory cortex neuroleptic drug effects. Biological Psychiatiy, 22: 479-
494.
Buchsbaum MS, Potkin SG, Siegel BV, et al. (1992). Striatal metabolic rate and clinical
response to neuroleptics in schizophrenia. Archives ofGeneral Psychiatry, 49:
966-974.
Buchsbaum MS, Elaier RJ, Potkin SG, et al. (1992). Frontostriatal disorder of cerebral
metabolism in never-medicated schizophrtenics. Archives ofGeneral Psychiatry,
49: 935-942.
186
Buchsbaum MS, Someya T, Teng CY, et cil. (1996). PET and MRl of the thalamus in
never-medicated patients with schizophrenia. American Journal ofPsychiatry,
153: 191-199.
Buckley P, O'Callaghan E, Mulvany F, et al (1995). Basal ganglia relaxation times in
schizophrenia: a quantitative MRI study in relation to tardive dyskinesia.
Psychiatry Research: Neuroimaging, 61: 95-102.
Budinger TF & Lauterbur PC (1984). Nuclear magnetic resonance technology for
medical studies. Science, 226: 288-298.
Bullmore E, Brammer E, Harvey I, Ron M (1995). Against the laterality index as a
measure of cerebral asymmetry. Psychiatry Research: Neuroimaging, 61: 121-
124.
Busatto GF, Costa DC, Ell PJ, Pilowsky LS, David AS, Kerwin RW (1994). Regional
cerebral blood flow in schizophrenia during verbal memory activation: a HMPAO-
SPET study. PsychologicalMedicine, 24: 463-472.
Busatto GF, David AS, Costa DC, Ell PJ, Pilowsky LS, Lucey JV, Kerwin RW (1994).
Schizophrenic auditory hallucinations are asssociated with increased regional
cerebral blood flow during verbal memory activation in a SPET study. Psychiatric
Research: Neuroimaging, 24: 463-472.
Busatto GF, Pilowsky LS, Costa DC, Ell PJ, Kerwin RW (1995). GABA-A receptor
changes in schizophrenia assessed using 1231-Iomazenil SPET: a preliminary
report. Schizophrenia Research, 15: 78-79.
187
Cannon M & Jones P (1996). Neuroepidemiology: schizophrenia. Journal ofNeurology,
Neurosurgery andPsychiatry, 61: 604-613.
Cannon ID, Mednick SA, Parnas J (1989). Genetic and perinatal determinants of
structural brain deficits in schizophrenia. Archives ofGeneral Psychiatiy, 46: 883-
889.
Carlen PL, Wortzmann G, Holgate RC, et al. (1978). Reversible cerebral atrophy in
recently abstinent chronic alcoholics measured by CT scans. Science, 200:1076-8.
Carpenter WT, Buchanan RW, Kirkpatrick B, Tamminga C, Wood F (1993). Strong
inference, theory testing and the neuroanatomy of schizophrenia. Archives of
General Psychiatry, 50: 825-831.
Castle DJ & Murray RM (1991). The neurodevelopmental basis of sex differences in
schizophrenia. Psychological Medicine, 21: 565-575.
Catafau AM, Parallada E, Lomena FJ, et al. (1994). Prefrontal and temporal blood flow
in schizophrenia: resting and activation Technetium-99m-HMPAO SPECT
patterns in young acute neuroleptic-naive patients. Journal of Nuclear Medicine,
35: 935-941.
Chakos MH, Lieberman JA, Bilder RM, et al. (1994). Increase in Caudate Nuclei
Volumes ofFirst-Episode Schizophrenic Patients Taking Antipsychotic Drugs.
American Journal ofPsychiatry 151: 1430-1436.
Chakos MH, Lieberman JA, Alvir J, Bilder R, Ashtari M (1995). Caudate nuclei volumes
in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet,
345: 456-7.
Cleghorn JM, Garnett ES, Nahmias C, et al. (1989). Increased frontal and reduced
parietal glucose metabolism in acute untreated schizophrenia. Psychiatry
Research, 28:119-33.
188
Cleghorn JM, Garnett ES, Nahmias C, et al. (1990). Regional brain metabolism during
auditory hallucinations in chronic schizophrenia. British Journal ofPsychiatry,
157: 562-570.
Cleghorn JM, Franco S, Szechtman B, et al, (1992). Towards a brain map of auditory
hallucinations. American Journal ofPsychiatry, 149: 1062-1069.
Coffinan JA (1989). Computed Tomography. In: Brain Imaging: application in
psychiatry Ed.NC Andreason, APA:Washington DC
Cohen J (1988). Statisticalpower analysisfor the behavioural sciences (2nd edition).
Lawrence Erlbaum Associates, Hillsdale, New Jersey.
Cohen MB, Lake RR, Graham LS, et al. (1989a). Quantitative Iodine-123 IMP imaging
ofbrain perfusion in schizophrenia. Journal ofNuclear Medicine, 30: 1616-1620.
Cohen RM, Semple WE, Gross M et al. (1987). Dysfunction in a prefrontal
substrate of sustained attention in schizophgrenia. Life Science, 40: 2031-2039.
Cohen RM, Semple WE, GrossM et al. (1989b). Evidence for common alterations
in cerebral glucose metabolism in major affective disorders and schizophrenia.
Neuropsychopharmacology, 2: 241-254.
Collins DL, Neelin P, Peters TM, Evans AC (1994). Automatic 3D intersubject
registration ofMR volumetric data in standardised Talairach space. Journal of
Computer Assisted Tomography, 18: 192-205.
Colombo C, Abbruzzese M, Livian S, et al. (1993). Memory functions and temporal-
limbic morphology in schizophrenia. Psychiatry Res: Neuroimaging, 50: 45-56.
Cooper B (1961). Social Class and Prognosis in Schizophrenia. Part I & II. British
Journal ofPreventative andSocialMedicine 15: 17-41.
Coppen HJ, SlooffCJ, Paans AMJ, et al. (1991). High central D2-dopamine receptor
occupancy as assessed with PET in medicated but therapy-esistant schizophrenic
patients. BiologicalPsychiatry, 29: 629-634.
189
Coppola R, Myslobodsky M, Weinberger DR (1995). Midline abnormalities and
psychopathology: how reliable is the midsaggittal magnetic resonance 'window'
into the brain ? PsychiatryResearch: Neuroimaging, 61: 33-42.
Cowell PE, Kostianovsky DJ, Gur RC, el al. (1996). Sex differences in neuroanatomical
and clinical correlations in schizophrenia. American Journal ofPsychiatry, 153:
799-805.
Creese I, Burt DR, Snyder SH (1976). Dopamine receptor binding predicts clinical and
pharmacological potencies of antipsychotic drugs. Science, 192: 481-3.
Cross AJ, Crow TJ, Owen F (1979). GABA in the brain in schizophrenia. Lancet, i: 559-
560.
Crosson B, Williamson DJG, Shukla SS, Honeyman JC, Nadeau SE (1994). A technique
to localise activation in the human brain with Technetium-99m-HMPAO SPECT: a
validation study using visual stimulation. Journal ofNuclearMedicine, 35: 755-
763.
Crow TJ (1980). Molecular pathology of schizophrenia: more than one disease process?
British Medical Journal 280: 66-68.
Crow TJ (1990). Temporal lobe asymmetries as the key to the aetiology of schizophrenia.
Schizophrenia Bulletin, 16: 433-443.
Crow TJ (1994). Sexual selection, Machiavellian intelligence and the origins of psychosis.
Lancet, 342: 594-598.
190
Damasio, A. (1995). Descartes' error. Grosset/Putnam: New York, USA.
DandyWE (1918), Roentography of the brain after injection of air into the spinal cord.
Annals ofSurgery, 70: 397-403.
Daniel DG, Matthew RJ, WilsonWH (1988). Sex roles and regional cerebral blood flow.
Psychiatry Research, 27: 55-64.
Daniel DG, Klim E, Kostianovsky D, el al. (1991a). Computerised Tomography
measurements of brain density in schizophrenia. Biological Psychiatry, 29: 745-
756.
Daniel DG, Goldberg TE, Gibbons RD, Weinberger DR (1991b). Lack of a bimodal
distribution ofventricular size in schizophrenia: a gaussian mixture analysis of
1056 cases and controls. Biological Psychiatry, 30: 887-903,
Dauphinais D, DeLisi LE, Crow TJ, et al. (1990). Reduction in Temporal Size in Siblings
With Schizophrenia: A Magnetic Resonance Imaging Study. Psychiatric Research:
Neuroimaging 35: 137-147
Davis JM (1976). Recent Developments in the Drug Treatment of Schizophrenia.
American Journal ofPsychiatry 133: 208-214.
Davis KL, Kahn RS, Ko G, DavidsonM (1991). Dopamine in schizophrenia: a review
and reconceptualisation. American Journal ofPsychiatry, 148: 1474-1481.
Deakin JFW, Slater P, Simpson MDC, et al. (1989). Frontal cortical and left temporal
glutamatergic dysfunction in schizophrenia. Journal ofNeurochemistry, 52: 1781-
1786.
DegreefG, Ashtari M, Bogerts B, et al. (1992). Volumes of Ventricular System
Subdivisions Measured From Magnetic Resonance Images in First- Episode
Schizophrenic Patients. Archives of General Psychiatry 49: 531-537
Deicken RE, Calabrese G, Merrin EL, et al. (1994). 31 -Phosphurus MRS of the frontal
and parietal lobes in chronic schizophrenia. Biological Psychiatry, 36: 503-510.
191
DeLisi LE, Schwartz CC, Targum SD, etal. (1983). Ventricular brain enlargement and
outcome of acute schizopreniform disorder. Psychiatry Research, 9: 9-16;
DeLisi LE, Buchsbaum MS, Holcomb HH, et al. (1985a). Clinical correlates of relative
hypofrontality in PET of schizophrenic patients. American Journal ofPsychiatry,
142: 78-81.
DeLisi LE, Holcomb HH, Cohen RM, et al. (1985b). PET in schizophrenic patients with
and without neuroleptic medication. Journal ofCerebral BloodFlow and
Metabolism, 5: 201-206.
DeLisi LE, Buchsbaum MS, Holcomb HH, et al. (1985c). Increased temporal lobe
glucose activity with PET in schizophrenic patients. Biological Psychiatry, 25:
835-851.
DeLisi LE, Dauphinais D, Gershon ES (1988). Perinatal complications and reduced size
ofbrain limbic structures in familial schizophrenia. Schizoprenia Bulletin, 14:
185-191.
DeLisi LE, HoffAL, Schwartz JE, et al. (1991). Brain Morphology in First-
Episode Schizophrenia-Like Psychotic Patients: A Quantitative Magnetic
Resonance Imaging Study. Biological Psychiatry 29: 159-175.
DeLisi LE, Stritzke P, Riordan H, et al. (1992). The timing ofBrain Morphological
Changes in Schizophrenia and their relationship to Clinical Outcome. Biological
Psychiatry 31: 241-254.
DeLisi LE, Tew W, Xie S, et al. (1994a). A Prospective Follow-up Study ofBrain
Morphology and Cognition in First-Episode Schizophrenic Patients: Preliminary
Findings. Biological Psychiatry 38: 349-360.
DeLisi LE, HoffAL, Neale C, KushnerM (1994b). Asymmetries in the superior temporal
lobe in male and female first-episode schizophrenic patients: measures of the
planum temporale and superior temporal gyrus by MRI. Schizophrenia Research,
12: 19-28.
192
Delvenne V, Lotstra F, Goldman S, et al. (1995). Brain hypometabolism of glucose in
anorexia nervosa: a PET scan study. Biological Psychiatiy, 37: 161-172.
DeMyer MK, Gilmor RL, Hendrie HC, et al. (1988). MR brain images in schizophrenic
and normal subjects: influence of diagnosis and education. Schizophrenia Bulletin,
14: 21-32.
DeQuardo JR, Bookstein FL, Green WDK, Brunberg JA, Tandon R (1996). Spatial
relationships ofneuroanatomic landmarks in schizophrenia Psychiatiy Research:
Neuroimaging, 67: 81-95.
Devous MD Sr (1989). Imaging brain function by Single-Photon Emission Computer
Tomography. In: Andreasen NC (Ed). Brain Imaging-Applications in Psychiatiy,
APA:Washington.
Devous MD Sr (1995). Instrumentation, Radiopharmaceuticals, and Technical Factors.
(pp3-19). In: Van Heertum & Tikofsky (Eds), Cerebral SPECT imaging. Raven
Press: New York.
DiMichele V, Rossi A, Stratta P, et al. (1992). Neuropsychological and clinical correlates
of temporal lobe anatomy in schizophrenia. Acta Psychiatrica Scandinavica, 85:
484-488.
Dolan RJ, Bench CJ, Liddle PF, Friston KJ, Frith CD, Grasby PM, Frackowiak RSJ
(1993). Dorsolateral prefrontal cortex dysfunction in the major psychoses;
symptom or disease specificity? Journal ofNeurology, Neurosurgeiy and
Psychiatry 56: 1290-1294.
Dolan RJ, Fletcher P, Frith CD, et al. (1995). Dopaminergic modulation of impaired
cognitive activation in the anterior cingulate cortex in schizophrenia. Nature, 378:
180-2.
Donnelly EF, Weinberger DR, Waldman IN, et al. (1980). Cognitive impairment
associated with morphological brain abnormalities. Journal ofNer\>ous and
Mental Disease, 168: 305-308
193
Dousse M, Mamo H, Ponsin JC, Dinh YT (1988). Cerebral blood flow in schizophrenia.
Experimental Neurology, 199: 98-111.
Dupont RM, Lehr PP, Lamoureux G, el al. (1994). Preliminary report: cerebral blood
flow abnormalities in older schizophrnic patients. Psychiatric Research:
Neuroimaging, 55: 121-130.
DuvernoyH, (1991). The Human Brain: Surface, Three-Dimensional Sectional
Anatomy andMR!. Wien: Springer-Verlag.
Early TS, Reiman EM, Raichle ME, Spitznagel EL (1987). Left globus pallidus
abnormality in never-medicated patients with schizophrenia. Proceedings of the
NationalAcademy ofSciences, 84: 561-563.
Ebmeier KP (1994). Brain Imaging and Schizophrenia. In Advances in the
Neurobiology ofSchizophrenia, Eds Den Boer, Westenberg & Von Praag. New
York: Wiley.
Ebmeier KP, Dougall NJ, Austin M-PV, et al. (1991). The Split-Dose Technique for the
study ofPsychological and Pharmacological Activation with the Cerebral Blood
Flow marker Exametazime and Single Photon Emission Computed Tomography
(SPECT): Reproducibility and Rater Reliability. InternationalJournalofMethods
in Psychiatric Research. 1: 27-38.
Ebmeier KP, Blackwood DHR, Murray C, et al (1992). Single-Photon Emission
Computed Tomography with 99mTc-Exametazime in Unmedicated Schizophrenic
Patients. Biological Psychiatry 33: 487-495.
194
Ebmeier KP, Murray CL, Dougail NJ, O'Carroll RE, Goodwin GM (1992). Unilateral
voluntary hand movement and regional cerebral uptake ofTechnetium-99m-
Exametazime in human control subjects. Journal ofNuclear Medicine, 33: 1637-
1641.
Ebmeier KP, Lawrie SM, Blackwood DHR, Johnstone EC, Goodwin GM (1995).
Hypofrontality revisited: a high resolution SPECT study in schizophrenia.
Journal ofNeurology, Neurosurgery andPsychiatry, 58: 452-456.
Egan MF, Duncan CC, Suddath RL, el al. (1994). Event-related potential abnormalities
correlate with structural brain alterations and clinical features in patients with
chronic schizophrenia. Schizophrenia Research, 11: 259-271.
ElkashefAM, Buchanan RW, Gellad F, Munson RC, Breier A (1994). Basal ganglia
pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study.
American Journal ofPsychiatry, 151: 752-755.
Erbas B, Kumbasser H, Erbengi G, Bekdik C (1990). Tc-99m-HMPAO/SPECT
determination of regional cerebral blood flow changes in schizophrenics. Clinical
NuclearMedicine, 12: 904-907.
Eckelman WC, Reba RC, Rzeszotarski WJ, el al. (1984). External imaging of cerebral
muscarinic acetycholine receptors. Science, 223: 291-293.
195
Farde L, Ehrin E, Eriksson L, et al. (1985). Substituted benzamides as ligands for
visualisation of dopamine receptor binding in the human brain by PET.
Proceedings of the National Academy ofSciences, 82: 3863-3867.
Farde L, Wiesel F-A, Hall H, Halldin C, Stone-Elander S, Sedvall G (1987). No D2
receptor increase in PET study of schizophrenia. Archives ofGeneral Psychiatry,
44: 671-2.
Farde L, Wiesel F-A, Stone-Elander S, et al. (1990). D2-Dopamine receptors in
neuroleptic-naive schizophrenic patients. Archives General Psychiatry 47:213-19.
Farde L, Nordstrom A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992). PET analysis
of central D1 and D2 dopamine receptor occupancy in patients treated with
classical neuroleptics and clozapine. Archives ofGeneral Psychiatry, 49: 538-544.
Farkas T, Wolfe AP, Jaeger J, et al. (1984). Regional brain glucose metabolism in chronic
schizophrenia: a positron emission transaxial tomographic study. Archives of
General Psychiatry, 41: 293-300.
Feighner JP, Robins E, Guze SB, et al (1972). Diagnostic Criteria for Use in Psychiatric
Research. Archives ofGeneralPsychiatry 26: 57-63.
Flaum M, Swayze VW, O'Leary DS,etal. (1995). Effects of Laterality, and Gender on
BrainMorphology in Schizophrenia. American Journal of Psychiatiy 152: 704-
714.
Folstein MF, Folstein SE, McHugh PR (1975). "Mini-Mental State": A practical method
for grading the cognitive state of patients for the clinician. Journal ofPsychiatric
Research 12: 189-198.
Ford RA, Lewis SW, Syed GMS, Reveley A, Toone BK (1992). Ventricular size and
regional cerebral blood flow in schizophrenia: an attempted replication. Psychiatry
Research: Neuroimaging, 45: 209-213.
Fox PT, Mintun MA, Raichle ME, et al. (1986). Mapping human visual cortex with
positron emission tomography. Nature, 323: 806-809.
196
Fox PT, Raichle ME (1986). Focal physiological uncoupling of cerebral blood flow and
oxidative metabolism during somatosensory stimulation in human subjects.
Proceedings of the National Academy ofSciences 83: 1140-1143.
Fox PT, Raichle ME, Mintun MA, Dence C (1988). Nonoxidative glucose consumption
during focal physiologic neural activity. Science, 241: 462-464.
Franzen G, Ingvar DEI (1975). Absence of activation in frontal structures during
psychological testing of chronic schizophrenics. Journal ofNeurology,
Neurosurgery andPsychiatry, 38: 1027-1032.
Frazier JA, Giedd JN, Kaysen D, et al. (1996). Childhood-onset schizophrenia: brain MRI
rescan after 2 years of clozapine maintenance treatment. American Journal of
Psychiatry, 153: 564-566.
Friedman L, Knutson L, Shurell M, Meltzer HY (1991). Prefrontal sulcal prominence is
inversely related to response to clozapine in schizophrenia. Biological Psychiatry
29: 865-77.
Friedman L, Lys C, Schulz SC (1992). The relationship of structural brain imaging
parameters to antipsychotic treatment response: a review. Journal ofPsychiatry
andNeuroscience, 17: 42-54.
Friston KJ, Frith CD, Liddle PF, et al. (1990). The relationship between global and local
changes in PET scans. Journal Cerebral Blood Flow andMetabolism, 10:458-66.
Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ (1992a). Functional connectivity: the
principal component analaysis of large PET data sets. Journal ofCerebal Blood
Flow andMetabolism, 13: 5-14.
Friston KJ, Liddle PF, Frith CD, Hirsch SR, Frackowiak RSJ (1992b). The left medial
temporal region and schizophrenia. Brain, 115: 367-382.
Frith CD (1992). The cognitive neuropsychology ofschizophrenia. LEA: Hove, UK.
197
Frith CD, Friston KJ, Herold S, et al. (1995). Regional brain activity in chronic
schizophrenic patients during the performance of a verbal fluency task. British
Journal ofPsychiatry, 167: 343-349.
Frith CD, Leary J, Cahill C, Johnstone EC (1991). Disabilities and Circumstances of
Schizophrenic Patients. IV.Performance on Psychological Tests. British Journal of
Psychiatry 159 (supplement 13), 26-29
Fukuzako H, Fukuzako T, Hashiguchi T, et al. (1996). Reduction in hippocampal
formation volume is caused mainly by its shortening in chronic schizophrenia:
assessment by MRI. Biological Psychiatry, 39: 938-945.
Gattaz WF, Rost W, Kohlmeyer K, Bauer K, Hubner C, Gasser T (1988). CT scans and
neuroleptic response in schizophrenia: a multidimensional approach. Psychiatry
Research 26: 293-303.
Geddes JR & Lawrie SM (1995). Obstetric Complications and Schizophrenia: A Meta¬
analysis. British Journal ofPsychiatry 167: 786-793.
George MS, Ring HA, Costa DC, Ell PJ, Kouris K, Jarritt PH (1991). Neuroactivation
and neuroimaging with SPET. Springer-Verlag: London.
George MS, Ketter TA, Parekh PI, et al. (1995). Brain activity during transient sadness
and happiness in healthy women. American Journal ofPsychiatry, 152: 341-351.
Geraud G, Arne-Bes MC, Guell A, Bes A (1987). Reversibility of haemodynamically
measured hypofrontality in schizophrenia. Journal ofCerebral BloodFlow and
Metabolism 7: 9-12.
Giede JN, Kozuch P, Kaysen D, etal. (1995). Reliability of cerebral measures in repeated
examinations with MRI. Psychiatry Research: Neuroimaging 61: 113-119.
198
Gjedde A, Reith J, Wong D (1995). Dopamine receptors in schizophrenia. Lancet, 346:
1302-1303 (and further details from the authors).
Glass HI, Harper AM (1963). Measurement of regional blood flow in cerebral cortex of
man through intact skull. BritishMedical Journal', i: 1611.
Goldberg TE, Ragland JD, Torrey EF, et al. (1990). Neuropsychological Assessment of
Monozygotic Twins Discordant for Schizophrenia. Archives ofGeneral Psychiatry
47: 1066-1072.
Goldberg TE, Torrey EF, Gold JM, et al. (1993). Learning and Memory in monozygotic
twins discordant for schizophrenia. Psychological Medicine 23: 71-85.
Goldberg TE, Torrey EF, Berman KF, Weinberger DR (1994). Relations between
neuropsychological performance and brain morphological and physiological
measures in monozygotic twins discordant for schizophrenia. Psychiatry
Research: Neuroimaging, 55: 51-61.
Golden CJ, Moses JA, ZelazowskiR, et al. (1980). Cerebral Ventricular Size and
Neuropsychological Impairment in Young Chronic Schizophrenics: measurement
by the standardised Luria-Nebraska Neuropsychological Battery. Archives of
General Psychiatry 37: 619-623.
Golden CJ, Maclnnes WD, Ariel RN, et al. (1982). Cross-validation of the Luria-
Nebraska Neuropsychological battery to differentiate chronic schizophrenics with
and without ventricular enlargement. Journal of Consulting and Clinical
Psychology, 50: 87-95
Golman RS, Axelrod BN, Tandon R, et al. (1993). Neuropsychological prediction of
treatment efficacy and one-year outcome in schizophrenia. Psychopathology, 26:
122-126.
Gore SM, Altman DG (1982). Statistics in Practice. London: British Medical Association.
Greenberg J, Reivich M, Alavi A, et al. (1981). Metabolic mapping of functional activity
in human subjects with (18F)fluorodeoxyglucose technique. Science, 212: 678-80.
199
Guenther W, Moser E, Petsch R, et al. (1989). Pathological cerebral blood flow and
corpus callosm abnormalities in schizophrenia: relations to EEG mapping and PET
data. Psychiatry Research, 29: 453-455.
Guenther W, Brodie JD, Bartlett EJ, et a/. (1994). Diminished cerebral metabolic
response to motor stimulation in schizophrenics: a PET study. European Archives
ofPsychiatry and ClinicalNeuroscience, 244: 115-125.
Gunne L-M, Haggstrom J-E, Sjoquist B (1984). Association with persistent neuroleptic-
induced dyskinesia of regional changes in brain GABA synthesis. Nature, 309:
347-349.
Gur RC, Gur RE, Obrist WD, et al. (1982). Sex and handedness differences in cerebral
blood flow during rest and cognitive activity. Science 217: 256-261.
Gur RC, Gur RE, Obrist WD, et al. (1987a). Age and regional cerebral blood flow at rest
and during cognitive activity. Archives ofGeneralPsychiatry, 44: 617-621.
Gur RC, Mozley PD, Resnick SM, et al. (1991). Gender differences in age effect of brain
atrophy mesured by MRI. Proceedings of the NationalAcademy ofSciences, 88:
2845-2849.
Gur RE, Skolnick BE, Gur RC, et al. (1983). Brain function in psychiatric disorders, I:
regional cerebral blood flow in medicated schizophrenics. Archives ofGeneral
Psychiatry 40: 1250-1254.
Gur RE, Skolnick BE, Gur RC, et al. (1984). Brain function in psychiatric disorders, II:
regional cerebal blood flow in unmedicated unipolar depressives. Archives of
General Psychiatry, 41: 695-699.
Gur RE, Gur RC, Skolnick BE, et al.. (1985). Brain function in psychiatric disorders, III:
regional cerebral blood flow in unmedicated schizophrenics. Archives ofGeneral
Psychiatry, 42: 329-334.
Gur RE, Resnick SM, Alavi A, el al. (1987b). Regional brain function in schizophrenia I.
A PET study. Archives ofGeneral Psychiatry, 44: 119-125.
200
Gur RE, Resnick SM, Gur RC, et al. (1987c). Regional brain function in schizophrenia II.
Repeated evaluation with PET. Archives of General Psychiatry, 44: 126-129.
Gur RE, Mozley PD, Resnick SM, et al. (1991). Magnetic Resonance Imaging in
Schizophrenia. Volumetric Analysis ofBrain and Cerebrospinal Fluid. Arch Gen
Psychiatry 48: 407-412.
Gur RE, Mozley PD, Shatsel DL, et al. (1994). Clinical Subtypes of Schizophrenia:
Differences in Brain and CSF Volume. American Journal ofPsychiatry 151: 343-
350.
Gur RE, Mozley PD, Resnick SM, et al. (1995). Resting cerebral glucose metabolism in
first-episode and previously treated patients with schizophrenia relates to clinical
features. Archives ofGeneral Psychiatry, 52: 657-667.
Hanada S, Mita T, Nishino N, Tanaka C (1987). 3H-Muscimol binding sites in autopsied
brains of chronic schizophrenics. Life Sciences, 40: 259-266.
Handler LC, Stock MB, Smythe PM (1981). CT brain scans: part of a 20-year
development study following gross undernutrition during infancy. British Journal
ofRadiology, 54: 953-4.
Harrison PJ & Geddes JR (1996). Schziophrenia and the 5HT-2a receptor gene. Lancet
347: 1274.
Harvey I, McGufifin P, Williams M, Toone BK (1990a). The VBR in functional
psychoses: an admixture analysis. Psychiatry Res: Neuroimaging, 35: 61-69.
201
Harvey I, Williams M, Toone BK, Lewis SW, Turner SW, McGufFin P (1990b). The
VBR in functional psychoses: the relationship of lateral ventricular and total
intracranial area. PsychologicalMedicine, 20: 55-62.
Harvey I, Persaud R, Ron MA, Baker G, Murray RM (1994). Volumetric MRI in bipolars
compared with schizophrenics and helathy controls. PsychologicalMedicine, 24:
689-699.
Harvey I, Ron MA, Du Boulay G, et al. (1993). Reduction of cortical volume in
schizophrenia on magnetic resonance imaging. PsychologicalMedicine 23: 591 -
604.
Harvey I, Ron MA, Murray R, Lewis S, Barker G, McManus D (1991). MRI in
schizophrenia: basal ganglia and white matter T1 times. PsychologicalMedicine,
21: 587-98.
Haug JO (1982). Pneumoencephalographic evidence of brain atrophy in acute and chronic
schizophrenic patients. Acta Psychiatrica Scandinavica, 66: 374-383.
Heinz ER, Martinex J, Haenggell A (1977). Reversibility of cerebral atrophy in anorexia
nervosa and Cushing's syndrome. Journal ofComputer Assisted Tomography, 1:
415-417.
Hietala J, Syvalahti E, Vuorio K, et al. (1994). Striatal D2 dopamine receptor
characteristics in neuroleptic-naive schizophrenic patients studies with PET.
Archives ofGeneral Psychiatry, 51: 116-123.
Hietala J, Syvalahti E, Vuorio K, et al. (1995). Presynaptic dopamine function in striatum
of neuroleptic-naive schizophrenic patients. Lancet, 346: 1130-31.
HoffAL, Riordan H, O'Donnell D, et al. (1992). Anomalous lateral sulcus asymmetry and
cognitive function in first-episode schizophrenia. Schizophrenia Bulletin, 18: 257-
269.
202
Hokama H, Shenton ME, Nestor PG, et al. (1995). Caudate, putamen, and globus
pallidus volume in schizophrenia: a quantitative MRI study. Psychiatry Research:
Neuroimaging, 61: 209-229.
Holcomb HH, Links J, Smith C, Wong D (1989). PET: Measuring the metabolic and
neurochemical characteristics of the living human nervous system. In: Brain
Imaging (ed. Andeasen NC) pp 235-370.
Holcomb HH, Cascella NG, Thaker GK, et al. (1995). Functional sites of neuroleptic
drug action in the human brain: PET/FDG studies with and without haloperidol.
American Journal ofPsychiatry, 153: 41-49.
Honer WG, Bassett AS, Squires-Wheeler E, et al (1995). The temporal lobes, reversed
asymmetry and the genetics of schizophrenia Neuroreport, 7: 221-224.
Horowitz B & Sporns O (1994). Neural modelling and functional neuroimaging. Human
BrainMapping, 1: 269-283.
Hounsfield GN (1973). Computerised transverse axial scanning (tomography): parti:
description of system, part II: clinical applications, British Journal ofRadiology,
46: 1016-1022 & 1023-1047
Illowsky B, Juliano DM, Bigelow LB, el al. (1988). Stability of CT scan findings in
schizophrenia. Journal ofNeurology, Neurosurgury andPsychiatry, 51: 209-212.
Ingvar DH, Franzen G (1974a). Abnormalities of cerebral blood flow distribution in
patients with chronic schizophrenia. Acta Psychiatrica Scandinavica, 50: 425-
462.
203
Ingvar DH & Franzen G (1974b). Distribution of cerebral activity in chronic
schizophrenia. Lancet, i: 1484-1486.
Innis R, Zoghbi S, Johnston E, el al. (1991). SPECT imaging of the benzodiazepine
receptor in non-human primate brain with I-123-Ro 16-0154. European Journal
ofPharmacology, 193: 249-252.
Isaacs B, Kennie AT. The Set Test as an Aid to the Detection ofDementia in Old People.
British Journal ofPsychiatry 1973; 123: 467-470.
Jablensky A, SartoriusN, Ernberg G, et al. (1992). Schizophrenia: manifestations,
incidence and course in different cultures - A World Health Organisation Ten-
Country Study. Psychological Medicine, Supplement 20.
Jack CR, Gehring DG, Sharbrough FW, et al. (1988). Temporal lobe volume
measurement from MR images: accuracy and left-right asymmetry in normal
persons. Journal ofComputer Assisted Tomography, 12: 21-29.
Jacobson RR, Turner SW, Baldy RE, Lishman WA (1985). Densitometric analysis of
scans: important sources of artifacts. PsychologicalMedicine, 15: 879-889.
Jacobi A, Winkler H (1927). Encephalographischen studien an schizophrenen.
Archives ofPsychology (Frankfurt), 84: 208-26.
Jaskiw GE, Juliano DM, Goldber TE, Hertzman M, Urow-Hamell E, Weinberger DR
(1994). Cerebral ventricular enlargement in schizophreniform disorder does not
progress: a seven year follow-up study. Schizophrenia Research, 14: 23-28.
Javitt DC, Zylberman I, Zukin SR, et al. (1994). Amelioration of negative symptomsin
schizophrenia by glycine. American Journal ofPsychiatry, 151: 1234-1236.
204
Jernigan TL, Sargent T, Pfefferbaum A, et al. (1985). 18FDG PET in schizophrenia.
Psychiatry Research, 16: 317-329.
Jernigan TL, Zisook S, Heaton RK, et al. (1991). Magnnetic resonance Imaging
Abnormalities in Lenticular Nuclei and Cerebbral Cortex in Schizophrenia.
Archives of General Psychiatry 48: 881-890
Jewart RD, Lewine RJ, Manning DE, et al. (1991). MRI findings as a predictor of
clozapine response. Schizophrenia Research 4: 406.
Johnson EW, Woods SW, Zoghbi S, McBride BJ, Baldwin RM, Innis RB (1990).
Rceptor binding characterisation of the benzodiazepine radioligand I-123-Ro 16-
0154: potential probe for SPECT brain imaging. Life Sciences, 47: 1535-1546.
Johnstone EC (1991). Disabilities and Circumstances of Schizophrenic Patients - A
Follow-Up Study. British Journal ofPsychiatry 159 (supplement 13).
Johnstone EC, Crow TJ, Frith CD, et al. (1976). Cerebral ventricular size and cognitive
impairment in chronic schizophrenia. Lancet ii: 924-926.
Johnstone EC, Crow TJ, Frith CD, et al. (1978). The dementia of dementia praecox. Acta
Psychiatrica Scandinavica 57: 305-324.
Johnstone EC, Crow TJ, MacMillan JF, Owens DGC, Bydder GM, Steiner RE (1986). A
magnetic resonance study of early schizophrenia. Journal of Neurology,
Neurosurgery and Psychiatiy 49: 136-139.
Johnstone EC, Owens DGC, Bydder GM, et al. (1989a). The spectrum of structural brain
changes in schizophrenia: age of onset as a predictor of cognitive and clinical
impairments and their cerebral correlates. Psychological Medicine, 19: 91-103.
Johnstone EC, Owens DGC, Crow TJ, et al. (1989b). Temporal lobe structure as
determined by nuclear magnetic resonance in schizophrenia and bipolar affective
disorder. Journal of Neurology Neurosurgery andPsychiatry 52: 736-741.
205
Juijus GJ, Nasrallah HA, Olson SC, Schwarzkopf SB (1993). Cavum septum pellucidum
in schizophrenia, affective disorder and normal controls: a magnetic resonance
imaging study. Psychological Medicine 23: 319-22.
Kaiya H, Uematsu M, Ofuji M, Nishida A, Morikiyo M, Adachi S (1989). Computerised
tomography in schizophrenia: familial versus non-familial forms of illness. British
Journal ofPsychiatry 155: 444-450.
Kane JM, Lieberman JA (1987). Maintenance Pharmacotherapy in Schizophrenia. In
Pstchopharmacology: The Third Generation ofProgress, ed. Meltzer HY,
pp.1103-1109. New York: Raven Press.
Kaplan MJ, LazoffM, Kelly K, et al. (1990). Enlargement ofCerebral Third Ventricle in
Psychotic Patients with Delayed Response to Neuroleptics. Biological Psychiatry
27: 205-214.
Kaplan RD, Szechtman H, Franco S, et al. (1993). Three clinical syndromes of
schizophrenia in untreated subjects: relation to brain glucose activity by PET.
Schizophrenia Research, 11: 47-54.
Kareken DA, Gur RC, Mozley PD, et al. (1995). Cognitive functioning and
neuroanatomic volume measures in schizophrenia. Neuropsychology, 9: 211-219.
Karlik SJ (1986). Common pharmaceuticals alter tissue protein NMR relaxation
properties. Magnetic Resonance inMedicine 3: 181-193.
Kasanin J (1933). The Acute Schizoaffective Psychoses. American Journal ofPsychiatry
90: 97-126.
206
Katz M, Buchsbaum MS, Siegel BV, et al. (1996). Correlational patterns of cerebral
glucose metabolism in never-medicated schizophrenics. Neuropsychohiology,
33: 1-11.
Kawasaki Y, Suzuki M, Maeda Y, et al (1992). Regional cerebral blood flow in patients
with schizophrenia. European Archives ofPsychiary and Clinical Neuroscience,
241: 195-200.
Kawasaki Y, Maeda Y, Suzuki M, et al (1993). SPECT analysis of regional cerebral
blood flow changes in patients with schizophrenia during the Wisconsin Card
Sorting Test. Schizophrenia Research, 10: 109-116.
Kawasai Y, Maeda Y, Urata K, et al. (1993). A Quantitative Magnetic Resonance
Imaging Study ofPatients with Schizophrenia. European Archives ofPsychiatry
and Clinical Neurosciences 242: 268-272.
KeefeRSE. (1995). The Contribution ofNeuropsychology to Psychiatry. American
Journal ofPsychiatry, 152: 6-15.
Kelsoe JR, Cadet JL, Picard D, Weinberger DR (1988). Quantitative Neuroanatomy in
Schizophrenia. Archives of General Psychiatry 45: 533-541.
Kemali D, Maj S, Galderisi MG, et al. (1985). Clinical and neuropsychological correlates
of cerebral ventricular enlargement in schizophrenia Journal of Psychiatric
Research, 4: 587-596.
Kemali D, Maj M, Galderisi S, et al. (1989). VBR in schizophrenia: a controlled follow-
up study. Biological Psychiatry, 26: 756-762.
Kendler KS, Kessler RC, Walters EE, et al. (1995). Stressful life events, genetic liability
and onset of an episode ofmajor depression in women. American Journal of
Psychiatry, 152: 833-842.
Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW
(1994a). Changes in caudate volume with neuroleptic treatment. Lancet, 344:
1434.
207
Keshavan MS, Anderson S, Pettegrew J (1994). Is schizophrenia due to excesssive
synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited.
Journal ofPsychiatric Research, 28: 239-265.
Kety SS, Schmidt CF (1948). The nitrous oxide method for quantitative determination of
cerebral blood flow in man: theory, procedure, and normal values. Journal of
Clinical Investigation 27: 475-483.
Kety SS, Woodford RB, Harmel MH, Freyhan FA, Appel KE, Schmidt CF (1948).
Cerebral blood flow and metabolism in schizophrenia. American Journal of
Psychiatry, 104: 765-770.
Kishimoto H, Kuwahara H, Ohno S, et al. (1987). Three sub-types of chronic
schizophrenia identified using 1 lC-glucose PET. Psychiatry Research, 21: 285-
292.
Kiuchi Y, Kobayashi T, Takeuchi J, Shimizu H, Ogata H, Torn M (1989).
Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics.
European Archives ofPsychiatry andNeurological Science, 239: 71-78.
Kleinschmidt A, Falkai P, Huang Y, et al. (1994). In vivo morphometry of planum
temporale asymmetry in first-episode schizophrenia. Schizophrenia Research, 12:
9-18.
Klemm E, Grunwald F, Kaspar S, et al. (1996). IBZM SPECT for imaging of striatal D2
receptors in 56 schizophrenic patients taking various neuroleptics. American
Journal ofPsychiatry, 153: 183-190.
Kling AS, Metter EJ, Riege WH, Kuhl DE (1986). Comparison ofPET measurement of
local brain glucose metabolism and CAT measurement ofbrain atrophy in chronic
schizophrenia and depression. American Journal ofPsychiatry, 143: 175-180.
Kohn MI, Tanna NK, Herman GT, et al. (1991). Analysis of brain and cerebrospinal fluid
volumes with MR imaging. Radiology, 178: 115-122.
208
Kouris K, Jaritt PH, Costa DC, Ell PJ (1992). Physical assessment of the GE/CGR
Neurocam and comparison with a single rotating gamma camera. European
Journal ofNuclearMedicine, 19: 236-242.
Kolokowska T, Williams AO, Ardern M, et al (1985). Schizophrenia with Good and Poor
Outcome. I: Early Clinical Features, Response to Neuroleptics and Signs of
Organic Dysfunction. British Journal ofPsychiatry 146: 229-246.
Kraepelin E (1919). Dementia Praecox andParaphrenia. Edinburgh: Churchill
Livingstone.
Krawiecka M, Goldberg D, Vaughn M. (1977) A standardised psychiatric assessment
scale for rating chronic psychotic patients. Acta Psychiatrica Scandinavica 55:
299-308.
Kulynych JJ, Vladar K, Fantie B, Jones DW, Weinberger DR (1995). Normal asymmetry
of the planum temporale in patients with schizophrenia. British Journal of
Psychiatry, 166: 742-749.
Kulynych JJ, Vladar K, Jones DW, Weinberger DR (1996). Superior Temporal Gyrus
volume in schizophrenia: a study using MRI morphometry assisted by surface
rendering. American Journal ofPsychiatry, 153: 50-56.
Kurachi M, Kobayashi K, Matsubara R, et al.. (1985). Regional cerebral blood flow in
schizophrenics disorders. European Neurology, 24: 176-181.
209
Langfeldt G (1960). Diagnosis and Prognosis of Schizophrenia. Proceedings of the Royal
Society ofMedicine 53: 1047-1052.
Larrue V, Celsis P, Bes A, Marc-Vegnes JP (1994). The functional anatomy of attention
in humans: cerebral blood flow changes induced by reading, naming, and the
stroop effect. Journal ofCerebral BloodFlow andMetabolism, 14: 958-962.
Lauterbur PC (1973). Image formation by induced local interactions: examples
employing nuclear magnetic resonance. Nature 242:190-1.
Lee T, Seeman P, Tourtellotte WW, Farley IJ, Hornyheiwicz O (1978). Binding of 3H-
neuroleptics and 3H-apomorphine in schizophrenic brains. Nature, 274: 897-900.
Lewine RRJ, Hudgins P, Brown F, Caudle J, Risch SC (1995). Differences in qualitative
brain morphology findings in schizophrenia, major depression, bipolar disorder and
normal volunteers. Schizophrenia Research 15: 253-9.
Lewis SW (1989). Congenital risk factors for schizophrenia PsychologicalMedicine,
19: 5-13
Lewis SW (1990). Computerised tomography in schizophrenia: 15 years on. British
Journal ofPsychiatry 157 (supplement 9): 16-24.
Lewis SW, Ford RA, Syed GM, Reveley AM, Toone BK (1992). A controlled study of
HMPAO-SPET in chronic schizophrenia. Psychological Medicine, 22: 27-35.
Lichtshtein D, Dobkin J, Ebstein RP, Biederman J, Rimon R, Belmaker RH (1978).
GABA in the CSF of schizophrenic patients before and after neuroleptic treatment.
British Journal ofPsychiatry, 132: 145-8.
Liddle PF, Friston KJ, Frith CD, et al. (1992). Patterns ofCerebral Blood Flow in
Schizophrenia. British Journal ofPsychiatry 160: 179-186.
Lieberman J, Bogerts B, Degreef G, Ashtari M, Lantos G, Alvir J (1992). Qualitative
assessment ofbrain morphology in acute and chronic schizophrenia. American
Journal ofPsychiatry 149: 784-94.
210
Lieberman JA, Sobel SN (1993). Predictors of treatment response and course of
schizophrenia. Current Opinion in Psychiatry, 6: 63-69.
Lim KO, Sullivan EV, Zipursky RB, Pfefferbaum A (1996). Cortical gray matter volume
deficits in schizophrenia: a replication. Schizophrenia Research, 20: 157-164.
Losonzy MF, Song IS, Mohs RC, et al. (1986). Correlates of Lateral Ventricular Size in
Chronic Schizophrenia, I: Behavioural and Treatment Response Measures.
American Journal ofPsychiatry 143: 976-981.
Luchins DJ, Lewine RRJ, Meltzer HY (1983). CT in first onset schizophrenia.
Schizophrenia Bulletin, 19: 518-523
Luchins DJ, Jackman H, Meltzer HY (1983). Lateral ventricular size and drug-induced
Parkinsonism. Psychiatry Research, 9: 9-16.
Luchins DJ, Lewine RRJ, Meltzer HY (1984). Lateral Ventricular Size, Psychopathology,
and Medication Response in the Psychoses. Biological Psychiatry 19: 29-44.
Lyon M & Barr CE (1991). Possible interactions of obstetrical complications and
abnormal fetal brain development in schizophrenia. In: Fetal Neural Development
andAdult Schizophrenia (eds SA Mednick, TD Cannon, CE Barr & M Lyon).
CUP: New York pp 134-149.
211
MacMillan JF, Crow TJ, Johnson AL, Johnstone EC (1986). The Northwick Park Study
of first episodes of schizophrenia -II: Short-term outcome in trial entrants and trial
eligible patients. British Journal ofPsychiatry 148: 128-133.
Maher BA, Manschrek TC, Woods BT, et al. (1995). Frontal brain volume and context
effects in short-term recall in schizophrenia. Biological Psychiatry, 37: 144-150.
Maier M, Ron MA, Barker GJ, Tofts PS (1995). Proton MRS: an in vivo method of
estimating hippocampal neuronal depletion in schizophrenia. Psychological
Medicine, 25: 1201-1209.
Marsh L, Suddath RL, Higgins N, et al. (1994). Medial Temporal Lobe Structures in
Schizophrenia: Relationship of size to Duration of Illness. Schizophrenia
Research 11: 225-238
Martin P, Albers M (1995). Cerebellum and schizophrenia: a selective review.
Schizophrenia Bulletin 21: 241-250.
Matsuda H, Gyobu T, Masayasu ZD, Hisada K (1988). Increased accumulation of IMP in
the left auditory area in a schizophrenic patient with auditory hallucinations.
ClinicalNuclearMedicine, 13: 53-55.
Matsuda H, Jibiki I, Kinuya K (1991). HMPAO SPECT analysis of neuroleptic effects on
regional brain function. Clinical NuclearMedicine, 16: 660-664.
Mathew RJ, Partain CL, Prakesh R, et al. (1985). A study of the septum pellucidum and
corpus callosum in schizophrenia with MRI. Acta Psychiatrica Scandinavica, 72:
414-421.
Mathew RJ, Meyer JS, Semchuk KM, et al. (1980). Regional cerebral blood flow in
depression: a preliminary report. Jounal ofClinical Psychiatry 41: 71-2.
Mathew RJ, Meyer JS, Francis DJ, et al. (1981). Regional cerebral blood flow in
schizophrenia: a preliminary report. American Jounal ofPsychiatry, 138: 112-113.
Mathew RJ, Duncan GC, Weinman ML, et al. (1982). Regional cerebral blood flow in
schizophrenia. Archives ofGeneral Psychiatry, 39: 1121 -1124.
212
Mathew RJ, Barr DL, Weisman ML (1983). Caffeine and cerebral blood flow. British
JournalofPsychiatry 143: 604-8.
Mathew RJ, WilsonWH, Tant SR (1986). Determinants of resting regional cerebral
blood flow in normal subjects. Biological Psychiatry 21: 907-14.
Mathew RJ, Wilson WH, Tant SR, Robinson L, Prakash R (1988). Abnormal resting
regional cerebral blood flow patterns and their correlates in schizophrenia.
Archives ofGeneral Psychiatry, 45: 542-549.
Mathew RJ, WilsonWH (1990). Anxiety and cerebral blood flow. American Journal of
Psychiatry, 147: 838-849.
Mathew RJ, WilsonWH (1991). Substance abuse and cerebral blood flow. American
Journal ofPsychiatiy, 148: 292-305.
May PRA, Dencker SJ, Hubbard JW, et al (1988). A Systematic Approach to Treatment
Resistance in Schizophrenic Disorders. In Treatment Resistance in Schizophrenia,
eds. Dencker SJ, & Kulhanek F, p22-33. Braunschweig/Wiesbaden:ViewagVerlag.
May PRA, Goldberg SC (1978). Prediction of Schizophrenic Patients' Response to
Pharmacotherapy. In Psychopharmacology: A Generation ofProgress, eds.
Lipton MA, DiMascio A, Killam KF, pp. 1139-1 153. New York: Raven Press.
Mazziotta JC (1985). Human cerebral metabolism: studies in normal subjects and patients
with dementia and amnesia. Annals of the New York Academy ofScience, 444:
269-286.
McCarley RW, Shenton ME, O'Donnell BF, et al. (1993). Auditory P300 abnormalities
and left posterior superior temporal gyrus volume reduction in schizophrenia.
Archives ofGeneral Psychiatry, 50: 190-197.
McCreadie RG, The Scottish Schizophrenia Research Group, MacDonald HL, Best JJK
(1989). The Scottish first episode schizophrenia study: VI. CT brain scans in
patients and controls. British Journal ofPsychiatry 154: 492-98.
213
McGlashan TH (1984). The Chestnut Lodge Follow-up Study. II: Long-term Outcome of
Schizophrenia and the Affective Disorders. Archives ofGeneral Psychiatry 41:
586-601.
McGuffin P, Owen M, Farmer AE (1995). Genetic basis of schizophrenia. Lancet, 346:
678-682.
McGuire PK, Shah GMS, Murray RM (1993). Increased blood flow in Broca's area
during auditory hallucinations in schizophrenia. Lancet, 342: 703-706.
McGuire PK, Silbersweig DA, Wright I, Murray RM, David AS, Frackowiak RSJ, Frith
CD (1995). Abnormal monitoring of inner speech: a physiological basis for
auditory hallucinations. Lancet, 346: 596-600.
McKenna PJ (1991). Memory, knowledge and delusions. British Journal ofPsychiatry,
159 (supplement 14): 36-41.
Menon RR, Barta PE, Aylward EH, et al. (1995). Posterior superior temporal gyrus in
schizophrenia: grey matter changes and clinical correlates. Schizophrenia
Research, 16: 127-135.
Morretti JL, Caglar M, Weinmann P (1995). Cerebral perfusion imaging tracers for
SPECT: which one to chose? Journal ofNuclear Medicine 36: 359-363.
Mortimer AM & McKenna PJ (1994). Levels of explanation - symptoms,
neuropsychological deficit and morphological abnormalities in schizophrenia.
Psychological Medicine, 24: 541-545.
Mozley PD, Gur RE, Resnick SM, et al. (1994). MRI in schizophrenia: relationship with
clinical measures. Schizophrenia Research, 12: 195-203.
Musalak M, Podreka I, Walter H, et al. (1989). Regional brain function in hallucinations:
a study of regional cerebral blood flow with 99m-Tc-HMPAO-SPECT in patients
with auditory hallucinations, tactile hallucinations and normal controls.
Comprehensive Psychiatry, 30: 99-108.
214
Murphy DGM, DeCarli C, Mcintosh AR, et al. (1996). Sex differences in human brain
morphometry and metabolism: an in vivo quantatative MRI and PET study on the
effect of aging. Archives ofGeneral Psychiatry, 53: 585-594.
Murray RM & Lewis SW (1987). Is schizophrenia a neurodevelopmental disorder?
British Medical Journal, 295: 681-2.
Murray RM, Lewis SW, Reveley AM (1985). Towards an aetiological classification of
schizophrenia. Lancet, I: 1023-1026.
Naber D, Albus M, Burke H, et al.{1985) Neuroleptic withdrawal in chronic
schizophrenia: CT and endocrine variables relating to psychopathology. Psychiatry
Research 16: 207-219.
Nakashima Y, Momose T, Sano I, et al. (1994). Cortical control of saccade in normal and
schizophrenic subjects: a PET study using a task-evoked rCBF paradigm.
Schizophrenia Research, 12: 259-264.
Nasrallah HY, Kuperman S, Hamra BJ, McCalley-Whitters M (1983a). Clinical
differences between schizophrenic patients with and without large cerebral
ventricles. Journal ofClinical Psychiatry 44: 407-409.
Nasrallah HA, Kuperman S, Jacoby CG, McCalley-Whitters M, Hamra B (1983b).
Clinical correlates of sulcal widening in chronic schizophrenia. Psychiatry
Research 10: 237-242.
Nasrallah HA, Olsen SC, McCalley-Whitters M, et al. (1986a). Cerebral ventricular
enlargement in schizophrenia: a preliminary follow-up study. Archives ofGeneral
Psychiatry, 43: 157-159.
215
Nasrallah HA, Andreasen NC, Coffman JA, et al. (1986b). A controlled MRI study of
corpus callosum thickness in schizophrenia. Biological Psychiatry, 21: 274-282.
Nelson HE. National Adult Reading Test (NART): TestManual. Windsor: NFER-Nelson
1982.
Nelson T, Lucignani G, SokoloffL (1986). Measurement of brain deoxyglucose
metabolism by NMR. Science, 232: 776-7.
Nestor PG, Shenton ME, McCarley RW, et al. (1993). Neuropsychological correlates of
MRI temporal lobe abnormalities in schizophrenia. American Journal of
Psychiatry, 150: 1849-55.
Nimgaonkar VL, Wessely S, Tune LE, Murray RM (1988). Response to drugs in
schizophrenia: the influence of family history, obstetric complications and
ventricular enlargement. PsychologicalMedicine, 18: 583-592.
Noga JT, Aylward E, Barta PE, Pearlson GD (1995). Cingulate gyrus in schizophrenic
patients and normal volunteers. Psychiatry Research: Neuroimaging, 61: 201-
208.
Nopoulos P, Torres I, Flaum M, et al. (1995). Brain morphology in first-episode
schizophrenia. American Journal ofPsychiatry, 152: 1721-1723.
Nordstrom A-L, Farde L, Eriksson L, Halldin C (1995). No elevated D2 dopamine
receptors in neuroleptic-naive schizophrenic patients revealed by PET and [11C]N-
methylspiperone. Psychiatry Research: Neuroimaging 61: 67-83.
Norussis MJ / SPSS Inc. SPSSfor windows: release 6.0. Chicago: SPSS, 1993.
216
O'Callaghan E, Buckley P, Redmond O, et al. (1992). Abnormalities of Cerebral
Structure in Schizophrenia on Magnetic Resonance Imaging: Interpretation in
Relation to the Neurodevelopmental Hypothesis. Journal of the Royal Society of
Medicine 85: 227-231.
O'Donnell BF, Shenton ME, McCarley RW, et al. (1993). The auditory N2 component in
schizophrenia: relationship to MRI temporal lobe gray matter and to other ERP
abnormalities. Biological Psychiatry, 34: 26-40.
Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia.
Archives ofGeneral Psychiatry, 52: 998-1007.
Owen F, Cross AJ, Crow TJ, Longden A, Poulter M, Riley GJ (1978). Increased
dopamine-receptor sensitivity in schizophrenia. Lancet, ii: 223-6.
Owen AM, Downes JJ, Sahakian BJ, et al. (1990). Planning and Spatial Working Memory
following Frontal Lobe Lesions in Man. Neuropsychologia 28: 1021-1034.
Owens DGC, Johnstone EC, Crow TJ, et al. (1985). Lateral ventricular size in
schizophrenia: relationship to the disease process and its clinical manifestations.
PsychologicalMedicine, 14: 27-41.
217
Pandurangi AK, Goldberg SC, Brink DD, et al. (1989). Amphetamine challenge test,
response to treatment and lateral ventricular size in schizophrenia. Biological
Psychiatry, 25: 207-214.
Paralleda E, Catafau AM, Bernardo M, el al. (1994). Prefrontal dysfunction in young
acute neuroleptic-naive schizophrenic patients: a resting and activation SPECT
study. Psychiatric Research: Neuroimaging, 55: 131-139.
Paulesu E, Frith CD, Frackowiak RSJ (1993). The neural correlates of the verbal
component ofworking memory. Nature, 362: 342-345.
Paulman RG, Devous MD, Gregory RR et al. (1990). Hypofrontality and cognitive
impairment in schizophrenia: dynamic SPET neuropsychological assessment of
schizophrenic brain function. Biological Psychiatry, 27: 377-399.
Pearlson GD, Garbacz DJ, Breakey WR, et al. (1984). Lateral ventricular enlargement
associated with persistent unemployment and negative symptoms in both
schizophrenia and bipolar disorder. Psychiatry Research, 12: 1-9.
Pearlson GD, Garbacz DJ, Moberg PJ, et al. (1985). Symptomatic, familial, perinatal
and social correlates ofCT changes in schizophrenia and bipolar disorder. Journal
ofNervous andMentalDisease, 173: 42-50.
Pearlson GD, Kim WS, Kubos KL, et al (1989). Ventricle-Brain Ratio, Computed
Tomographic Density and Brain Area in 50 Schizophrenics. Archives ofGeneral
Psychiatry, 41: 690-697.
Pearlson GD, Wong DF, Tune LE, et al. (1995). In vivo D2 dopamine receptor density in
psychotic and non-psychotic patients with bipolar disorder. Archives ofGeneral
Psychiatry, 52: 471-477.
Perry TL, Kish SJ, Buchanan J, Hansen S (1979). GABA deficiency in brain of
schizophrenic patients. Lancet, i: 237-9.
Petersen SE, Fox PT, Posner MI, et al. (1988). Positron emission tomographic studies of
the cortical anatomy of single-word processing. Nature 331: 585-9.
218
Petty RG, Barta PE, Pearlson GD, et al. (1995). Reversal of asymmetry of the planum
temporale in schizophrenia. American Journal ofPsychiatry, 152: 715-721.
Pfefferbaum A, Zipursky RB, Lim KL, el al. (1988). CT evidence for generalised sulcal
and ventricular enlargement in schizophrenia. Archives ofGeneral Psychiatry, 45:
633-640.
Pfefferbaum A, Mathalon DH, Sullivan EV, Rawles JM, Zipursky RB, Lim KO (1994). A
quantatative MRI study of changes in brain morphology from infancy to late
adulthood. Archives ofGeneral Psychiatry, 51: 874-887.
Phelps ME, Kuhl DE, Mazziotta JC (1981a). Metabolic mapping of the brain's response
to visual stimulation: studies in humans. Science, 211: 1445-1448.
Phelps ME, Mazziotta JC, Kuhl DE, et al. (1981b). Tomographic mapping of human
cerebral metabolism: visual stimulation and deprivation. Neurology 31: 517-529.
Pilowsky LS, Costa DC, Ell PJ, Murray RM, VerhoeffNLPG, Kerwin RW (1992).
Clozapine, SPET, and the dopamine receptor blockade hypothesis of
schizophrenia. Lancet, 340: 199-202.
Pilowsky LS, Costa DC, Ell PJ, Murray RM, VerhoefFNLPG, Kerwin RW (1993).
Antipsychotic medication, D2 receptor blockade and clinical response: a IBZM-
SPET study. PsychologicalMedicine, 23: 791-797.
Plante E, Turkstra L (1991). Sources of error in the quantatative analysis ofMRI scans.
Magnetic Resonance Imaging, 9: 589-595.
Prohovnik I, Hakansson K, Risberg J (1980). Observations of the functional significance
of regional cerebral flood flow in 'resting' normal subjects. Neuropsychologia, 18:
203-217.
219
Rajaprabhakaran R, Gupta S, Andreasen NC (1995). Volume of the pineal gland in
schizophrenia: and MRI study. Schizophrenia Research, 14: 253-255.
Rauch SL, Savage CR, Alpert NM, et al. (1995). A PET study of simple phobic symtpom
provocation. Archives ofGeneral Psychiatry, 52: 20-28.
Rauch SL, van der Kolk BA, Fisler RE, et al. (1996). A symptom provocation study in
posttraumatic stress disorder using PET and script driven-imagery. Archives of
General Psychiatry, 53: 380-387.
Raichle ME, Grubb RL, Gado MH, et al. (1976). Correlation between regional cerebral
blood flow and oxidative metabolism. Archives ofNeurology, 33: 523-526.
Raine A, Harrison GN, Reynolds GP, et al. (1990). Structural and functional
characteristics of the corpus callosum in schizophrenics, psychiatric controls, and
normal controls. Archives ofGeneral Psychiatry, 47: 1060-1064.
Raine A, Lencz T, Reynolds GP et al. (1992). An evaluation of structural and functional
prefrontal deficits in schizophrenia: MRI and neuropsychological mesures.
Psychiatry Research: Neuroimaging, 45: 123-137.
Rangel-Guerra RA, Perez-Payan M, Todd LE, et al. (1982). Nuclear magnetic resonance
in bipolar affective disorders. Magnetic Resonance Imaging 1: 229-230.
Raz S, Raz N (1990). Structural brain abnormalities in the major psychoses: a quantitative
review of the evidence from CT. Psychological Bulletin, 108: 93-108.
Reiman EM, Raichle ME, Butler FK, Herscovitch P, Robins E (1984). A focal brain
abnormality in panic disorder, a sever form of anxiety. Nature 310: 683-685.
Reiman EM, Raichle ME, Robins E, et al. (1986). The application ofPET to the study of
panic disorder. American Journal ofPsychiatry, 143: 469-477.
Reiman EM, Fusselman MJ, Fox PT, Raichle ME (1989). Neuroanatomical correlates of
anticipatory anxiety. Science, 243: 1071-1074 [correction, 256: 1696],
Reitan RM (1958). Qualitative versus quantitative changes following brain damage.
Journal of Psychology 46: 339-346.
220
Reith J, Benkelfat C, Sherwin A, et al. (1994). Elevated dopa decarboxylase activity in
living brain of patients with psychosis. Proceedings of the National Academy of
Sciences, 91: 11651-11654.
Renshaw PF, Yurgelun-Todd DA, Cohen BM (1994). Greater haemodynamic response to
photic stimulation in schizophrenic patients: an echo planar MRI study. American
Journal ofPsychiatry, 151: 1493-1495.
Renshaw PF, Yurgelun-Todd DA, Tohen M, et al. (1995). Temporal lobe MRS of
patients with first-episode psychosis. American Journal ofPsychiatry, 152: 444-
446.
Resnick SM, Gur RE, Alavi A, et al. (1988). PET and subcortical glucose metabolism in
schizophrenia. Psychiatry Research, 24: 1-11,
Reveley AM, Reveley MA, Clifford CA, Murray RM (1982). Cerebral ventricular size in
twins discordant for schizophrenia. Lancet, i: 540-1.
Reveley MA, Reveley AM, Baldy R (1987). Left hemisphere hypodensity in discordant
schizophrenic twins: a controlled study. Archives ofGeneral Psychiatry, 44: 625-
632.
Reynolds GP, Czudek C, Andrews HB (1990). Deficit and hemispheric asymmetry of
GABA uptake sites in the hippocampus in schizophrenia. Biological Psychiatry,
27: 1038-1044.
Reynolds GP, Stroud D (1993). Flippocampal benzodiazepine receptors in schizophrenia.
Jounal ofNeural Transmission, 93: 151-155.
Rieder RO, Mann LS, Weinberger DR, et al. (1983). CT scans in patients with
schizophrenia, schizaffective and bipolar affective disorder. Archives ofGeneral
Psychiatry, 40: 735-739.
Roberts G (1992). The origin of delusions. British Journal ofPsychiatry, 161: 298-308.
Roland PE (1993). Brain activation. John Wiley: Chichester.
221
Rosenthal MS, Cullom J, Hawkins W, Moore SC, Tsui BMW, Yester M (1995).
Quantitative SPECT imaging: a review and recommendations by the focus
committee of the society of nuclear medicine computer and instrumentation
council. Journal ofNuclearMedicine, 36: 1489-1513.
Rosenthal J, Strauss A, Minkoff L, et al (1986). Identifying lithium-responsive bipolar
depressed patients using nuclear magnetic resonance imaging. American Journal
ofPsychiatry 143: 779-80.
Rossi A, Stratta PM, Gallucci M, et al. (1989). Quantification of corpus callosum and
ventricles in schizophrenia with NMRI: a pilot study. American Journal of
Psychiatry, 146: 99-101.
Rossi A, Stratta P, Di Michele V, et al. (1991). Temporal lobe structure by magnetic
resonance in bipolar affective disorders and schizophrenia Schizophrenia
Research, 21: 19-22.
Rossi A, Stratta P, Mancini F, et al. (1994a). Magnetic Resonance Imaging Findings of
Amygdala-Anterior Hippocampus Shrinkage in Male Patients with Schizophrenia.
Psychiatry Research 52: 43-53.
Rossi A, Stratta P, Mattei P, et al. (1994b). Planum temporale in schizophrenia: a MR
study. Schizophrenia Research, 7: 19-22.
Rossi A, Serio A, Stratta P, et al. (1994c). Planum temporale asymmetry and thought
disorder in schizophrenia. Schizophrenia Research, 12: 1-7.
Rubin P, Holm S, Friberg L, et al. (1991). Altered modulation of prefrontal and
subcortical brain activity in newly diagnosed schizophrenia and schiophreniform
disorder: a rCBF study. Archives ofGeneral Psychiatiy, 48: 987-995.
Rubin P, Hemmingsen R, Holm S, et al. (1994). Relationship between brain structure and
function in disorders of the schizophrenic spectrum: SPECT, CT and
psychopathology of first episodes. Acta Psychiatrica Scandinavica, 90: 281-289.
222
Rutter M (1995). Relationships between mental disorders in childhood and adulthood.
Acta Psychiatrica Scandinavica, 91: 73-85.
Sagawa K, Kawakutsu S, Shibuya I, et al. (1990). Correlation of regional cerebral blood
flow with performance on neuropsychological tests in schizophrenic patients.
Schizophrenia Research, 3: 241-246.
Sands JR & Harrow M (1995). Vulnerability to psychosis in unipolar major depresssion:
is premorbid functioning involved? American Journal ofPsychiatry, 152: 1009-
1015.
Saykin AJ, Gur RC, Gur RE, et al. (1991). Neuropsychological Function in
Schizophrenia: Selective Impairment in Memory and Learning. Archives of
General Psychiatry 48: 618-624.
Schild HH (1990). MR1 made easy. Heenemann: Berlin.
Schlaepfer TE, Harris GJ, Tien AY, et al. (1994). Decreased Regional Gray Matter
Volume in Schizophrenia. American Journal ofPsychiatry 151: 842-848.
Schlaepfer TE, Harris GJ, Tien AY, Peng L, Lee S, Pearlson GD (1995). Structural
differences in the cerebral cortex of healthy female and male subjects: a MRI study.
Psychiatry Research: Neuroimaging, 61: 129-135.
Schroder J, Geider FJ, Sauer H (1993). Can Computerised Tomography be Used to
Predict Early Treatment Response in Schizophrenia? British Journal ofPsychiatry
163 (supplement 21), 13-15.
Schroder J, Buchsbaum MS, Siegel BV, et al. (1994). Patterns of cortical activity in
schizophrenia. PsychologicalMedicine, 24: 947-955.
223
Schroder J, Wenz F, Schad LR, Baudendistel K, Knopp MV (1995). Sensorimotor cortex
and supplemantary motor area changes in schizophrenia: a study with functional
magnetic resonance imaging. British Journal ofPsychiatry, 167: 197-201.
Schroder J, Bubeck B, Sauer H, Demisch S (1995b). benzodiazepine receptors in
schizophrenia: a study with Iomazenil-SPET. Schizophrenia Research, 15: 97-98.
Schroder J, Buchsbaum MS, Siegel BV, et al. (1996). Cerebral metabolic activity
correlates of subsyndromes in chronic schizophrenia. Schizophrenia Research, 19:
41-53.
Schulz SC, Roller MM, Kishore PR, et al. (1983a). Ventricular enlargement in teenage
patients with schizophrenia spectrum disoreder. American Journal ofPsychiatry,
140: 1592-1595.
Schulz SC, Sinicrope PS, Kishore P, Friedel RO (1983b). Treatment Response and
Ventricular Brain Enlargement in Young Schizophrenic Patients.
Psychopharmacology Bulletin 19: 510-512.
Schwartz JM, Aylward E, Barta PE, et al. (1992). Sylvian fissure size in schizophrenia as
measured with the magnetic resonance imaging rating protocol of the consortium
to establish a registry for alzheimer's disease. American Journal of Psychiatry,
149:1195-98.
Schwartz JM, Stoessel PW, Baxter LR, Martin Km, Phelps ME (1996). Systematic
changes in cerebral glucose metabolic rate after successful behaviour modification
treatment of obsessive-compulsive disorder. Archives ofGeneralPsychiatry, 53:
109-113.
Schwartzkopf SB, Nasrallah HA, Olson SC, et al (1991). Family history and brain
morphology in schizophrenia: an MRI study. Psychiatry Research:
Neuroimaging, 40: 49-60.
Sedvall G, Farde L, Persson A, Wiesel F-A (1986). Imaging of neurotransmitter receptors
in the living human brain. Archives ofGeneral Psychiatiy, 43: 995-1005.
224
Seeman P, Lee T, Chau-Wong M, Wong K (1976). Antipsychotic drug doses and
neuroleptic/dopamine receptors. Nature, 261: 717-719.
Seeman P, Ulpian C, Bergeron C, et a/. (1984). Bimodal distribution of dopamine
receptor densities in brains of schizophrenics. Science, 225: 728-731.
Seeman P, Niznik HB, Guan H-C, et al (1990). Elevation ofDopamine D2 receptors in
schizophrenia is underestimated by radioactive raclopride. Archives ofGeneral
Psychiatry, 47: 1170-1172.
Seeman P, Guan H-C, Van Tol HM (1993). Dopamine D4 receptors elevated in
schizophrenia. Nature, 365: 441-445.
Seidman LJ, Yurgelun-Todd D, Kremen WS, et al. (1994). Relationship of prefrontal and
temporal lobe MRI measures to neuropsychological performance in chronic
schizophrenia. Biological Psychiatry, 35: 235-246.
Selemon LD, Rajkowska G, Goldman-Rakic PS (1995). Abnormally high neuronal
density in the schizophrenic cortex. Archives ofGeneral Psychiatry, 52: 805-818.
Shakow D (1981). The Place ofCooperation in the Examination ofMental Disorder.
Journal ofNervous andMental Disease 169: 127-137.
Shallice T, Burgesss PW, Frith CD (1991). An the neuropsychological case-study
approach be applied to schizophrenia? PsychologicalMedicine, 21: 661-673,
Shallice T, Fletcher P, Frith CD, et at. (1994). Brain regions associated with acquisition
and retrieval of verbal episodic memory. Nature, 368: 633-635.
Shapiro RM (1993). Regional neuropathology in schizophrenia: Where are we? Where
are we going? Schizophrenia Research, 10: 187-239.
Shedlack KJ, Hunter R, Wyper D, McLuskie R, Fink G, Goodwin GM (1991). The
pattern of cerebral activity underlying verbal fluency shown by split-dose single
photon emission tomography (SPET or SPECT) in normal volunteers.
PsychologicalMedicine, 21: 687-696.
225
Shenton ME, Kikinis R, McCarley et al. (1991). Application ofAutomated MRI
Volumetric Measurement Techniques to the Ventricular System in Schizophrenics
and Normal Controls. Schizophrenia Research 5: 103-113.
Shenton ME, Kikinis R, Jolesz FA, et al. (1992) Abnormalities of the left temporal lobe
and thought disorder in schizophrenia: a quantitative magnetic resonance imaging
study. New EnglandJournal ofMedicine 327: 604-612.
Sheppard G, Gruzelier J, Manchanda R, et al. (1983). 150-PET scanning in
predominantly never-treated acute schizophrenic patients. Lancet, ii: 1148-1152.
Sherer J, Tatsch K, Schwartz J, et al. (1994). D2-dopamine receptor occupancy differs
between patients with and without extrapyramidal side effects. Acta Psychiatrica
Scandinavica, 90: 266-268.
Sherman AD, Davidson AT, Baruah S, Hegwood TS, Waziri R (1991). Evidence of
glutamatergic deficiency in schizophrenia. Neuroscience Letters, 121: 77-80.
Siegel BV, BuchsbaumMS, Bunney WE, et al. (1993). Cortical-Striatal-Thalamic Circuits
and Brain Glucose Metabolic Activity in 70 Unmedicated Male Schizophrenic
Patients. American Journal ofPsychiatry 150: 1325-1336.
Silbersweig DA, Stern E, Frith C, et al. (1996). A functional neuroanatomy of auditory
hallucinations. Nature, MS: 176-179.
Simpson MDC, Royston MC, Slater P, Deakin JFW, Skan WJ (1989). Reduced GABA
uptake sites in the temoral lobe in schizophrenia. Neuroscience Letters, 107: 211-
215.
Simpson MDC, Slater P, Royston MC, Deakin JFW (1992). Regionally selective deficits
in uptake sites for glutamate and GABA in the basal ganglia in schizophrenia.
Psychiatry Research, 42: 273-282.
Smith GN, Iacono WG (1986). Lateral ventricular size in schizophrenia and choice of
control group. Lancet, i: 1450.
226
Smith GN, Iacono WG, Moreau M, et al. (1988). Choice of comparison group and CT
findings in schizophrenia. British Journal ofPsychiatry, 153: 667-674.
Smith RC, Largen J, Calderon M, et al. (1983). CT scans and neuropsychological
predictors of clinical response in schizophrenics. Schizophrenia Bulletin, 19: 505-
519.
Smith RC, Maser J (1983). Morphological and neuropsychological abnormalities as
predictors of clinical response to psychotropic drugs. Psychopharmacology
Bulletin, 19: 505-9.
Smith RC, Baumgartner R, Ravichandran GK, et al. (1985). Lateral Ventricular
Enlargement and Clinical Response in Schizophrenia. Psychiatry Research 14:
241-253.
Smith RC, Baumgartner R, Ravichandran GK, et al. (1987a). Cortical atrophy and white
matter density in the brains of schizophrenics and clinical response to neuroleptics.
Acta Psychiatriatria Scandinavica, 75: 11-19.
Smith RC, Baumgartner R, Chalderon M (1987b). MRI studies of the brains of
schizophrenic patients. Psychiatry Research, 20: 33-46.
Smith RC, Largen J, Vroulis G, Ravichandran GK (1992). Neuropsychological test scores
and clinical response to neuroleptics in schizophrenic patients. Comprehensive
Psychiatry, 33: 139-145.
Spitzer RL, Endicott J (1978). Schedulefor Affective Disorders and Schizophrenia -
lifetime version. New York: New York State Psychiatric Institute.
Spokes EGS, Garrett NJ, Rossor MN, Iversen LL (1980). Distribution ofGABA in post¬
mortem brain tissue from control, psychotic and Huntingdon's chorea subjects.
Journal of the Neurological Sciences, 48: 303-313.
Squire LR, Ojemann JG, Miezin FM, et al. (1992). Activation of the hippocmpus in
normal humans: a functional anatomical study. Proceedings of the National
Academy ofSciences, 89:1837-41.
227
Squires RF, Lajtha A, Saederup E, Palkovits M (1993). Reduced 3H-flunitrazepam
binding in cingulate cortex and hippocampus of postmortem schizophrenic brains -
us selective loss of glutamatergic neurons assocted with major psychoses.
Neurochemistry Research, 18: 219-223.
Stanley JA, Williamson PC, Drost DJ, et al. (1995). An in vivo study of the prefrontal
cortex of schizophrenic patients at different stages of illness via MRS. Archives of
General Psychiatry, 52: 399-406.
Steinberg JL, Devous MD Sr, Moeller FG, Paulman RG, Raese JD, Gregory RR (1995a).
Cerebellar blood flow in schizophenic patients and normal control subjects.
Psychiatry Research: Neuroimaging, 61: 16-31.
Steinberg JL, Devous MD Sr, Paulman RG, Gregory RR (1995b). Regional cerebral
blood flow in first break and chronic schizophenic patients and normal controls.
Schizophrenia Research, 17: 229-240.
Steinberg JL, Devous MD Sr, Paulman RG (1996). WCST activated rCBF in first break
and chronic schizophrenic patients and normal controls. Schizophrenia Research,
19: 177-187.
Stevens JR (1992). Abnormal reinnervations as a basis for schizophrenia: a hypothesis.
Archives ofGeneral Psychiatry, 49: 238-243.
Stroop JR (1935). Studies of interference in serial verbal reactions. Journal of
Experimental Psychology 18, 643-662.
Suddath RL, Christison GW, Torrey EF, et al. (1990) Anatomical abnormalities in the
brains ofmonozygotic twins discordant for schizophrenia. New EnglandJournal
ofMedicine 322: 789-794.
Suga H, Hayashi T, Mitsugi O (1994). SPECT findings using N-Isopropyl-p-
[1231]iodoamphetamine (123I-1MP) in schizophtrenia, and atypical psychosis.
Japanese Journal ofPsychiatry, 48: 833-848.
228
Sullivan EV, Shear PK, Lim KO, Zipursky RB, Pfefferbaum A (1996). Cognitive and
motor impairments are related to gray matter volume deficits in schizophrenia.
Biological Psychiatry, 39: 234-240.
Suzuki M, Yuasa S, Minabe Y, Murata Y, Kurachi M (1993). Left superior temoral
blood flow increases in schizoprenic and schizophreniform patients with auditory
hallucinations: a longitudinal case study using IMP SPECT. European Archives of
Psychiatry and ClinicalNeuroscience, 242: 257-261.
Swayze VW, Andreasen NC, Alliger RJ, et al. (1992). Subcortical and Temporal
Structures in Affective Disorder and Schizophrenia: A Magnetic Resonance
Imaging Study. Biological Psychiatry 32:221-240.
Sybirska E, Seibyl JP, Bremner JD, et al (1993). 1231-Iomazenil SPECT imaging
demonstrates significant benzodiazepine receptor reserve in human and nonhuman
primate brain. Neuropharmacology, 32: 671-680.
Szechtmann H, Nahmias C, Garnett S, et al. (1988). Effect of neuroleptics on altered
cerebral glucose metabolism in schizophrenia. Archives ofGeneral Psychiatry,
45: 523-532.
229
Talairach J, Zikha G, Tournoux P, et al. (1988/ Atlas d'anatomie stereotactique du
telencephale. Masson: Paris
Tamlyn D, McKenna PJ, Mortimer AM, et al. (1992). Memory impairment in
schizophrenia: its extent, affiliations and neuropsychological character.
Psychological Medicine 22: 101-115.
Tamminga CA, Thaker GK, Buchanan R, et al. (1992). Limbic System Abnormalities
Identified in Schizophrenia Using Positron Emission Tomography With
Fluorodeoxyglucose and Neocortical Alterations With Deficit Syndrome. Archives
ofGeneral Psychiatry 49: 522-530.
Tiihonen J, Kuikka J, Hakola P, et al. (1994). Acute ethanol-induced changes in cerebral
blood flow. American Journal ofPsychiatry, 151: 1505-1508.
Turner SW, Toone BK, Breet-Jones JR (1986). CT scan changes in early chronic
schizophrenia - their relationship to perinatal trauma, family history and alcohol
intake: preliminary findings. PsychologicalMedicine, 14: 219-225.
Torn M, Watanabe S, Shibuya H, et al. (1988). Neurotransmitters, receptors and
neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta
Psychiatrica Scandina\>ica, 78: 121-137.
Tune LE, Wong DF, Pearlson G, et al. (1993). Dopamine D2 receptor density estimates
in schizophrenia: a PET study with 1 lC-N-Methylspiperone. Psychiatry
Research, 49: 219-237.
Turetsky B, Cowell PE, GUR RC, et al. (1995). Frontal and Temporal Lobe Brain
Volumes in Schizophrenia. Archives of General Psychiatry 52: 1061-1070.
230
Uematsu M, Kaiya H (1988a). The morphology of the corpus callosum in schizophenia:
an MRI study. Schizophrenia Research, 1: 391-398.
Uematsu M, Kaiya H (1988b). Cerebellar vermal size predicts treatment response in
schizophrenic patients: a MRI study. Progress in Nearo-Pharmacology and
Biological Psychiatry, 12: 837-848.
Vaillant GE. (1964). Prospective Prediction of Schizophrenic Remission. Archives of
General Psychiahy 11: 509-518.
Van Heertum RL, Tikofsky RF (1989). Advances in cerebral SPECT imaging (Eds).
Trivirum:New York.
Van Heertum RL, Tikofsky RF (1995). Cerebral SPECT imaging (2nd edition - Eds).
Raven Press:New York.
Van Horn JD, McManus IC (1992). Ventricular enlargement in schizophrenia: a meta¬
analysis of studies of the VBR. British Journal ofPsychiatry, 160: 687-697.
Van Kammen DP, Gelertner J (1987). Biochemical instability in schizophrenia II: the
serotonin and GABA systems. In: Psychopaharmaocoloy: the third eneration of
progress (EdMeltzer HY) pp753-8. Raven Press: New York.
Van Kammen DP, Sternberg DE, Hare TA, Waters RN, BunneyWE (1982). CSF levels
ofGABA in schizophrenia: low levels in recently ill patients. Archives ofGeneral
Psychiatry, 39: 91-97.
231
VerhoefFNPLG, Erbas B, Kapuco O, Busemann SE, Blok H, Van Royen EA (1993).
Quantification of central benzodiazepine receptorbinding potantial in the brain with
1231-iomazenil SPECT: technical and interobserver variability. Nuclear Medicine
Communications, 14: 634-643.
Vita A, Sacchetti E, Calzeroni A, Cazzullo CL (1988). Cortical atrophy in schizophrenia:
prevalence and associated features. Schizophrenia Research 1: 329-337.
Vita A, Dieci M, Giobbio GM, et al. (1995a). Language and thought disorder in
schizophrenia: brain morphological correlates. Schizophrenia Research, 15: 243-
251.
Vita A, Bressi S, Perani D, et al. (1995b). High-resolution SPECT study of regional
cerebral blood flow in drug-free and drug-naive schizophrenic patients. American
Journal ofPsychiatry, 152: 876-882.
Vocisano C, Klein DN, Keefe RSE, Dienst ER, Kincaid MM (1996). Demographics,
family history, premorbid functioning, developmental characteristics and course f
patients with affective disorder. American Journal ofPsychiatiy, 153: 248-255.
Volk S, Maul FD, Hor G, et al. (1994). Dopamine D2 receptor occupancy measured by
IBZM-SPET in chronic schizophrenia. Psychiatry Research: Neuroimaging, 55:
111-118.
Volkow ND, Brodie JD, WolfAP, Angrist B, Russell J, Cancro R (1986). Brain
metabolism in patients with schizophrenia before and after acute neuroleptic
administration. JournalNeurology, Neurosurgery andPsychiatry, 49: 1199-1202.
Volkow ND, WolfAP, van Gelder P, et al. (1987). Phenomenological correlates of
metabolic activity in patients with chronic schizophrenia. American Journal of
Psychiatry, 144: 151-8.
232
Waddington JL, O'Callaghan E, Larkin C, Redmond O, Stack J, Ennis JT (1990).
Magnetic resonance imaging and spectroscopy in schizophrenia. British Journal
ofPsychiatry 51 (supplemnet 9): 56-65.
Wang G-J, Volkow ND, Wolf AP, et al. (1994). Intersubject variability of brain glucose
metabolic measurements in young normal males. Journal of. Nuclear Medicine,
35:1457-1466.
Wagner HN, Burns HD, Dannals RF, et al. (1983). Imaging dopamine receptors in the
human brain by positron tomography. Science 223:1264-1266.
Warkentin S, Nilsson A, Risberg J, el al. (1990). Regional cerebral blood flow in
schizophrenia: repeated studies during a psychotic episode. Psychiatry Research:
Neuroimaging, 35: 27-38.
Weinberger DR (1987). Implications ofNormal Brain Development for the Pathogenesis
of Schizophrenia. Archives ofGeneral Psychiatry 44: 660-669.
Weinberger DR & Wyatt RJ (1982). Brain morphology in schizophrenia: in vivo studies.
In: Schizophrenia as a Brain Disease, Henn FA & Nasrallah HA (Eds), OUP.
Weinberger DR, Torrey EF, Neophytides AN, Wyatt RJ (1979). Structural abnormalities
of cerebral cortex in chronic schizophrenia. Archives ofGeneral Psychiatry 36:
935-9.
Weinberger DR, Bigelow LB, Kleinman JE, et al. (1980). Cerebral Ventricular
Enlargement in Chronic Schizophrenia: An Association with Poor Response to
Treatment. Archives ofGeneral Psychiatry 37: 11-13.
Weinberger DR, DeLisi LE, Perman GP, et al. (1982). CT scans in schizophreniform
disorder and other acute psychiatric patients. Archives ofGeneral Psychiatry, 39:
778-783.
Weinberger DR, Berman KF, Zee RF (1986). Physiologic dysfunction of dorsolateral pre¬
frontal cortex in schizophrenia, I: regional cerebral blood flow evidence. Archives
ofGeneral Psychiatry, 43: 114-124.
233
Weinberger DR, Berman KF, Illowsky BP (1988). Physiologic dysfunction of dorsolateral
pre-frontal cortex in schizophrenia, III: a new cohort and evidence for a
monoaminergic mechanism. Archives ofGeneral Psychiatry, 45: 609-615.
Weinberger DR, Berman KF, Suddath R, Torrey EF (1992). Evidence of dysfunction of a
prefrontal-limbic network in schizophrenia: a MRI and rCBF study of discordant
monozygotic twins. American Journal ofPsychiatry, 149: 890-897.
Wechsler D (1981). Wechsler Adult Intelligence Scale - Revised (WAIS-R). New York:
Psychological Corporation.
Wible CG, Shenton ME, Hokama H, et al. (1995). Prefrontal Cortex and Schizophrenia.
Archives of General Psychiatry 52: 279-288.
Wiesel FA, Wik G, Sjogren I, et al. (1987a). Regional brain glucose metabolism in drug
free schizophrenic patients and clinical correlates. Acta Psychiatrica
Scandinavica, 76: 628-641.
Wiesel FA, Wik G, Sjogren I, et al. (1987b). Altered relationships between metabolic
rates of glucose in brain regions in schizophrenic patients. Acta Psychiatrica
Scandinavica, 76: 642-647.
Williams AO, Reveley MA, Kolakowska T, et al. (1985). Schizophrenia with Good and
Poor Outcome. II: Cerebral Ventricular Size and its Clinical Significance. British
Journal ofPsychiatry 146: 239-246.
Williamson P, Pelz D, Merskey H, et al. (1991). Correlation of negative symptoms in
schizophrenia with frontal lobe parameters on MRI. British Journal ofPsychiatry,
159: 130-34.
Wilms G, Van Oongeval C, Baert AL, et al. (1992). Ventricular enlargement, clinical
correlates and treatment outcome in chronic schizophrenic inpatients. Acta
Psychiatrica Scandinavica 85: 306-312.
Wilson B, Cockburn J, Baddeley A (1985). The RivermeadBehaviouralMemory Test.
Reading: Thames Valley Test Company.
234
Wilson BA, Cockburn J, Halligan PW (1987). Behavioural Inattention Test. Reading:
Thames Valley Test Company.
Wing JK, Cooper JE, Sartorius N (1974). Description and Classification ofPsychiatric
Symptoms: The Present State Examination. Cambridge: Cambridge University
Press.
Wojcik JD, Gelenberg AJ, Labrie RA, Mieske M (1980). Prevalence of Tardive
Dyskinesia in an Outpatient Population. Comprehensive Psychiatry 21: 370-380.
Wolkin A, Jaeger J, Brodie JD, et al. (1985). Persistence of cerebral metabolic
abnormalities in chronic schizophrenia determined by PET. American Jounal of
Psychiatry,142: 564-71.
Wolkin A, Angrist B, Wolf A, et al. (1988). Low frontal glucose utilisation in chronic
schizophrenia: a replication study. American Journal ofPsychiatry, 145: 251-3.
Wolkin A, Barouche F, WolfAP, et al. (1989). Dopamine blockade and clinical response:
evidence for two biological sub-groups of schizophrenia. American Jounal of
Psychiatry, 146: 905-8.
Wolkin A, Sanfilipo M, Wolf AP, et al. (1992). Negative symptoms and hypofrontality in
chronic schizophrenia. Archives ofGeneral Psychiatry, 49: 959-965.
Wolkin A, Sanfilipo M, Angrist B, et al. (1994). Acute d-amphetamine challenge in
schizophrenia: effects on cerebral glucose utilisation and clinical symptomatology.
Biological Psychiatry, 36: 317-325.
Wolkin A, Sanfilipo M, Duncan E, et al. (1996). Blunted change in cerebral glucose
utilisation after haloperidol treatment in schizoprenic patients with prominent
negative symptoms. American Jounal ofPsychiatry, 153: 346-354.
Wolkowitz OM, Pickar D (1991). Benzodiazepines in the treatment of schizophrenia: a
review and reappraisal. American Jounal ofPsychiatry 148: 714-726.
235
Wong DF, Wagner HN, Dannals RF, et al. (1984). Effects of age on dopamine and
serotonin receptors measured by PET in the living human brain. Science, 226:
1393-1396.
Wong DF, Wagner HN, Tune LE, et a/. (1986). PET reveals elevated D2 receptors in
drug-naive schizophrenics. Science, 234: 1558-63.
Wood FB, Flowers DL (1990). Hypofrontal vs. hypo-Sylvian blood flow in
schizophrenia. Schizophrenia Bulletin, 16: 413-424.
WoodruffPWR, McManus IC, David AS (1995). Meta-analysis of corpus callosum size
in schizophrenia. JournalNeurology, Neurosurgery andPsychiatry, 58: 457-461.
WoodruffPWR, Pearlson GD, Geer MJ, et al. (1993). A computerised MRI study of
corpus callosum morphology in schizophrenia. PsychologicalMedicine, 23: 45-
56.
Woods BT, Yurgelun-Todd D, Benes FM, et al. (1990). Progressive ventricular
enlargement in schizophrenia: comparison to bipolar affective diorder and
correlation with clinical course. Biological Psychiatry, 27: 341-352.
Woods BT, Douglass A, Gescuk B (1991). Is the VBR still a useful measure of changes
in the cerebral ventricles. Psychiatry Research: Neuroimaging, 40: 1-10.
Woods SW, Hegeman IM, Zubal IG, et al. (1991). Visual stimulation increases
Technetium-99m-HMPAO distribution in human visual cortex. Journal of
NuclearMedicine, 32: 210-215.
Woods SW, Seibyl JP, Goddard AW, et al. (1992). Dynamic SPECT imaging after
injection of the benzodiazepine receptor ligand 1231-iomazenil in healthy human
subjects. Psychiatry Research: Neuroimaging, 45: 67-77.
Wright IC, McGuire PK, Poline JB, et al. (1995). A voxel-based method for the statistical
analysis of gray and white matter density applied to schizophrenia. Neuroimage,
2: 244-252.
236
Young AH, Blackwood DHR, Roxborough H, et al. (1991). A MRI study of
schizophrenia: brain structure and clinical symptoms. British Journal of
Psychiatry, 158: 158-164.
Yuasa S, Kurachi M, Suzuki M, et al. (1995). Clinical symptoms and regional cerebral
blood flow in schizophrenia. European Archives ofPsychiatry and Clinical
Neuroscience, 246: 7-12.
Yurgelun-Todd DA, Waternaux CM, Cohen BM, Gruber SA, English CD, Renshaw PF
(1996). Functional magnetic resonance imaging of schizophrenic patients and
comparison subjects during word production. American Journal ofPsychiatry,
153: 200-205.
Zipursy RB, Lim KO, Pfefferbaum A (1991). Volumetric assessment of cerebral
asymmetry from CT scans. Psychiatry Research: Neuroimaging, 35: 71-89.
Zipursy RB, Lim KO, Sullivan EV, Brown BW, Pfefferbaum A (1992). Widespread
cerebral gray matter volume deficits in schizophrenia. Archives ofGeneral
Psychiatry, 49: 195-205.
Zipursky RB, Marsh L, Lim KO, et al. (1994). Volumetric MRI assessment of temporal
lobe structures in schizophrenia. Biological Psychiatry, 35: 501-516.
Zohar J, Insel TR, Berman KF, Foa EB, Hill JL, Weinberger DR (1989). Anxiety and
cerebral blood flow during behavioural challenge. Archives ofGeneral Psychiatry,
46: 505-510.
237
